A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
provide for the regulation of in vitro clinical tests, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
3
(a) SHORT TITLE.—This Act may be cited as the 
4
‘‘Verifying Accurate Leading-edge IVCT Development Act 
5
of 2020’’ or the ‘‘VALID Act of 2020’’. 
6
(b) TABLE OF CONTENTS.—The table of contents of 
7
this Act is as follows: 
8
‘‘Sec. 1. Short title; table of contents. 
‘‘Sec. 2. Definitions. 
‘‘Sec. 3. Regulation of in vitro clinical tests. 
01:17 Mar 17, 2020
H6102
2 
•HR 6102 IH
‘‘SUBCHAPTER J—IN VITRO CLINICAL TESTS 
‘‘SUBCHAPTER J. In Vitro Clinical Tests 
‘‘Sec. 587. Definitions. 
‘‘Sec. 587A. Applicability. 
‘‘Sec. 587B. Premarket review. 
‘‘Sec. 587C. Breakthrough in vitro clinical tests. 
‘‘Sec. 587D. Technology certification. 
‘‘Sec. 587E. Mitigating measures. 
‘‘Sec. 587F. Regulatory pathway redesignation. 
‘‘Sec. 587G. Advisory committees. 
‘‘Sec. 587H. Request for informal feedback. 
‘‘Sec. 587I. Registration and listing. 
‘‘Sec. 587J. Test design and quality requirements. 
‘‘Sec. 587K. Labeling requirements. 
‘‘Sec. 587L. Adverse event reporting. 
‘‘Sec. 587M. Corrections and removals. 
‘‘Sec. 587N. Restricted in vitro clinical tests. 
‘‘Sec. 587O. Appeals. 
‘‘Sec. 587P. Accredited persons. 
‘‘Sec. 587Q. Recognized standards. 
‘‘Sec. 587R. Investigational use. 
‘‘Sec. 587S. Collaborative communities for in vitro clinical tests. 
‘‘Sec. 587T. Comprehensive test information system. 
‘‘Sec. 587U. Preemption. 
‘‘Sec. 587V. Adulteration. 
‘‘Sec. 587W. Misbranding. 
‘‘Sec. 587X. Postmarket surveillance. 
‘‘Sec. 587Y. Electronic format for submissions. 
‘‘Sec. 587Z. Postmarket remedies. 
‘‘Sec. 4. Enforcement and other provisions. 
‘‘Sec. 5. Transition. 
‘‘Sec. 6. Emergency use authorization. 
‘‘Sec. 7. Antimicrobial susceptibility tests. 
‘‘Sec. 8. Combination products. 
‘‘Sec. 9. Resources.’’. 
SEC. 2. DEFINITIONS. 
1
(a) IN GENERAL.—Section 201 of the Federal Food, 
2
Drug, and Cosmetic Act (21 U.S.C. 321) is amended— 
3
(1) by adding at the end the following: 
4
‘‘(ss)(1) The term ‘in vitro clinical test’— 
5
‘‘(A) means a test intended by its developer (as 
6
defined in section 587) to be used in the collection, 
7
preparation, analysis, or in vitro clinical examination 
8
01:17 Mar 17, 2020
H6102
3 
•HR 6102 IH
of specimens taken or derived from the human body 
1
for the purpose of— 
2
‘‘(i) identifying or diagnosing a disease or 
3
condition; 
4
‘‘(ii) providing information for diagnosing, 
5
screening, measuring, detecting, predicting, 
6
prognosing, analyzing, or monitoring a disease 
7
or condition, including by making a determina-
8
tion of an individual’s state of health; or 
9
‘‘(iii) selecting, monitoring, or informing 
10
therapy or treatment for a disease or condition; 
11
and 
12
‘‘(B) may include— 
13
‘‘(i) a test protocol or laboratory test pro-
14
tocol; 
15
‘‘(ii) an instrument (as defined in section 
16
587(11)); 
17
‘‘(iii) an article for taking, deriving, hold-
18
ing, or transporting specimens from the human 
19
body (as defined in section 587(16)); 
20
‘‘(iv) software, excluding software that is 
21
excluded by section 520(o) from the definition 
22
of a device under section 201(h), and excluding 
23
modifications that are exempt in accordance 
24
with section 587A(l)(2)(A); and 
25
01:17 Mar 17, 2020
H6102
4 
•HR 6102 IH
‘‘(v) subject to subparagraph (2), a compo-
1
nent or part of a test, a test protocol, an instru-
2
ment, an article, or software described in any of 
3
clauses (A) through (D) of such subparagraph, 
4
whether alone or in combination, including re-
5
agents, calibrators, and controls. 
6
‘‘(2) Notwithstanding subparagraph (1)(v), an article 
7
intended to be used as a component or part of an in vitro 
8
clinical test described in subparagraph (1) is excluded 
9
from the definition in subparagraph (1) if the article con-
10
sists of any of the following: 
11
‘‘(A) Blood, blood components, or human cells 
12
or tissues, from the time of acquisition, donation, or 
13
recovery of such article, including determination of 
14
donor eligibility, as applicable, until such time as the 
15
article is released as a component or part of an in 
16
vitro clinical test by the establishment that collected 
17
such article. 
18
‘‘(B) An article used for invasive sampling, a 
19
needle, or a lancet, except to the extent such article, 
20
needle, or lancet is an integral component of an arti-
21
cle for holding, storing, or transporting a specimen. 
22
‘‘(C) General purpose laboratory equipment, in-
23
cluding certain pre-analytical equipment, as deter-
24
mined by the Secretary. 
25
01:17 Mar 17, 2020
H6102
5 
•HR 6102 IH
‘‘(D) An article used solely for personal protec-
1
tion during the administering, conducting, or other-
2
wise performing of test activities.’’; 
3
(2) by adding at the end of section 201(g) the 
4
following: 
5
‘‘(3) The term ‘drug’ does not include an in vitro clin-
6
ical test.’’; and 
7
(3) in section 201(h), by striking ‘‘section 
8
520(o)’’ and inserting ‘‘section 520(o) or an in vitro 
9
clinical test’’. 
10
(b) EXCLUSION FROM DEFINITION OF BIOLOGICAL 
11
PRODUCT.—Section 351(i)(1) of the Public Health Serv-
12
ice Act (42 U.S.C. 262(i)(1)) is amended— 
13
(1) by striking ‘‘(1) The term ‘biological prod-
14
uct’ means’’ and inserting ‘‘(1)(A) The term ‘biologi-
15
cal product’ means’’; and 
16
(2) by adding at the end the following: 
17
‘‘(B) The term ‘biological product’ does not in-
18
clude an in vitro clinical test as defined in section 
19
201(ss) of the Federal Food, Drug, and Cosmetic 
20
Act.’’. 
21
(c) IN VITRO CLINICAL TEST DEFINITION.—In this 
22
Act, the term ‘‘in vitro clinical test’’ has the meaning given 
23
such term in section 201(ss) of the Federal Food, Drug, 
24
and Cosmetic Act, as added by subsection (a). 
25
01:17 Mar 17, 2020
H6102
6 
•HR 6102 IH
SEC. 3. REGULATION OF IN VITRO CLINICAL TESTS. 
1
The Federal Food, Drug, and Cosmetic Act (21 
2
U.S.C. 301 et seq.) is amended— 
3
(1) by amending the heading of chapter V to 
4
read as follows: ‘‘DRUGS, DEVICES, AND IN 
5
VITRO CLINICAL TESTS’’; and 
6
(2) by adding at the end of chapter V the fol-
7
lowing: 
8
‘‘Subchapter J—In Vitro Clinical Tests 
9
‘‘SEC. 587. DEFINITIONS. 
10
‘‘In this subchapter: 
11
‘‘(1) ANALYTICAL VALIDITY.— 
12
‘‘(A) The term ‘analytical validity’ means, 
13
with respect to an in vitro clinical test, the abil-
14
ity of the in vitro clinical test, to— 
15
‘‘(i) sufficiently identify, measure, de-
16
tect, calculate, or analyze one or more 
17
analytes, biomarkers, substances, or other 
18
targets intended to be identified, measured, 
19
detected, calculated, or analyzed by the 
20
test; or 
21
‘‘(ii) as applicable, assist in such iden-
22
tification, measurement, detection, calcula-
23
tion, or analysis. 
24
‘‘(B) For an article for taking or deriving 
25
specimens from the human body described in 
26
01:17 Mar 17, 2020
H6102
7 
•HR 6102 IH
section 201(ss)(1)(B)(iii), the term ‘analytical 
1
validity’ means that such article performs as in-
2
tended and will support the analytical validity 
3
of an in vitro clinical test with which it is used. 
4
‘‘(2) APPLICABLE STANDARD.—The term ‘ap-
5
plicable standard’, with respect to an in vitro clinical 
6
test, means a reasonable assurance of analytical and 
7
clinical validity, except that such term— 
8
‘‘(A) with respect to test instruments, 
9
means a reasonable assurance of analytical va-
10
lidity; and 
11
‘‘(B) with respect to articles for taking or 
12
deriving specimens from the human body for 
13
purposes described in clause (i) or (ii) of section 
14
201(ss)(1)(A) means a reasonable assurance of 
15
analytical validity and, where applicable, safety. 
16
‘‘(3) CLINICAL
USE.—The term ‘clinical use’ 
17
means the operation, application, or functioning of 
18
an in vitro clinical test in connection with human 
19
specimens, including patient, consumer, and donor 
20
specimens, for the purpose for which it is intended 
21
as described in section 201(ss)(1)(A). 
22
‘‘(4) CLINICAL
VALIDITY.—The term ‘clinical 
23
validity’ means the ability of an in vitro clinical test 
24
01:17 Mar 17, 2020
H6102
8 
•HR 6102 IH
to achieve the purpose for which it is intended as de-
1
scribed in section 201(ss)(1)(A). 
2
‘‘(5) CROSS-REFERENCED
TEST.—The term 
3
‘cross-referenced test’ means an in vitro clinical test 
4
that references in its labeling the name or intended 
5
use of another medical product that is not an in 
6
vitro clinical test. 
7
‘‘(6) DEVELOP.—The term ‘develop’, with re-
8
spect to an in vitro clinical test, means— 
9
‘‘(A) 
designing, 
validating, 
producing, 
10
manufacturing, remanufacturing, propagating, 
11
or assembling an in vitro clinical test; 
12
‘‘(B) importing an in vitro clinical test; 
13
‘‘(C) modifying an in vitro clinical test ini-
14
tially developed by a different person in a man-
15
ner that— 
16
‘‘(i) changes any of the listing ele-
17
ments that define indications for use speci-
18
fied 
in 
paragraph 
(10), 
performance 
19
claims, or, as applicable, the safety of such 
20
in vitro clinical test; or 
21
‘‘(ii) affects the analytical or clinical 
22
validity of the in vitro clinical test as in-
23
tended by the developer; or 
24
01:17 Mar 17, 2020
H6102
9 
•HR 6102 IH
‘‘(D) adopting, using, or disseminating for 
1
use as an in vitro clinical test an article not 
2
previously intended for clinical use. 
3
‘‘(7) DEVELOPER.—The term ‘developer’ means 
4
a person who engages in an activity described in 
5
paragraph (6) for clinical use. 
6
‘‘(8) FIRST OF A KIND.—The term ‘first-of-a- 
7
kind’ means, with respect to an in vitro clinical test, 
8
a test that has an intended use and a combination 
9
of the elements specified in paragraph (10) that dif-
10
fer from the intended use and such elements of 
11
other in vitro clinical tests that already are legally 
12
available in the United States. 
13
‘‘(9) HIGH-RISK.— 
14
‘‘(A) IN
GENERAL.—Subject to subpara-
15
graph (B), the term ‘high-risk’, with respect to 
16
an in vitro clinical test or category of in vitro 
17
clinical tests, means that an undetected inac-
18
curate result from such test or category— 
19
‘‘(i) presents potential unreasonable 
20
risk for serious or irreversible harm or 
21
death to a patient or patients, or would 
22
otherwise cause serious harm to the public 
23
health; or 
24
01:17 Mar 17, 2020
H6102
10 
•HR 6102 IH
‘‘(ii) is potentially likely to result in 
1
the absence, delay, or discontinuation of 
2
life-supporting or life-sustaining medical 
3
treatment. 
4
‘‘(B) EXCEPTION.—The term ‘high-risk’ 
5
does not include an in vitro clinical test de-
6
scribed in subparagraph (A) if mitigating meas-
7
ures are established and applied to sufficiently 
8
mitigate the risk of inaccurate results as de-
9
scribed in subparagraph (A), including— 
10
‘‘(i) the degree to which the tech-
11
nology for the intended use of the in vitro 
12
clinical test is well-characterized, and the 
13
criteria for performance of the test are 
14
well-established to be sufficient for the in-
15
tended use; and 
16
‘‘(ii) the clinical circumstances under 
17
which the in vitro clinical test is used, and 
18
the availability of other tests (such as con-
19
firmatory or adjunctive tests) or relevant 
20
material standards. 
21
‘‘(10) INDICATIONS FOR USE.—The term ‘indi-
22
cations for use’ means one or more in vitro clinical 
23
tests that have all of the following notification ele-
24
ments in common: 
25
01:17 Mar 17, 2020
H6102
11 
•HR 6102 IH
‘‘(A) Substance or substances measured by 
1
the in vitro clinical test, such as an analyte, 
2
protein, or pathogen. 
3
‘‘(B) Test method. 
4
‘‘(C) Test purpose or purposes, as de-
5
scribed in section 201(ss)(1)(A). 
6
‘‘(D) Diseases or conditions for which the 
7
in vitro clinical test is intended for use, includ-
8
ing intended patient populations. 
9
‘‘(E) Context of use, such as in a clinical 
10
laboratory, in a health care facility, prescription 
11
home use, over-the-counter use, or direct-to- 
12
consumer testing. 
13
‘‘(11) INSTRUMENT.—The term ‘instrument’ 
14
means an in vitro clinical test that is hardware in-
15
tended by the hardware’s developer to be used with 
16
one or more in vitro clinical tests to generate a clin-
17
ical test result, including software used to effectuate 
18
the hardware’s functionality. 
19
‘‘(12) INSTRUMENT FAMILY.—The term ‘instru-
20
ment family’ means more than one instrument for 
21
which the developer demonstrates and documents, 
22
with respect to all such instruments, that all— 
23
01:17 Mar 17, 2020
H6102
12 
•HR 6102 IH
‘‘(A) have the same basic architecture, de-
1
sign, and performance characteristics, such as 
2
tolerance limits and signal range; 
3
‘‘(B) have the same intended use or uses 
4
and function; 
5
‘‘(C) share the same measurement prin-
6
ciples, detection methods, and reaction condi-
7
tions; and 
8
‘‘(D) produce the same or similar analyt-
9
ical results from samples of the same specimen 
10
type or types. 
11
‘‘(13) LABORATORY
OPERATIONS.—The term 
12
‘laboratory operations’— 
13
‘‘(A) means the conduct of a laboratory ex-
14
amination or other laboratory procedure on ma-
15
terials derived from the human body, including 
16
the conduct of an in vitro clinical test and asso-
17
ciated activities within or under the oversight of 
18
a laboratory and not related to the design of an 
19
in vitro clinical test; and 
20
‘‘(B) includes— 
21
‘‘(i) performing pre-analytical and 
22
post-analytical processes for an in vitro 
23
clinical test; 
24
01:17 Mar 17, 2020
H6102
13 
•HR 6102 IH
‘‘(ii) conducting standard operating 
1
procedures; and 
2
‘‘(iii) preparing reagents or other test 
3
materials that do not meet the definition of 
4
a in vitro clinical test for clinical use under 
5
section 201(ss). 
6
‘‘(14) LOW-RISK.—The term ‘low-risk’, with re-
7
spect to an in vitro clinical test or category of in 
8
vitro clinical tests, means that— 
9
‘‘(A) an undetected inaccurate result from 
10
such in vitro clinical test, or such category of 
11
in vitro clinical tests, when used as intended— 
12
‘‘(i) would cause minimal or no harm, 
13
or minimal or no disability, or immediately 
14
reversible harm, or would lead to only a re-
15
mote risk of adverse patient impact or ad-
16
verse public health impact; or 
17
‘‘(ii) could cause non-life threatening 
18
injury, harm that is medically reversible, or 
19
a delay in necessary treatment; or 
20
‘‘(B) mitigating measures are sufficient to 
21
ensure the test meets the requirements of sub-
22
paragraph (A) 
23
‘‘(15) 
MITIGATING
MEASURES.—The 
term 
24
‘mitigating measures’— 
25
01:17 Mar 17, 2020
H6102
14 
•HR 6102 IH
‘‘(A) means requirements that the Sec-
1
retary determines, based on available evidence, 
2
are necessary— 
3
‘‘(i) for an in vitro clinical test, or a 
4
category of in vitro clinical tests, to meet 
5
the applicable standard; or 
6
‘‘(ii) to mitigate the risk of harm en-
7
suing from an inaccurate result or mis-
8
interpretation of any result; and 
9
‘‘(B) includes, as appropriate, applicable 
10
requirements regarding labeling, performance 
11
standards, performance testing, submission of 
12
clinical data, advertising, website posting of in-
13
formation, clinical studies, postmarket surveil-
14
lance, user comprehension studies, training, and 
15
conformance to standards. 
16
‘‘(16) 
SPECIMEN
RECEPTACLE.—The 
term 
17
‘specimen receptacle’ means an in vitro clinical test 
18
specifically intended for the holding, storing, or 
19
transporting of specimens derived from the human 
20
body or for in vitro examination for purposes de-
21
scribed in clause (i) or (ii) of section 201(ss)(1)(A). 
22
‘‘(17) TECHNOLOGY.—The term ‘technology’— 
23
‘‘(A) means a developer’s grouping of in 
24
vitro clinical tests that do not significantly dif-
25
01:17 Mar 17, 2020
H6102
15 
•HR 6102 IH
fer in control mechanisms, energy sources, or 
1
operating principals and for which design, de-
2
velopment, and manufacturing, including ana-
3
lytical and clinical validation as applicable, of 
4
the tests would be addressed in a similar man-
5
ner or through similar procedures; and 
6
‘‘(B) may include clot detection, colori-
7
metric 
(non-immunoassay), 
electrochemical 
8
(non-immunoassay), 
enzymatic 
(non- 
9
immunoassay), flow cytometry, fluorometry 
10
(non-immunoassay), immunoassay, mass spec-
11
trometry or chromatography (such as HPLC), 
12
microbial culture, next generation sequencing 
13
(also known as ‘NGS’), nephlometric or turbi-
14
dimetric (non-immunoassay), singleplex or mul-
15
tiplex non-NGS nucleic acid analysis, single- 
16
based technology, spectroscopy, and any other 
17
technology, as the Secretary determines appro-
18
priate. 
19
‘‘(18) TEST.—The term ‘test’, unless otherwise 
20
provided, means an in vitro clinical test. 
21
‘‘(19) VALID SCIENTIFIC EVIDENCE.—The term 
22
‘valid scientific evidence’— 
23
‘‘(A) means, with respect to an in vitro 
24
clinical test, evidence— 
25
01:17 Mar 17, 2020
H6102
16 
•HR 6102 IH
‘‘(i) that has been generated and eval-
1
uated by persons qualified by training or 
2
experience to do so, using procedures gen-
3
erally accepted by other persons so quali-
4
fied; and 
5
‘‘(ii) from which it can be fairly and 
6
responsibly concluded by qualified experts 
7
whether the applicable standard has been 
8
met by the in vitro clinical test for its in-
9
tended use; and 
10
‘‘(B) may include evidence described in 
11
subparagraph (A) consisting of— 
12
‘‘(i) peer-reviewed literature; 
13
‘‘(ii) clinical guidelines; 
14
‘‘(iii) reports of significant human ex-
15
perience with an in vitro clinical test; 
16
‘‘(iv) bench studies; 
17
‘‘(v) case studies or histories; 
18
‘‘(vi) clinical data; 
19
‘‘(vii) consensus standards; 
20
‘‘(viii) reference standards; 
21
‘‘(ix) data registries; 
22
‘‘(x) postmarket data; 
23
‘‘(xi) real world data; 
24
‘‘(xii) clinical trials; and 
25
01:17 Mar 17, 2020
H6102
17 
•HR 6102 IH
‘‘(xiii) data collected in countries 
1
other than the United States if such data 
2
are demonstrated to be adequate for the 
3
purpose of making a regulatory determina-
4
tion under the applicable standard in the 
5
United States. 
6
‘‘(20) WELL-CHARACTERIZED.—The term ‘well- 
7
characterized’, with respect to an in vitro clinical 
8
test, means well-established and well-recognized by 
9
the scientific or clinical community, if adequately 
10
evidenced by one or more of the following: 
11
‘‘(A) Peer-reviewed literature. 
12
‘‘(B) Practice guidelines. 
13
‘‘(C) Consensus standards. 
14
‘‘(D) Recognized standards of care. 
15
‘‘(E) Technology in use for many years. 
16
‘‘(F) Scientific publication by multiple 
17
sites. 
18
‘‘(G) Adoption by the scientific or clinical 
19
community. 
20
‘‘(H) Real world data. 
21
‘‘SEC. 587A. APPLICABILITY. 
22
‘‘(a) IN GENERAL.— 
23
‘‘(1) APPLICABILITY OF THIS SUBCHAPTER.— 
24
01:17 Mar 17, 2020
H6102
18 
•HR 6102 IH
‘‘(A) IN
GENERAL.—An in vitro clinical 
1
test shall be subject to the requirements of this 
2
subchapter, except as otherwise provided this 
3
subchapter. 
4
‘‘(B) INTERSTATE
COMMERCE.—Any in 
5
vitro clinical test that is offered for clinical use 
6
in the United States is deemed to be introduced 
7
into interstate commerce for purposes of enforc-
8
ing the requirements of this Act. 
9
‘‘(C) NON-APPLICABLE
REQUIREMENT.— 
10
Subject to any exemption or exclusion in this 
11
section, an in vitro clinical test shall not be sub-
12
ject to any provision or requirement of this Act 
13
other than this subchapter unless such other 
14
provision or requirement— 
15
‘‘(i) applies expressly to in vitro clin-
16
ical tests; or 
17
‘‘(ii) describes the authority of the 
18
Secretary when regulating such in vitro 
19
clinical tests or subset of in vitro clinical 
20
tests, with respect to— 
21
‘‘(I) all articles regulated by the 
22
Secretary pursuant to this Act; or 
23
‘‘(II) a subset of such articles 
24
that includes in vitro clinical tests. 
25
01:17 Mar 17, 2020
H6102
19 
•HR 6102 IH
‘‘(2) LABORATORIES AND BLOOD AND TISSUE 
1
ESTABLISHMENTS.— 
2
‘‘(A) RELATION TO LABORATORY CERTIFI-
3
CATION
PURSUANT
TO
SECTION
353
OF
THE 
4
PHSA.—Nothing in this subchapter shall be 
5
construed to modify the authority of the Sec-
6
retary with respect to laboratories or clinical 
7
laboratories under section 353 of the Public 
8
Health Service Act. 
9
‘‘(B) AVOIDING DUPLICATION.—In imple-
10
menting this subchapter, the Secretary shall 
11
avoid issuing or enforcing regulations that are 
12
duplicative of regulations under section 353. 
13
‘‘(C) BLOOD
AND
TISSUE.—Nothing in 
14
this subchapter shall be construed to modify the 
15
authority of the Secretary with respect to lab-
16
oratories, establishments, or other facilities to 
17
the extent they are engaged in the propagation, 
18
manufacture, or preparation, including filling, 
19
testing, labeling, packaging, and storage, of 
20
blood, blood components, human cells, tissues, 
21
or tissue products under this Act or section 351 
22
or 361 of the Public Health Service Act. 
23
‘‘(3) PRACTICE OF MEDICINE.— 
24
01:17 Mar 17, 2020
H6102
20 
•HR 6102 IH
‘‘(A) IN GENERAL.—Nothing in this sub-
1
chapter shall be construed to limit or interfere 
2
with the authority of a health care practitioner 
3
to prescribe or administer any legally marketed 
4
in vitro clinical test for any condition or disease 
5
within a health care practitioner-patient rela-
6
tionship pursuant to applicable Federal or State 
7
law. 
8
‘‘(B) RULES OF CONSTRUCTION.— 
9
‘‘(i) SALE, 
DISTRIBUTION, 
LABEL-
10
ING.—Nothing in this paragraph shall be 
11
construed to limit the authority of the Sec-
12
retary to establish or enforce restrictions 
13
on the sale, distribution, or labeling of an 
14
in vitro clinical test under this Act. 
15
‘‘(ii) PROMOTION
OF
UNAPPROVED 
16
USES.—Nothing in this paragraph shall be 
17
construed to alter any prohibition on the 
18
promotion of unapproved uses of legally 
19
marketed in vitro clinical tests. 
20
‘‘(4) SPECIAL RULE.— 
21
‘‘(A) PREMARKET REVIEW APPLICABLE.— 
22
Notwithstanding the exemptions from pre-
23
market review under section 587B set forth in 
24
subsections (b), (c), (d), (e), (f), (g), (h), (j), 
25
01:17 Mar 17, 2020
H6102
21 
•HR 6102 IH
and (k) an in vitro clinical test (including any 
1
article for taking or deriving specimens) shall 
2
be subject to the requirements of section 587B 
3
if the Secretary determines, in accordance with 
4
subparagraph (B), that— 
5
‘‘(i)(I) there is insufficient valid sci-
6
entific evidence to support the analytical 
7
validity or the clinical validity of such in 
8
vitro clinical test; and 
9
‘‘(II) such in vitro clinical test is 
10
being offered by its developer with materi-
11
ally deceptive or fraudulent analytical or 
12
clinical claims; 
13
‘‘(ii) it is reasonably possible that 
14
such in vitro clinical test will cause serious 
15
adverse health consequences; or 
16
‘‘(iii) in the case of specimen recep-
17
tacles, there is sufficient valid scientific 
18
evidence indicating that a specimen recep-
19
tacle did not perform as intended, will not 
20
support the analytical validity of tests with 
21
which it is used, or as applicable, is not 
22
safe for use. 
23
‘‘(B) PROCESS.— 
24
01:17 Mar 17, 2020
H6102
22 
•HR 6102 IH
‘‘(i) REQUEST FOR INFORMATION.—If 
1
the Secretary has valid scientific evidence 
2
indicating that the criteria listed in sub-
3
paragraph (A) apply to an in vitro clinical 
4
test, the Secretary may request that the 
5
developer of the test submit information— 
6
‘‘(I) pertaining to such criteria; 
7
and 
8
‘‘(II) establishing the basis for 
9
any claimed exemption from pre-
10
market review. 
11
‘‘(ii) DEADLINE FOR SUBMITTING IN-
12
FORMATION.—Upon receiving a request for 
13
information under clause (i), the developer 
14
of an in vitro clinical test shall submit the 
15
information within 30 days of such receipt. 
16
‘‘(iii) REVIEW DEADLINE.—Upon re-
17
ceiving a submission under clause (ii), the 
18
Secretary shall— 
19
‘‘(I) review the submitted infor-
20
mation within 60 calendar days of 
21
such receipt; and 
22
‘‘(II) determine whether the cri-
23
teria listed in subparagraph (A) apply 
24
to the in vitro clinical test. 
25
01:17 Mar 17, 2020
H6102
23 
•HR 6102 IH
‘‘(iv) 
PREMARKET
REVIEW
RE-
1
QUIRED.— 
2
‘‘(I) IN
GENERAL.—If the Sec-
3
retary finds that the criteria listed in 
4
subparagraph (A) apply to the in vitro 
5
clinical test, the developer shall— 
6
‘‘(aa) promptly, and not 
7
later than 90 days after the date 
8
of receipt of such information, 
9
submit an application for pre-
10
market review of the test under 
11
section 587B; or 
12
‘‘(bb) cease to market the 
13
test. 
14
‘‘(II) 
EXTENSION.—The 
Sec-
15
retary may grant an extension to a 
16
developer of the 90-day time period 
17
under subclause (I)(aa), as appro-
18
priate. 
19
‘‘(v) CONTINUED
MARKETING.—Dur-
20
ing the period beginning on the date of a 
21
request for information under clause (ii) 
22
and ending on the date of the disposition 
23
of an application for premarket review of 
24
the in vitro clinical test under section 
25
01:17 Mar 17, 2020
H6102
24 
•HR 6102 IH
587B, the developer of the test may con-
1
tinue to market the test for clinical use, 
2
unless the Secretary issues an order to the 
3
developer under clause (vi) to immediately 
4
cease distribution of the test. 
5
‘‘(vi) ORDER
TO
CEASE
DISTRIBU-
6
TION.— 
7
‘‘(I) IN GENERAL.—If the devel-
8
oper of an in vitro clinical test fails to 
9
submit an application for premarket 
10
review of the test by the deadline ap-
11
plicable under clause (iv), or the Sec-
12
retary finds that the criteria listed in 
13
subparagraph (A) apply to an in vitro 
14
clinical test and that it is in the best 
15
interest of the public health, the Sec-
16
retary may issue an order, within 10 
17
calendar days of the applicable dead-
18
line or finding by the Secretary, re-
19
quiring the developer of such in vitro 
20
clinical test, and any other appro-
21
priate person (including a distributor 
22
or retailer of the in vitro clinical test) 
23
to immediately— 
24
01:17 Mar 17, 2020
H6102
25 
•HR 6102 IH
‘‘(aa) cease distribution of 
1
the test pending approval of an 
2
application for premarket review 
3
of the test under section 587B; 
4
and 
5
‘‘(bb) notify health profes-
6
sionals and other user facilities of 
7
the order to cease distribution 
8
and advise health care profes-
9
sionals to cease use of such in 
10
vitro clinical test. 
11
‘‘(II) HEARING
AND
REVIEW.— 
12
An order under subclause (I) shall 
13
provide the person subject to the 
14
order with an opportunity for an in-
15
formal hearing, to be held not later 
16
than 10 days after the date of the 
17
issuance of the order, on the actions 
18
required by the order and on whether 
19
the order should be amended to re-
20
quire a recall of such in vitro clinical 
21
test. If, after providing an opportunity 
22
for such a hearing, the Secretary de-
23
termines that inadequate grounds 
24
exist to support the actions required 
25
01:17 Mar 17, 2020
H6102
26 
•HR 6102 IH
by the order, the Secretary shall ter-
1
minate the order within 30 days of 
2
the hearing. Upon terminating an 
3
order, the Secretary shall provide 
4
written notice of such termination to 
5
the developer. 
6
‘‘(vii) AMENDMENT TO REQUIRE RE-
7
CALL.—If the Secretary determines that 
8
an order issued under clause (vi) should be 
9
amended to include a recall of the in vitro 
10
clinical test with respect to which the order 
11
was issued, the Secretary shall amend the 
12
order to require a recall. In such amended 
13
order, the Secretary shall specify a time-
14
table in which the in vitro clinical test re-
15
call will occur and shall require periodic re-
16
ports to the Secretary describing the 
17
progress of the recall. Upon termination of 
18
the recall, the Secretary shall provide writ-
19
ten notice of such termination to the devel-
20
oper. 
21
‘‘(viii) EFFECT OF TEST APPROVAL.— 
22
Any order issued under this paragraph 
23
with respect to an in vitro clinical test 
24
shall cease to be in effect if such test is 
25
01:17 Mar 17, 2020
H6102
27 
•HR 6102 IH
granted approval under section 587B, pro-
1
vided that the in vitro clinical test is devel-
2
oped and offered for clinical use in accord-
3
ance with such approval. 
4
‘‘(5) EMERGENCY USE.— 
5
‘‘(A) IN GENERAL.—In the case of a public 
6
health emergency under section 319 of the Pub-
7
lic Health Service Act, an in vitro clinical test 
8
is exempt from the requirements of this sub-
9
chapter and may be lawfully marketed in ac-
10
cordance with subparagraph (B). 
11
‘‘(B) CRITERIA.—An in vitro clinical test 
12
may be lawfully marketed in accordance with 
13
the exemption described in subparagraph (A) if 
14
such test— 
15
‘‘(i) is authorized for an emergency 
16
use under section 564(b); or 
17
‘‘(ii) is developed and used in labora-
18
tories for which a certificate is in effect 
19
under section 353 of the Public Health 
20
Service Act to conduct high-complexity 
21
testing and the developer— 
22
‘‘(I) is pursuing an emergency 
23
use authorization under section 564 
24
and provides updates to the Secretary 
25
01:17 Mar 17, 2020
H6102
28 
•HR 6102 IH
on efforts to pursue such authoriza-
1
tion; 
2
‘‘(II) validates such in vitro clin-
3
ical test prior to use; 
4
‘‘(III) notifies the Secretary of 
5
the assay validation; and 
6
‘‘(IV) includes a statement to-
7
gether with the results of the test that 
8
reads: ‘This IVCT was developed for 
9
use as a part of a response to a public 
10
health emergency. This test has not 
11
been reviewed by the Food and Drug 
12
Administration.’. 
13
‘‘(C) DISPOSITION OF PRODUCT.—With re-
14
spect to a previously unapproved in vitro clin-
15
ical test or an in vitro clinical tests with an un-
16
approved use, for which an emergency use au-
17
thorization under section 564(b) ceases to be 
18
effective, the Secretary shall consult with the 
19
manufacturer of such product with respect to 
20
the appropriate disposition of the product. 
21
‘‘(D) STREAMLINING OF APPLICATION RE-
22
VIEW.—A developer may include any data or in-
23
formation already submitted to the Secretary 
24
within the emergency use authorization as a 
25
01:17 Mar 17, 2020
H6102
29 
•HR 6102 IH
part of a premarket application under section 
1
587B or a technology certification application 
2
under section 587D. 
3
‘‘(b) COMPONENTS AND PARTS.— 
4
‘‘(1) EXEMPTION.— 
5
‘‘(A) IN
GENERAL.—Subject to subpara-
6
graph (B), a component, part, or raw material 
7
described in section 201(ss)(1)(F) is exempt 
8
from the requirements of this subchapter if it 
9
is— 
10
‘‘(i) intended for further development 
11
as described in paragraph (2); or 
12
‘‘(ii) is otherwise to be regulated 
13
based on its risk when used as intended by 
14
the developer, notwithstanding its subse-
15
quent use by a developer as a component, 
16
part, or raw material of another in vitro 
17
clinical test. 
18
‘‘(B) 
INAPPLICABILITY
TO
OTHER 
19
TESTS.—Notwithstanding subparagraph (A), an 
20
in vitro clinical test that is described in section 
21
201(ss)(1)(B) and that uses a component or 
22
part described in such subparagraph shall be 
23
subject to the requirements of this subchapter, 
24
01:17 Mar 17, 2020
H6102
30 
•HR 6102 IH
unless the test is otherwise exempted under this 
1
section. 
2
‘‘(2) FURTHER DEVELOPMENT.—A component, 
3
part, or raw material (as described in paragraph 
4
(1)(A)) is intended for further development (for pur-
5
poses of such paragraph) if— 
6
‘‘(A) it is intended solely for use in the de-
7
velopment of another in vitro clinical test; and 
8
‘‘(B) in the case of such a test that is in-
9
troduced or delivered for introduction into 
10
interstate commerce after the date of enactment 
11
of the Verifying Accurate Leading-edge IVCT 
12
Development Act of 2020, the labeling of such 
13
test bears the following statement: ‘This prod-
14
uct is intended solely for further development of 
15
an in vitro clinical test and is exempt from 
16
FDA regulation. This product must be evalu-
17
ated by the in vitro clinical test developer if it 
18
is used with or in the development of an in vitro 
19
clinical test.’. 
20
‘‘(c) GRANDFATHERED TESTS.— 
21
‘‘(1) EXEMPTION.—An in vitro clinical test that 
22
meets the criteria set forth in paragraph (2) is ex-
23
empt from the requirements of this subchapter, ex-
24
cept as provided under section 587A(a)(4), the reg-
25
01:17 Mar 17, 2020
H6102
31 
•HR 6102 IH
istration and listing requirements under section 
1
587I, and the adverse reporting requirements under 
2
section 587L, and may be lawfully marketed subject 
3
to the other applicable requirements of this Act, if— 
4
‘‘(A) each test report template for the test 
5
bears a statement of adequate prominence that 
6
reads as follows: ‘This in vitro clinical test was 
7
developed and first introduced prior to the date 
8
of enactment of the Verifying Accurate Lead-
9
ing-edge IVCT Development Act of 2020 and 
10
has not been reviewed by the Food and Drug 
11
Administration.’; and 
12
‘‘(B) the developer of the test— 
13
‘‘(i) maintains documentation dem-
14
onstrating that the test meets and con-
15
tinues to meet the criteria set forth in 
16
paragraph (2); and 
17
‘‘(ii) makes such documentation avail-
18
able to the Secretary upon request. 
19
‘‘(2) CRITERIA FOR EXEMPTION.—An in vitro 
20
clinical test is exempt as specified in paragraph (1) 
21
if the test— 
22
‘‘(A)(i) was first offered for clinical use by 
23
such laboratory before the date of enactment of 
24
01:17 Mar 17, 2020
H6102
32 
•HR 6102 IH
the Verifying Accurate Leading-edge IVCT De-
1
velopment Act of 2020; 
2
‘‘(ii) was developed by a clinical laboratory 
3
for which a certificate is in effect under section 
4
353 of the Public Health Service Act that 
5
meets the requirements under section 353 for 
6
performing high-complexity testing; and 
7
‘‘(iii) is performed— 
8
‘‘(I) in the same clinical laboratory in 
9
which it was developed; 
10
‘‘(II) by another clinical laboratory for 
11
which a certificate is in effect under sec-
12
tion 353 within the same corporate organi-
13
zation and having common ownership by 
14
the same parent corporation; or 
15
‘‘(III) by a laboratory within a public 
16
health laboratory network coordinated or 
17
managed by the Centers for Disease Con-
18
trol and Prevention; 
19
‘‘(B) does not have in effect an approval 
20
under section 515, a clearance under section 
21
510(k), 
an 
authorization 
under 
section 
22
513(f)(2), or an approval under section 520(m); 
23
and 
24
01:17 Mar 17, 2020
H6102
33 
•HR 6102 IH
‘‘(C) is not modified on or after the date 
1
of enactment of the Verifying Accurate Lead-
2
ing-edge IVCT Development Act of 2020 by its 
3
initial developer (or another person) in a man-
4
ner such that the test is a new in vitro clinical 
5
test under subsection (l). 
6
‘‘(3) MODIFICATIONS.—In the case of a modi-
7
fication to an vitro clinical test that is exempt as 
8
specified in paragraph (1) or determines that such 
9
modification is otherwise not subject to premarket 
10
review pursuant to section 587A(l), the test con-
11
tinues to qualify for such exemption if the person 
12
modifying such test— 
13
‘‘(A) documents each such modification 
14
and maintains a summary of the basis for such 
15
determination; and 
16
‘‘(B) provides such documentation and 
17
summary to the Secretary upon request or in-
18
spection. 
19
‘‘(d) TESTS EXEMPT FROM SECTION 510(k).— 
20
‘‘(1) EXEMPTION.—An in vitro clinical test is 
21
exempt from premarket review under section 587B 
22
and may be lawfully marketed subject to the other 
23
applicable requirements of this Act, if the in vitro 
24
clinical test— 
25
01:17 Mar 17, 2020
H6102
34 
•HR 6102 IH
‘‘(A)(i) was offered for clinical use prior to 
1
the date of enactment of the Verifying Accurate 
2
Leading-edge IVCT Development Act of 2020; 
3
and 
4
‘‘(ii) immediately prior to such date of en-
5
actment was exempt pursuant to subsection (l) 
6
or (m)(2) of section 510 from the requirements 
7
for submission of a report under section 510(k); 
8
or 
9
‘‘(B)(i) was not offered for clinical use 
10
prior to such date of enactment; 
11
‘‘(ii) is not a test platform; and 
12
‘‘(iii) falls within a category of tests that 
13
was exempt from the requirements for submis-
14
sion of a report under section 510(k) as of such 
15
date of enactment (including class II devices 
16
and excluding class I devices described in sec-
17
tion 510(l)). 
18
‘‘(2) EFFECT ON SPECIAL CONTROLS.—For any 
19
in vitro clinical test, or category of in vitro clinical 
20
tests, that is exempt from premarket review based 
21
on the criteria in paragraph (2), any special control 
22
that applied to a device within a predecessor cat-
23
egory immediately prior to the date of enactment of 
24
Verifying Accurate Leading-edge IVCT Development 
25
01:17 Mar 17, 2020
H6102
35 
•HR 6102 IH
Act of 2020 shall be deemed a mitigating measure 
1
applicable under section 587E to an in vitro clinical 
2
test within the successor category, except to the ex-
3
tent such mitigating measure is withdrawn or 
4
changed in accordance with section 587E. 
5
‘‘(3) NEAR-PATIENT TESTING.—Not later than 
6
1 year after the date of enactment of the Verifying 
7
Accurate Leading-edge IVCT Development Act of 
8
2020, the Secretary shall issue draft guidance indi-
9
cating categories of tests that shall be exempt from 
10
premarket review under section 587B when offered 
11
for near-patient testing (point of care), which were 
12
not exempt from submission of a report under sec-
13
tion 510(k) pursuant to subsection (l) or (m)(2) of 
14
section 510 and regulations imposing limitations on 
15
exemption for in vitro devices intended for near-pa-
16
tient testing (point of care). 
17
‘‘(e) LOW-RISK TESTS.— 
18
‘‘(1) EXEMPTION.—An in vitro clinical test is 
19
exempt from premarket review under section 587B 
20
and may be lawfully marketed subject to the other 
21
applicable requirements of this Act, including section 
22
587I(b)(6), if such test meets the definition of low- 
23
risk under section 587. 
24
‘‘(2) LIST OF LOW-RISK TESTS.— 
25
01:17 Mar 17, 2020
H6102
36 
•HR 6102 IH
‘‘(A) IN
GENERAL.—The Secretary shall 
1
maintain, and make publicly available on the 
2
website of the Food and Drug Administration, 
3
a list of in vitro clinical tests, and categories of 
4
in vitro clinical tests, that are low-risk in vitro 
5
clinical tests for purposes of the exemption 
6
under this subsection. 
7
‘‘(B) INCLUSION.—The list under subpara-
8
graph (A) shall consist of— 
9
‘‘(i) all in vitro clinical tests and cat-
10
egories of in vitro clinical tests that are ex-
11
empt from premarket review pursuant to 
12
subsection (d)(1) or (d)(3); and 
13
‘‘(ii) all in vitro clinical tests and cat-
14
egories of in vitro clinical tests that are 
15
designated by the Secretary pursuant to 
16
subparagraph (C) as low-risk for purposes 
17
of this subsection. 
18
‘‘(C) DESIGNATION
OF
TESTS
AND
CAT-
19
EGORIES.—Without regard to subchapter II of 
20
chapter 5 of title 5, United States Code, the 
21
Secretary may designate, in addition to the 
22
tests and categories described in subparagraph 
23
(B)(i), additional in vitro clinical tests, and cat-
24
egories of in vitro clinical tests, as low-risk in 
25
01:17 Mar 17, 2020
H6102
37 
•HR 6102 IH
vitro clinical tests for purposes of the exemption 
1
under this subsection. The Secretary may make 
2
such a designation on the Secretary’s own ini-
3
tiative or in response to a request by any per-
4
son. In making such a designation for a test or 
5
category of tests, the Secretary shall consider— 
6
‘‘(i) whether the test, or category of 
7
tests, is low-risk (as defined in section 
8
587); and 
9
‘‘(ii) such other factors as the Sec-
10
retary determines to be relevant to the pro-
11
tection of the public health. 
12
‘‘(f) MANUAL TESTS.— 
13
‘‘(1) EXEMPTION.—An in vitro clinical test is 
14
exempt from all requirements of this subchapter if 
15
the output of such in vitro clinical test is the result 
16
of direct, manual observation, without the use of 
17
automated instrumentation or software for inter-
18
mediate or final interpretation, by a qualified labora-
19
tory professional, and such in vitro clinical test— 
20
‘‘(A) is designed, manufactured, and used 
21
within a single clinical laboratory for which a 
22
certificate is in effect under section 353 of the 
23
Public Health Service Act that meets the re-
24
01:17 Mar 17, 2020
H6102
38 
•HR 6102 IH
quirements under section 353 for performing 
1
high-complexity testing; 
2
‘‘(B) is not a high-risk test, or is a high- 
3
risk test that the Secretary has determined 
4
meets at least one condition in paragraph (2) 
5
and is otherwise appropriate for this exemption; 
6
and 
7
‘‘(C) is not intended for testing donors, do-
8
nations, and recipients of blood, blood compo-
9
nents, human cells, tissues, cellular-based prod-
10
ucts, or tissue-based products. 
11
‘‘(2) HIGH-RISK TEST LIMITATION OR CONDI-
12
TION.—A high-risk test may be exempt under para-
13
graph (1) from the requirements of this subchapter 
14
only if— 
15
‘‘(A) no component or part of such test, in-
16
cluding any reagent, is introduced into inter-
17
state commerce under the exemption under sub-
18
section (b)(1) (relating to components or parts 
19
intended for further development), and any ar-
20
ticle for taking or deriving specimens from the 
21
human body used in conjunction with the test 
22
remains subject to the requirements of this sub-
23
chapter; or 
24
01:17 Mar 17, 2020
H6102
39 
•HR 6102 IH
‘‘(B) the test has been developed in accord-
1
ance with the applicable test design and quality 
2
requirements under section 587J. 
3
‘‘(g) HUMANITARIAN TEST EXEMPTION.— 
4
‘‘(1) IN GENERAL.—An in vitro clinical test is 
5
exempt from premarket review under section 587B 
6
and may be lawfully marketed subject to the other 
7
applicable requirements of this Act, if— 
8
‘‘(A) such in vitro clinical test— 
9
‘‘(i) is intended for use for a disease 
10
or condition for which no more than 
11
10,000 (or such other number determined 
12
by the Secretary) individuals would be sub-
13
ject to negative or positive diagnosis by 
14
such test in the United States per year; 
15
and 
16
‘‘(ii) is not intended to diagnose a 
17
contagious disease or condition that is 
18
highly likely to result in fatal or irrevers-
19
ibly debilitating outcome and for which 
20
prompt and accurate diagnosis offers the 
21
opportunity to mitigate a public health im-
22
pact of the condition; and 
23
‘‘(B) the developer of the test— 
24
01:17 Mar 17, 2020
H6102
40 
•HR 6102 IH
‘‘(i) maintains documentation (which 
1
may include literature citations in special-
2
ized medical journals, textbooks, special-
3
ized medical society proceedings, govern-
4
mental statistics publications, or, if no 
5
such studies or literature citations exist, 
6
credible conclusions from appropriate re-
7
search or surveys) demonstrating that such 
8
test meets and continues to meet the cri-
9
teria described in this paragraph; and 
10
‘‘(ii) makes such documentation avail-
11
able to the Secretary upon request. 
12
‘‘(2) CROSS-REFERENCED TESTS.—In order to 
13
be eligible for an exemption under this subsection, 
14
the developer of a cross-referenced test shall submit 
15
a request under section 587H for informal feedback. 
16
‘‘(h) CUSTOM TESTS AND LOW-VOLUME TESTS.—An 
17
in vitro clinical test is exempt from premarket review 
18
under section 587B, the quality requirements under sec-
19
tion 587J, and the notification requirements under section 
20
587I, and may be lawfully marketed subject to the other 
21
applicable requirements of this Act, if— 
22
‘‘(1) such in vitro clinical test— 
23
‘‘(A) is a low-volume test performed in a 
24
laboratory in which it was developed or devel-
25
01:17 Mar 17, 2020
H6102
41 
•HR 6102 IH
oped in a laboratory within the same corporate 
1
organization with the laboratory in which such 
2
test is performed and is administered to no 
3
more than 5 patients per year, unless otherwise 
4
determined by the Secretary; or 
5
‘‘(B) is a custom test developed or modi-
6
fied to diagnose a unique pathology or physical 
7
condition of a specific patient for which no 
8
other in vitro clinical test is commercially avail-
9
able in the United States, and is— 
10
‘‘(i) not intended for use with respect 
11
to other patients; and 
12
‘‘(ii) after the development of the cus-
13
tom test, not included in any test menu, 
14
template test report, or other promotional 
15
materials, and not otherwise advertised; 
16
and 
17
‘‘(2) the developer of the test— 
18
‘‘(A) 
maintains 
documentation 
dem-
19
onstrating that such test meets and continues 
20
to meet the applicable criteria described in 
21
paragraph (1); 
22
‘‘(B) makes such documentation, such as a 
23
prescription order requesting the custom test 
24
01:17 Mar 17, 2020
H6102
42 
•HR 6102 IH
for an individual patient, available to the Sec-
1
retary upon request; and 
2
‘‘(C) informs the Secretary, on an annual 
3
basis, in a manner prescribed by the Secretary 
4
by guidance, that such test was introduced into 
5
interstate commerce. 
6
‘‘(i) PUBLIC HEALTH SURVEILLANCE ACTIVITIES.— 
7
‘‘(1) IN GENERAL.—The provisions of this sub-
8
chapter shall not apply to a test intended by the de-
9
veloper to be used solely for public health surveil-
10
lance activities, including the collection and testing 
11
of information or biospecimens, conducted, sup-
12
ported, requested, ordered, required, or authorized 
13
by a public health authority. 
14
‘‘(2) LIMITATION.—Such activities— 
15
‘‘(A) are limited to those necessary to 
16
allow a public health authority to identify, mon-
17
itor, assess, or investigate potential public 
18
health signals, onsets of disease outbreaks, or 
19
conditions of public health importance (includ-
20
ing trends, risk factors, patterns in diseases, or 
21
increases in injuries from using consumer prod-
22
ucts); and 
23
‘‘(B) include those associated with pro-
24
viding timely situational awareness and priority 
25
01:17 Mar 17, 2020
H6102
43 
•HR 6102 IH
setting during the course of a threat to the pub-
1
lic health (including natural or man-made dis-
2
asters and deliberate attacks on the United 
3
States). 
4
‘‘(3) EXCLUSION.—An in vitro clinical test is 
5
not excluded from the provisions of this subchapter 
6
if such test is intended for use in making clinical de-
7
cisions for individual patients. 
8
‘‘(j) LAW ENFORCEMENT OR EMPLOYER TESTING.— 
9
An in vitro clinical test that is intended solely for use in 
10
forensic analysis, law enforcement activity, or employment 
11
purposes is exempt from the requirements of this Act. An 
12
in vitro clinical test that is intended for use in making 
13
clinical decisions for individual patients, or whose individ-
14
ually identifiable results may be reported back to an indi-
15
vidual patient or the patient’s health care provider, even 
16
if also intended for law enforcement or employment testing 
17
purposes, is not intended solely for use in law enforcement 
18
or employment testing for purposes of this subsection. 
19
‘‘(k) IN VITRO CLINICAL TESTS UNDER A TECH-
20
NOLOGY CERTIFICATION ORDER.—An in vitro clinical test 
21
that is within the scope of a technology certification order, 
22
as described in section 587D(a)(2), is exempt from pre-
23
market review under section 587B. 
24
‘‘(l) MODIFIED TESTS.— 
25
01:17 Mar 17, 2020
H6102
44 
•HR 6102 IH
‘‘(1) IN
GENERAL.—An in vitro clinical test 
1
that is modified, by the initial developer of the test 
2
or a different person, is a new in vitro clinical test 
3
subject to the requirements of this subchapter if the 
4
modification— 
5
‘‘(A) affects the analytical or clinical valid-
6
ity of such test; 
7
‘‘(B) causes the test to no longer comply 
8
with applicable mitigating measures under sec-
9
tion 587E or restrictions under section 587N; 
10
or 
11
‘‘(C) as applicable, affects the safety of an 
12
article for taking or deriving specimens from 
13
the human body for a purpose described in sec-
14
tion 201(ss)(1). 
15
‘‘(2) 
EXEMPTIONS.—Notwithstanding 
para-
16
graph (1), an in vitro clinical test that is modified 
17
by the initial developer of the test or a different per-
18
son is not a new in vitro clinical test if the modifica-
19
tion— 
20
‘‘(A) is a software update that does not 
21
have an adverse effect on the analytical or clin-
22
ical validity or result in an increased risk to pa-
23
tients and consumers; 
24
01:17 Mar 17, 2020
H6102
45 
•HR 6102 IH
‘‘(B) is made pursuant to methods or cri-
1
teria included in the change protocol premarket 
2
submission, amendment, or supplement ap-
3
proved by the Secretary for the in vitro clinical 
4
test being modified; 
5
‘‘(C) is a labeling change that is appro-
6
priate to address patient or user harm; or 
7
‘‘(D) is a specimen-related modification 
8
that is made to extend specimen stability or 
9
aligns with the data and information submitted 
10
in an approved application for premarket review 
11
under section 587B or an order issued under 
12
section 587D. 
13
‘‘(3) DOCUMENTATION.—When a person modi-
14
fies an in vitro clinical test that was developed by 
15
another person, such modified test is exempt from 
16
the requirements of this subchapter provided that 
17
such person— 
18
‘‘(A) documents the modification that was 
19
made and the basis for determining that the 
20
modification, considering the changes individ-
21
ually and collectively, was not a type of modi-
22
fication described in paragraph (1); and 
23
‘‘(B) provides such documentation to the 
24
Secretary upon request or inspection. 
25
01:17 Mar 17, 2020
H6102
46 
•HR 6102 IH
‘‘(m) INVESTIGATIONAL USE.—An in vitro clinical 
1
test for investigational use is exempt from the require-
2
ments of this Act, except as provided in section 587R. 
3
‘‘(n) TRANSFER OR SALE OF IN VITRO CLINICAL 
4
TESTS.— 
5
‘‘(1) TRANSFER
AND
ASSUMPTION
OF
REGU-
6
LATORY OBLIGATIONS.—If ownership of an in vitro 
7
clinical test is sold or transferred in such manner 
8
that the developer transfers the regulatory submis-
9
sions and obligations applicable under this sub-
10
chapter with respect to the test, the transferee or 
11
purchaser becomes the developer of the test and 
12
shall have all regulatory obligations applicable to 
13
such a test under this subchapter. The transferee or 
14
purchaser shall update the registration and listing 
15
information under section 587I for the in vitro clin-
16
ical test. 
17
‘‘(2) TRANSFER OR SALE OF PREMARKET AP-
18
PROVAL.— 
19
‘‘(A) NOTICE REQUIRED.—If a developer 
20
of an in vitro clinical test transfers or sells the 
21
approval of the in vitro clinical test, the trans-
22
feror or seller shall— 
23
‘‘(i) submit a notice of the transfer or 
24
sale to the Secretary and update the reg-
25
01:17 Mar 17, 2020
H6102
47 
•HR 6102 IH
istration and listing information under sec-
1
tion 587I for the in vitro clinical test; and 
2
‘‘(ii) submit a supplemental applica-
3
tion if required under section 587B(h). 
4
‘‘(B) EFFECTIVE
DATE
OF
APPROVAL 
5
TRANSFER.—A transfer or sale described in 
6
subparagraph (A) shall become effective upon 
7
completion of a transfer or sale described in 
8
paragraph (1) or the approval of a supple-
9
mental application under section 587B(h) if re-
10
quired, whichever is later. The transferee or 
11
purchaser shall update the registration and list-
12
ing information under section 587I for the in 
13
vitro clinical test within 15 calendar days of the 
14
effective date of the transfer or sale. 
15
‘‘(3) TRANSFER OR SALE OF TECHNOLOGY CER-
16
TIFICATION.— 
17
‘‘(A) REQUIREMENTS FOR TRANSFER OR 
18
SALE
OF
TECHNOLOGY
CERTIFICATION.—An 
19
unexpired technology certification can be trans-
20
ferred or sold if the transferee or purchaser— 
21
‘‘(i) is an eligible person under section 
22
587D(b)(1); and 
23
‘‘(ii) maintains, upon such transfer or 
24
sale, the site, test design and quality re-
25
01:17 Mar 17, 2020
H6102
48 
•HR 6102 IH
quirements, 
processes 
and 
procedures 
1
under the scope of technology certification, 
2
and scope of the technology certification 
3
identified in the applicable technology cer-
4
tification order. 
5
‘‘(B) NOTICE REQUIRED.—If a developer 
6
of an in vitro clinical test transfers or sells a 
7
technology certification order that has not ex-
8
pired, the transferor or seller shall submit a no-
9
tice of the transfer or sale to the Secretary and 
10
shall update the registration and listing infor-
11
mation under section 587I for all in vitro clin-
12
ical tests covered by the technology certifi-
13
cation. 
14
‘‘(C) EFFECTIVE
DATE
OF
TECHNOLOGY 
15
CERTIFICATION TRANSFER.—The transfer of a 
16
technology certification shall become effective 
17
upon completion of a transfer or sale described 
18
in subparagraph (A). The transferee or pur-
19
chaser shall update the registration and listing 
20
information under section 587I for the in vitro 
21
clinical test within 30 calendar days of the ef-
22
fective date of the technology certification 
23
transfer. 
24
01:17 Mar 17, 2020
H6102
49 
•HR 6102 IH
‘‘(D) NEW
TECHNOLOGY
CERTIFICATION 
1
REQUIRED.—If the requirements of subclause 
2
(A)(ii) are not met, then the technology certifi-
3
cation order cannot be transferred and the 
4
transferee or purchaser of an in vitro clinical 
5
test must submit an application for technology 
6
certification and obtain a technology certifi-
7
cation order prior to offering the test for clin-
8
ical use. 
9
‘‘(o) GENERAL LABORATORY EQUIPMENT.—Any in-
10
strument that does not produce an analytical result, and 
11
that functions as a component of pre-analytical procedures 
12
related to in vitro clinical tests, is not subject to the re-
13
quirements of this subchapter, provided that— 
14
‘‘(1) the instrument is operating in a clinical 
15
laboratory that is certified under section 353 of the 
16
Public Health Service Act; and 
17
‘‘(2) the instrument can be serviced by the 
18
manufacturer of such instrument or, if that manu-
19
facturer is no longer in business, a third party with 
20
the ability to service such instrument. 
21
‘‘(p) INSTRUMENT FAMILIES.—In the case of an in-
22
strument family, premarket approval under section 
23
587B(d) of one version of the in vitro clinical test is re-
24
quired, and previous and updated versions of the same test 
25
01:17 Mar 17, 2020
H6102
50 
•HR 6102 IH
within such instrument family shall be deemed to be sub-
1
ject to the approval pursuant to that section, unless the 
2
Secretary determines otherwise, as set forth in guidance. 
3
‘‘(q) GENERAL EXEMPTION AUTHORITY.—The Sec-
4
retary may, by order published in the Federal Register 
5
following notice and an opportunity for comment, exempt 
6
a class of persons from any section under this subchapter 
7
upon a finding that such exemption is appropriate for the 
8
protection of the public health and other relevant consider-
9
ations. 
10
‘‘(r) REGULATIONS.—The Secretary may issue regu-
11
lations to implement this subchapter. 
12
‘‘SEC. 587B. PREMARKET REVIEW. 
13
‘‘(a) IN GENERAL.—No person shall introduce or de-
14
liver for introduction into interstate commerce any in vitro 
15
clinical test, unless— 
16
‘‘(1) an approval of an application filed pursu-
17
ant to subsection (c) or (d) is effective with respect 
18
to test; or 
19
‘‘(2) the test is exempt under section 587A 
20
from premarket review under this section. 
21
‘‘(b) TRANSPARENCY AND PREDICTABILITY.— 
22
‘‘(1) PRE-SUBMISSION
MEETING
OR
REQUEST 
23
FOR
INFORMAL
FEEDBACK.—Pursuant to section 
24
587H, prior to filing an application under subsection 
25
01:17 Mar 17, 2020
H6102
51 
•HR 6102 IH
(c) or (d), any person may request a meeting or 
1
written correspondence with the Secretary to discuss 
2
the eligibility of an in vitro clinical test for pre-
3
market review or other information related to the fil-
4
ing of an application. The Secretary shall respond to 
5
such request within 45 calendar days. 
6
‘‘(2) STREAMLINING OF APPLICATIONS.— 
7
‘‘(A) 
PREMARKET
APPLICATION
AND 
8
TECHNOLOGY
CERTIFICATION.—If a person 
9
files a premarket application under this section 
10
and provides any additional documentation re-
11
quired under section 587D, the in vitro clinical 
12
test that is the subject of the application may 
13
be utilized as the representative test reviewed 
14
by the Secretary to provide an approval for 
15
both a premarket application under this section 
16
and a technology certification order under sec-
17
tion 587D. 
18
‘‘(B) REPRESENTATIVE ASSAYS FOR PRE-
19
MARKET APPROVAL.—With respect to a tech-
20
nology certification application filed under sec-
21
tion 587D, the representative test, as described 
22
in subparagraph (A), used to issue a technology 
23
certification order under section 587D shall be 
24
01:17 Mar 17, 2020
H6102
52 
•HR 6102 IH
deemed a test with premarket approval under 
1
this section. 
2
‘‘(c) APPLICATION.— 
3
‘‘(1) FILING.—Any person may file with the 
4
Secretary an application for premarket approval of 
5
an in vitro clinical test. 
6
‘‘(2) APPLICATION
CONTENT.—An application 
7
submitted under paragraph (1) with respect to an in 
8
vitro clinical test shall include the following, in such 
9
format as the Secretary specifies: 
10
‘‘(A) General information regarding the in 
11
vitro clinical test, including— 
12
‘‘(i) the name and address of the ap-
13
plicant; 
14
‘‘(ii) the table of contents for the ap-
15
plication and the identification of the infor-
16
mation the applicant claims as trade secret 
17
or confidential commercial or financial in-
18
formation; 
19
‘‘(iii) a description of the test’s in-
20
tended use; 
21
‘‘(iv) an explanation regarding test 
22
function and any significant performance 
23
characteristics; and 
24
01:17 Mar 17, 2020
H6102
53 
•HR 6102 IH
‘‘(v) an explanation of how the devel-
1
opment and validation activities support 
2
the test meeting the applicable standard. 
3
‘‘(B) A summary of the data and informa-
4
tion in the application for the in vitro clinical 
5
test, including— 
6
‘‘(i) a brief description of any existing 
7
alternative practices or procedures for di-
8
agnosing the disease or condition for which 
9
the in vitro clinical test is intended, as ap-
10
plicable; 
11
‘‘(ii) a brief description of the foreign 
12
and domestic marketing history of the test, 
13
if any, including a list of all countries in 
14
which the test has been marketed and a 
15
list of all countries in which the test has 
16
been withdrawn from marketing for any 
17
reason related to the applicable standard 
18
of the in vitro clinical test, if known by the 
19
applicant; 
20
‘‘(iii) a summary of the any studies 
21
submitted for such test, including a de-
22
scription of the objective of the study, a 
23
description of the experimental design of 
24
the study, a brief description of how the 
25
01:17 Mar 17, 2020
H6102
54 
•HR 6102 IH
data were collected and analyzed, a brief 
1
description of the results of the technical 
2
data submitted, and a brief description of 
3
any nonclinical or clinical studies; 
4
‘‘(iv) a risk assessment of the test; 
5
and 
6
‘‘(v) conclusions drawn from any stud-
7
ies described in clause (iii), including a dis-
8
cussion demonstrating that the data and 
9
information in the application constitute 
10
valid scientific evidence and meet the appli-
11
cable standard under section 587(10), an 
12
explanation of how the development and 
13
validation activities, as applicable, support 
14
that the test meets the applicable standard 
15
under section 587(10), and a discussion of 
16
any adverse effects of the test on health 
17
and proposals to mitigate those risks, if 
18
any. 
19
‘‘(C) The signature of the person filing the 
20
premarket application or an authorized rep-
21
resentative. 
22
‘‘(D) A bibliography of all published re-
23
ports reasonably known to the applicant related 
24
to such test and a discussion of data and infor-
25
01:17 Mar 17, 2020
H6102
55 
•HR 6102 IH
mation relevant to the evaluation of the applica-
1
ble standard that may be met by such test. 
2
‘‘(E) A statement that the applicant be-
3
lieves to the best of the applicant’s knowledge 
4
that all data and information submitted to the 
5
Secretary are truthful and accurate and that no 
6
material fact has been omitted in the applica-
7
tion. 
8
‘‘(F) Except as provided under subsection 
9
(d), applicable information regarding the meth-
10
ods used in, or the facilities or controls used 
11
for, the development of the test to demonstrate 
12
compliance with the applicable quality require-
13
ments under section 587J. 
14
‘‘(G) Information demonstrating compli-
15
ance with any relevant— 
16
‘‘(i) mitigating measures under sec-
17
tion 587E; and 
18
‘‘(ii) standards established or recog-
19
nized under section 514 prior to the date 
20
of enactment of the Verifying Accurate 
21
Leading-edge IVCT Development Act of 
22
2020, or, after applicable standards are es-
23
tablished or recognized under section 
24
587Q, with such standards. 
25
01:17 Mar 17, 2020
H6102
56 
•HR 6102 IH
‘‘(H) Valid scientific evidence to support 
1
analytical and clinical validity of the test, which 
2
shall include— 
3
‘‘(i) summary information for all sup-
4
porting validation studies performed; and 
5
‘‘(ii) raw data, such as tabulations of 
6
data and results as required under section 
7
814.20(b)(6)(ii) of title 21, Code of Fed-
8
eral Regulations (or any successor regula-
9
tions); 
10
‘‘(iii) for nonclinical laboratory studies 
11
involving the test, a statement that studies 
12
were conducted in compliance with applica-
13
ble good laboratory practices; and 
14
‘‘(iv) 
for 
investigations 
involving 
15
human subjects, statements that any clin-
16
ical investigation involving human subjects 
17
was conducted in compliance with applica-
18
ble— 
19
‘‘(I) institutional review board 
20
regulations; 
21
‘‘(II) informed consent regula-
22
tions; and 
23
‘‘(III) investigational use require-
24
ments in section 587R. 
25
01:17 Mar 17, 2020
H6102
57 
•HR 6102 IH
‘‘(I) To the extent the application seeks 
1
authorization to make modifications to the test 
2
within the scope of the approval, a change pro-
3
tocol that includes validation procedures and 
4
acceptance criteria for anticipated modifications 
5
that could be made to the test within the scope 
6
of the approval. 
7
‘‘(J) Proposed labeling, in accordance with 
8
the requirements of section 587K. 
9
‘‘(K) Such other data or information as 
10
the Secretary may require in accordance with 
11
the least burdensome requirements of sub-
12
section (j). 
13
‘‘(3) GUIDANCE FOR PREMARKET AND SPECIAL 
14
PREMARKET
APPLICATIONS.—In accordance with 
15
section 5 of the Verifying Accurate Leading-edge 
16
IVCT Development Act of 2020, the Secretary shall 
17
issue draft guidance detailing the information to be 
18
provided in a premarket application and special pre-
19
market application under this section. The Secretary 
20
shall issue final guidance not later than 90 calendar 
21
days after the close of the comment period for such 
22
guidance. 
23
‘‘(4) REFUSE TO FILE A PREMARKET OR SPE-
24
CIAL PREMARKET APPLICATION.—If, after receipt of 
25
01:17 Mar 17, 2020
H6102
58 
•HR 6102 IH
an application under this section, the Secretary re-
1
fuses to file such application, the Secretary shall 
2
provide to the developer, within 60 calendar days of 
3
receipt of such application, a description of the rea-
4
son for such refusal, and identify the information re-
5
quired, if any, to allow for the filing of the applica-
6
tion. 
7
‘‘(5) SUBSTANTIVE REVIEW FOR DEFICIENT AP-
8
PLICATION.—If, after receipt of an application under 
9
this section, the Secretary determines that any por-
10
tion of such application is deficient, the Secretary 
11
shall provide to the applicant, within 75 calendar 
12
days of receipt of such application, a description of 
13
such deficiencies and identify the information re-
14
quired to correct such deficiencies. 
15
‘‘(d) SPECIAL PREMARKET REVIEW.— 
16
‘‘(1) IN GENERAL.—Any person may file with 
17
the Secretary an application for special premarket 
18
approval for— 
19
‘‘(A) an instrument; 
20
‘‘(B) a specimen receptacle; 
21
‘‘(C) an in vitro clinical test eligible for a 
22
technology certification order under section 
23
587D; or 
24
01:17 Mar 17, 2020
H6102
59 
•HR 6102 IH
‘‘(D) a first-of-a-kind test, unless it is a 
1
high-risk test, a direct-to-consumer test, or 
2
cross-referenced test that does not have miti-
3
gating measures. 
4
‘‘(2) APPLICATION
CONTENT.—An application 
5
under paragraph (1) shall include— 
6
‘‘(A) the information required for applica-
7
tions submitted under subsection (c)(2), except 
8
that applications under paragraph (1) need not 
9
include— 
10
‘‘(i) quality requirement information; 
11
or 
12
‘‘(ii) raw data unless explicitly re-
13
quested by the Secretary; 
14
‘‘(B) in the case of a specimen receptacle, 
15
safety information; and 
16
‘‘(C) data, as applicable, to support soft-
17
ware validation, electromagnetic compatibility, 
18
and electrical safety, and information dem-
19
onstrating compliance with maintaining quality 
20
systems documentation. 
21
‘‘(3) INSPECTIONS.—With respect to an appli-
22
cation under paragraph (1), preapproval inspections 
23
authorized by an employee of the Food and Drug 
24
Administration or a person accredited under section 
25
01:17 Mar 17, 2020
H6102
60 
•HR 6102 IH
587P need not occur unless requested by the Sec-
1
retary. 
2
‘‘(e) INSTRUMENT FAMILY.—When an in vitro clin-
3
ical test has been approved, or is otherwise legally mar-
4
keted, for use on a specific approved or legally marketed 
5
instrument within an instrument family, a submission 
6
under this section shall not be required for that in vitro 
7
clinical test in order for it to be used on a new instrument 
8
within that instrument’s family. 
9
‘‘(f) AMENDMENTS TO AN APPLICATION.— 
10
‘‘(1) IN GENERAL.—An applicant may amend 
11
an original or supplemental application under sub-
12
section (c) or (d). 
13
‘‘(2) REQUIRED
AMENDMENT
OR
SUPPLE-
14
MENT.—An applicant shall amend or supplement an 
15
application submitted under subsection (c) or (d) if 
16
the applicant becomes aware of information that— 
17
‘‘(A) could reasonably affect an evaluation 
18
of whether the applicable standard has been 
19
met; or 
20
‘‘(B) could reasonably affect the statement 
21
of contraindications, warnings, precautions, and 
22
adverse reactions in the proposed labeling. 
23
‘‘(3) REQUEST FOR AMENDMENT OR SUPPLE-
24
MENT.—The Secretary may request that an appli-
25
01:17 Mar 17, 2020
H6102
61 
•HR 6102 IH
cant amend or supplement an application under sub-
1
section (c) or (d) with any information necessary for 
2
review under this section. 
3
‘‘(g) ACTION ON AN APPLICATION FOR PREMARKET 
4
APPROVAL.— 
5
‘‘(1) REVIEW.— 
6
‘‘(A) DISPOSITION.—As promptly as pos-
7
sible, but not later than 90 calendar days after 
8
an application under subsection (c) is accepted 
9
for submission (unless the Secretary determines 
10
that an extension is necessary to review one or 
11
more major amendments to the application), or 
12
not later than 60 calendar days after an appli-
13
cation under subsection (d) is accepted for sub-
14
mission, the Secretary, after considering any 
15
applicable report and recommendations pursu-
16
ant to advisory committees under section 587G, 
17
or prior to the establishment of such advisory 
18
committees, any recommendations by a classi-
19
fication panel under section 513, shall issue an 
20
order approving the application, unless the Sec-
21
retary finds that the grounds for approval in 
22
paragraph (2) are not met. 
23
‘‘(B) RELIANCE
ON
PROPOSED
LABEL-
24
ING.—In determining whether to approve or 
25
01:17 Mar 17, 2020
H6102
62 
•HR 6102 IH
deny an application under paragraph (1), the 
1
Secretary shall rely on the intended use in-
2
cluded in the proposed labeling, provided that 
3
such labeling is not false or misleading based on 
4
a fair evaluation of all material facts. 
5
‘‘(2) APPROVAL OF AN APPLICATION.— 
6
‘‘(A) IN
GENERAL.—The Secretary shall 
7
approve an application submitted under sub-
8
section (c) with respect to an in vitro clinical 
9
test if the Secretary finds that there is a rea-
10
sonable assurance that the applicable standard 
11
is met, and— 
12
‘‘(i) except as provided under sub-
13
section (d), the applicant is in compliance 
14
with applicable quality requirements in sec-
15
tion 587J or as otherwise specified in a 
16
condition of approval, or maintains the 
17
documentation required to be in compli-
18
ance with such requirements if the appli-
19
cant is not required to submit such docu-
20
mentation as a part of the application 
21
under this section; 
22
‘‘(ii) the application does not contain 
23
a false statement of material fact; 
24
01:17 Mar 17, 2020
H6102
63 
•HR 6102 IH
‘‘(iii) based on a fair evaluation of all 
1
material facts, the proposed labeling is 
2
truthful and non-misleading and complies 
3
with the requirements of section 587K; 
4
‘‘(iv) except as provided under sub-
5
section (d), the applicant permits, if re-
6
quested, authorized employees of the Food 
7
and Drug Administration and persons ac-
8
credited under section 587P an oppor-
9
tunity— 
10
‘‘(I) to inspect at a reasonable 
11
time and in a reasonable manner the 
12
facilities and all pertinent equipment, 
13
finished and unfinished materials, 
14
containers, and labeling therein, in-
15
cluding all things (including records, 
16
files, papers, and controls) bearing on 
17
whether an in vitro clinical test is 
18
adulterated, misbranded, or otherwise 
19
in violation of this Act; and 
20
‘‘(II) to view and to copy and 
21
verify all records pertinent to the ap-
22
plication and the in vitro clinical test; 
23
‘‘(v) the test conforms with any appli-
24
cable performance standards under section 
25
01:17 Mar 17, 2020
H6102
64 
•HR 6102 IH
587Q and any applicable mitigating meas-
1
ures under section 587E; and 
2
‘‘(vi) all nonclinical laboratory studies 
3
and clinical investigations involving human 
4
subjects that are described in the applica-
5
tion were conducted in a manner that 
6
meets the requirements of this section. 
7
‘‘(B) CONDITIONS
OF
APPROVAL.—An 
8
order approving an application pursuant to this 
9
paragraph may require conditions of approval 
10
for the in vitro clinical test, including conform-
11
ance with performance standards under section 
12
587Q and restrictions under section 587N. 
13
‘‘(C) FIRST-OF-A-KIND TEST.—For a first- 
14
of-a-kind in vitro clinical test, an order approv-
15
ing an application pursuant to this paragraph— 
16
‘‘(i) may impose requirements for 
17
tests with the same indications for use, in-
18
cluding conformance with performance 
19
standards under section 587Q and miti-
20
gating measures under section 587E, and 
21
comply with restrictions under section 
22
587N; and 
23
‘‘(ii) shall indicate whether subsequent 
24
in vitro clinical tests with the same in-
25
01:17 Mar 17, 2020
H6102
65 
•HR 6102 IH
tended use may meet an exemption set 
1
forth in section 587A. 
2
‘‘(D) PUBLICATION.—The Secretary shall 
3
publish each order approving an application 
4
pursuant to this paragraph on the public 
5
website of the Food and Drug Administration 
6
and make publicly available a summary of the 
7
data used to grant the approval, except to the 
8
extent the Secretary determines that such 
9
order— 
10
‘‘(i) contains commercially confidential 
11
or trade secret information; or 
12
‘‘(ii) relates to national security or 
13
countermeasures is restricted from disclo-
14
sure pursuant to statutory provisions other 
15
than this section. 
16
‘‘(3) REVIEW
OF
DENIALS.—An applicant 
17
whose application submitted under subsection (c) or 
18
(d) has been denied approval may, by petition filed 
19
not more than 60 calendar days after the date on 
20
which the applicant receives notice of such denial, 
21
obtain review of the denial in accordance with sec-
22
tion 587O. 
23
‘‘(h) SUPPLEMENTS TO AN APPLICATION.— 
24
01:17 Mar 17, 2020
H6102
66 
•HR 6102 IH
‘‘(1) RISK
ANALYSIS.—Prior to implementing 
1
any modification to an in vitro clinical test, the hold-
2
er of the application approved under subsection (c) 
3
or (d) for such test shall perform risk analyses in 
4
accordance with section 587J, unless such modifica-
5
tion is included in the change protocol submitted by 
6
the applicant and approved under this section or ex-
7
empt under section 587A(l). 
8
‘‘(2) SUPPLEMENT REQUIREMENT.— 
9
‘‘(A) IN GENERAL.—Except as provided in 
10
subparagraph (B), or otherwise specified by the 
11
Secretary, the holder of the application ap-
12
proved under subsection (g) for an in vitro clin-
13
ical test shall submit to the Secretary and re-
14
ceive approval of a supplement before imple-
15
menting a modification to the test, unless such 
16
modification is exempt under section 587A(l). 
17
‘‘(B) ADJUSTMENTS
TO
CHANGE
PRO-
18
TOCOL.—A person may submit under this para-
19
graph a supplemental application adjusting the 
20
change protocol of the test at any time after the 
21
initial filing of an application under subsection 
22
(c) or (d). 
23
‘‘(C) EXCEPTIONS.—Subject to subpara-
24
graphs (D) and (E), and so long as the holder 
25
01:17 Mar 17, 2020
H6102
67 
•HR 6102 IH
of an approved application submitted under 
1
subsection (c) or (d) for an in vitro clinical test 
2
does not add a manufacturing site, or change 
3
activities at an existing manufacturing site, 
4
with respect to the test, the holder may, with-
5
out prior approval of a supplement, implement 
6
the following modifications to the test: 
7
‘‘(i) Modifications included in and im-
8
plemented in accordance with an approved 
9
change protocol under subsection (c)(2)(I). 
10
‘‘(ii) 
Modifications 
that 
do 
not 
11
change— 
12
‘‘(I) the analytical or clinical va-
13
lidity of the test; 
14
‘‘(II) the intended use of the test 
15
unless provided under an approved 
16
change 
protocol 
under 
subsection 
17
(c)(2)(I); or 
18
‘‘(III) the safety of the specimen 
19
receptacles. 
20
‘‘(iii) Labeling changes to address a 
21
safety concern. 
22
‘‘(iv) Modifications that are exempt 
23
under section 587A(l). 
24
01:17 Mar 17, 2020
H6102
68 
•HR 6102 IH
‘‘(D) REPORTING FOR CHANGE PROTOCOL 
1
MODIFICATIONS.—As a component of the report 
2
required under subsection (k), the holder of an 
3
application approved under subsection (g) for 
4
an in vitro clinical test shall— 
5
‘‘(i) report any modification to the 
6
test described in clause (i) or (ii) of sub-
7
paragraph (B) in the next annual report 
8
for the test under subsection (k) following 
9
the date on which the test, with such modi-
10
fication, is introduced into interstate com-
11
merce; and 
12
‘‘(ii) include in such report— 
13
‘‘(I) a description of the modi-
14
fication; and 
15
‘‘(II) as applicable, a summary of 
16
the analytical validity and clinical va-
17
lidity of the test, as modified, and any 
18
changes to acceptance criteria. 
19
‘‘(E) REPORTING FOR OTHER CATEGORY 
20
OF EXCEPTIONS.—The holder of the application 
21
approved under subsection (c) or (d) for an in 
22
vitro clinical test shall— 
23
‘‘(i) report to the Secretary any modi-
24
fication to the test described in clause (iii) 
25
01:17 Mar 17, 2020
H6102
69 
•HR 6102 IH
of subparagraph (C) not more than 60 
1
days after the date on which the test, with 
2
the modification, is introduced into inter-
3
state commerce; and 
4
‘‘(ii) include in the report— 
5
‘‘(I) a summary of the relevant 
6
change or changes; 
7
‘‘(II) the rationale for imple-
8
menting such change or changes; and 
9
‘‘(III) a description of how the 
10
change or changes were evaluated. 
11
‘‘(F) REQUEST FOR SUPPLEMENT.—Upon 
12
review of the information received under sub-
13
paragraph (D) and a finding that the relevant 
14
modification is inconsistent with the standard 
15
specified under subparagraph (C), the Secretary 
16
may require a supplement under subparagraph 
17
(A). If the Secretary determines that a supple-
18
ment under subparagraph (A) is required, the 
19
Secretary shall notify the applicant of such de-
20
termination. Such notification shall include a 
21
justification for the submission of a supplement. 
22
Prior to the submission of a supplement under 
23
this subparagraph, the applicant may request a 
24
meeting or written correspondence to gain agen-
25
01:17 Mar 17, 2020
H6102
70 
•HR 6102 IH
cy feedback as to the necessity of such supple-
1
mental filing. The Secretary shall respond to 
2
such meeting request within 30 calendar days 
3
of receipt. 
4
‘‘(3) CONTENTS OF SUPPLEMENT.—Unless oth-
5
erwise specified by the Secretary, a supplement 
6
under this subsection shall include— 
7
‘‘(A) for modifications other than manufac-
8
turing site changes— 
9
‘‘(i) a description of the modification; 
10
‘‘(ii) data to demonstrate that the ap-
11
plicable standard is met; 
12
‘‘(iii) acceptance criteria; and 
13
‘‘(iv) any revised labeling; and 
14
‘‘(B) for manufacturing site changes— 
15
‘‘(i) the matter listed in subparagraph 
16
(A); and 
17
‘‘(ii) information regarding the meth-
18
ods used in, or the facilities or controls 
19
used for, the development of the test to 
20
demonstrate compliance with the applicable 
21
quality requirements under section 587J. 
22
‘‘(4) ADDITIONAL DATA.—The Secretary may 
23
require, when necessary, data to evaluate a modifica-
24
tion to an in vitro clinical test that is in addition to 
25
01:17 Mar 17, 2020
H6102
71 
•HR 6102 IH
the data otherwise required under the preceding 
1
paragraphs if the data request is in accordance with 
2
the least burdensome requirements under subsection 
3
(j). 
4
‘‘(5) CONDITIONS OF APPROVAL.—In an order 
5
approving a supplement under this subsection, the 
6
Secretary may require conditions of approval for the 
7
in vitro clinical test, including compliance with re-
8
strictions under section 587N and conformance to 
9
performance standards under section 587Q. 
10
‘‘(6) APPROVAL.—The Secretary shall approve 
11
a supplement under this subsection if— 
12
‘‘(A) the data demonstrate that the modi-
13
fied in vitro clinical test meets the applicable 
14
standard; and 
15
‘‘(B) the holder of the application approved 
16
under subsection (g) for the test has dem-
17
onstrated compliance with applicable quality 
18
and inspection requirements, as applicable and 
19
appropriate. 
20
‘‘(7) PUBLICATION.—The Secretary shall pub-
21
lish on the public website of the Food and Drug Ad-
22
ministration notice of any order approving a supple-
23
ment under this subsection, except that such publi-
24
cation shall exclude— 
25
01:17 Mar 17, 2020
H6102
72 
•HR 6102 IH
‘‘(A) commercial confidential or trade se-
1
cret information; and 
2
‘‘(B) any other information that the Sec-
3
retary determines to relate to national security 
4
or countermeasures or to be restricted from dis-
5
closure pursuant to another provision of law. 
6
‘‘(8) REVIEW OF DENIAL.—An applicant whose 
7
supplement under this subsection has been denied 
8
approval may, by petition filed on or before the 60th 
9
calendar day after the date upon which the applicant 
10
receives notice of such denial, obtain review of the 
11
denial in accordance with section 587O. 
12
‘‘(i) WITHDRAWAL AND TEMPORARY SUSPENSION OF 
13
APPROVAL.— 
14
‘‘(1) ORDER WITHDRAWING APPROVAL.— 
15
‘‘(A) IN
GENERAL.—The Secretary may, 
16
within 10 calendar days of providing due notice 
17
and an opportunity for an informal hearing to 
18
the holder of an approved application for an in 
19
vitro clinical test under this section, issue an 
20
order withdrawing approval of the application if 
21
the Secretary finds that— 
22
‘‘(i) the grounds for approval in sub-
23
section (g) are no longer met; or 
24
01:17 Mar 17, 2020
H6102
73 
•HR 6102 IH
‘‘(ii) there is a reasonable likelihood 
1
that the test would cause death or serious 
2
adverse health consequences, including by 
3
causing the absence, delay, or discontinu-
4
ation of life-saving or life sustaining med-
5
ical treatment. 
6
‘‘(B) CONTENT.—An order under subpara-
7
graph (A) withdrawing approval of an applica-
8
tion shall state each ground for withdrawal and 
9
shall notify the holder of such application 60 
10
calendar days prior to issuing such order. 
11
‘‘(C) PUBLICATION.—The Secretary shall 
12
publish any order under subparagraph (A) on 
13
the public website of the Food and Drug Ad-
14
ministration, except that such publication shall 
15
exclude— 
16
‘‘(i) commercial confidential or trade 
17
secret information; and 
18
‘‘(ii) any other information that the 
19
Secretary determines to relate to national 
20
security or countermeasures or to be re-
21
stricted from disclosure pursuant to an-
22
other provision of law. 
23
‘‘(2) ORDER OF TEMPORARY SUSPENSION.—If, 
24
after providing due notice and an opportunity for an 
25
01:17 Mar 17, 2020
H6102
74 
•HR 6102 IH
informal hearing to the holder of an approved appli-
1
cation for an in vitro clinical test under this section, 
2
the Secretary determines there is a reasonable likeli-
3
hood that the in vitro clinical test would cause death 
4
or serious adverse health consequences, including by 
5
causing the absence, delay, or discontinuation of life- 
6
saving or life-sustaining medical treatment, the Sec-
7
retary shall by order temporarily suspend the ap-
8
proval of the application. If the Secretary issues 
9
such an order, the Secretary shall proceed expedi-
10
tiously under paragraph (1) to withdraw approval of 
11
such application. 
12
‘‘(j) LEAST BURDENSOME REQUIREMENTS.— 
13
‘‘(1) IN GENERAL.—In carrying out this sub-
14
chapter, the Secretary shall consider the least bur-
15
densome means necessary to provide a reasonable 
16
assurance of analytical and clinical validity, or appli-
17
cable standard, and other regulatory requirements, 
18
as determined by the Secretary. 
19
‘‘(2) NECESSARY DEFINED.—For purposes of 
20
paragraph (1) and paragraph (3), the term ‘nec-
21
essary’ means the minimum required information 
22
that would support a determination by the Secretary 
23
that the application provides a reasonable assurance 
24
of analytical and clinical validity, or other applicable 
25
01:17 Mar 17, 2020
H6102
75 
•HR 6102 IH
standard or regulatory requirement, as determined 
1
by the Secretary. 
2
‘‘(3) 
CONSIDERATION
OF
ROLE
OF 
3
4
subsection, the Secretary shall consider the role of 
5
postmarket information in determining the least bur-
6
densome appropriate means necessary to dem-
7
onstrate that the applicable standard and other reg-
8
ulatory requirements have been met. 
9
‘‘(k) ANNUAL REPORT.— 
10
‘‘(1) IN GENERAL.—Unless the Secretary speci-
11
fies otherwise, the holder of an approved application 
12
under this section shall submit an annual report 
13
each year at a time designated by the Secretary in 
14
the approval order. Such report shall— 
15
‘‘(A) identify all modifications required to 
16
be reported that an approved application holder 
17
has made to any test that is covered by the ap-
18
proval order, including any modification that 
19
requires a supplement under subsection (h)(2); 
20
and 
21
‘‘(B) include any other information re-
22
quired by the Secretary. 
23
‘‘(2) EXCEPTION.—The annual reporting re-
24
quirement in paragraph (1) shall not apply to in 
25
01:17 Mar 17, 2020
H6102
76 
•HR 6102 IH
vitro clinical tests that are deemed to have a pre-
1
market approval based on a prior approval under 
2
section 515(c), clearance under section 510(k), or 
3
authorization under section 513(f). 
4
‘‘(l) SERVICE OF ORDERS.—Orders of the Secretary 
5
under this section with respect to applications under sub-
6
section (c) or (d) or supplements under subsection (h) 
7
shall be served— 
8
‘‘(1) in person by any officer or employee of the 
9
Department of Health and Human Services des-
10
ignated by the Secretary; or 
11
‘‘(2) by mailing the order by registered mail or 
12
certified mail or electronic equivalent addressed to 
13
the applicant at the last known address in the 
14
records of the Secretary. 
15
‘‘SEC. 587C. BREAKTHROUGH IN VITRO CLINICAL TESTS. 
16
‘‘(a) IN GENERAL.—The purpose of this section is 
17
to encourage the Secretary and provide the Secretary with 
18
sufficient authority to apply efficient and flexible ap-
19
proaches to expedite the development of, and prioritize the 
20
review of, in vitro clinical tests that represent break-
21
through technologies. 
22
‘‘(b) ESTABLISHMENT OF PROGRAM.—The Secretary 
23
shall establish a program to expedite the development of, 
24
01:17 Mar 17, 2020
H6102
77 
•HR 6102 IH
and provide for the priority review of, in vitro clinical 
1
tests. 
2
‘‘(c) ELIGIBILITY.—The program developed under 
3
subsection (b) shall be available for any in vitro clinical 
4
test that— 
5
‘‘(1) provides or enables more effective treat-
6
ment or diagnosis of life-threatening or irreversibly 
7
debilitating human disease or conditions compared 
8
to existing approved or precertified alternatives; and 
9
‘‘(2) is a test— 
10
‘‘(A) that represents a breakthrough tech-
11
nology; 
12
‘‘(B) for which no approved or precertified 
13
alternative exists; 
14
‘‘(C) that offers a clinically meaningful ad-
15
vantage over existing approved or precertified 
16
alternatives, including the potential, compared 
17
to existing approved or precertified alternatives, 
18
to reduce or eliminate the need for hospitaliza-
19
tion, improve patient quality of life, facilitate 
20
patients’ ability to manage their own care (such 
21
as through self-directed personal assistance), or 
22
establish long-term clinical efficiencies; or 
23
‘‘(D) the availability of which is in the best 
24
interest of patients or public health. 
25
01:17 Mar 17, 2020
H6102
78 
•HR 6102 IH
‘‘(d) DESIGNATION.— 
1
‘‘(1) REQUEST.—To receive breakthrough ap-
2
proval under this section, an applicant may request 
3
that the Secretary designate the in vitro clinical test 
4
for expedited development and priority review. Any 
5
such request for designation may be made at any 
6
time prior to the submission of an application under 
7
section 587B, and shall include information dem-
8
onstrating that the test is eligible for designation 
9
under subsection (c). 
10
‘‘(2) DETERMINATION.—Not later than 60 cal-
11
endar days after the receipt of a request under para-
12
graph (1), the Secretary shall determine whether the 
13
in vitro clinical test that is the subject of the request 
14
meets the criteria described in subsection (c). If the 
15
Secretary determines that the test meets the criteria, 
16
the Secretary shall designate the test for expedited 
17
development and priority review. 
18
‘‘(3) REVIEW.—Review of a request under para-
19
graph (1) shall be undertaken by a team that is 
20
composed of experienced staff and senior managers 
21
of the Food and Drug Administration. 
22
‘‘(4) WITHDRAWAL.— 
23
‘‘(A) IN GENERAL.—The designation of an 
24
in vitro clinical test under this subsection is 
25
01:17 Mar 17, 2020
H6102
79 
•HR 6102 IH
deemed to be withdrawn, and such in vitro clin-
1
ical test shall no longer be eligible for designa-
2
tion under this section, if an application for ap-
3
proval under section 587B is denied. Such test 
4
would be eligible for designation upon a new re-
5
quest for such designation. 
6
‘‘(B) EXCEPTION.—The Secretary may not 
7
withdraw a designation granted under this sub-
8
section based on the subsequent approval or 
9
technology certification of another test that— 
10
‘‘(i) is designated under this section; 
11
or 
12
‘‘(ii) was given priority review under 
13
section 515B. 
14
‘‘(e) ACTIONS.—For purposes of expediting the devel-
15
opment and review of in vitro clinical tests under this sec-
16
tion, the Secretary may take the actions and additional 
17
actions set forth in section 515B(e) when reviewing such 
18
tests. Any reference or authorization in section 515B(e) 
19
with respect to a device shall be deemed a reference or 
20
authorization with respect to an in vitro clinical test for 
21
purposes of this section. 
22
‘‘(f) GUIDANCE.— 
23
‘‘(1) IN GENERAL.—Not later than one year 
24
after the date of enactment of the Verifying Accu-
25
01:17 Mar 17, 2020
H6102
80 
•HR 6102 IH
rate Leading-edge IVCT Development Act of 2020, 
1
the Secretary shall issue draft guidance on the im-
2
plementation of this section. Such guidance shall— 
3
‘‘(A) set forth the process by which a per-
4
son may seek a designation under subsection 
5
(d); 
6
‘‘(B) provide a template for request under 
7
subsection (d); 
8
‘‘(C) identify the criteria the Secretary will 
9
use in evaluating a request for designation; and 
10
‘‘(D) identify the criteria and processes the 
11
Secretary will use to assign a team of staff, in-
12
cluding team leaders, to review in vitro clinical 
13
tests designated for expedited development and 
14
priority review, including any training required 
15
for such personnel to ensure effective and effi-
16
cient review. 
17
‘‘(2) PROCESS.—Prior to finalizing the guid-
18
ance under paragraph (1), the Secretary shall seek 
19
public comment on the draft guidance. The Sec-
20
retary shall issue final guidance one year after the 
21
close of the comment period for the draft guidance. 
22
‘‘(g) ANNUAL REPORT.—Unless otherwise specified 
23
by the Secretary, the requirements under section 587B(k) 
24
01:17 Mar 17, 2020
H6102
81 
•HR 6102 IH
apply to in vitro clinical tests designated under this sec-
1
tion. 
2
‘‘(h) SERVICE OF ORDERS.—Orders of the Secretary 
3
under this section shall be served— 
4
‘‘(1) in person by any officer or employee of the 
5
Department of Health and Human Services des-
6
ignated by the Secretary; or 
7
‘‘(2) by mailing the order by registered mail or 
8
certified mail or electronic equivalent addressed to 
9
the applicant at his last known address in the 
10
records of the Secretary. 
11
‘‘SEC. 587D. TECHNOLOGY CERTIFICATION. 
12
‘‘(a) IN GENERAL.— 
13
‘‘(1) ELIGIBILITY.—Any eligible person may 
14
seek a technology certification in accordance with 
15
this section. 
16
‘‘(2) EXCEPTION.—An in vitro clinical test is 
17
exempt from premarket review under section 587B 
18
if the developer is eligible under this section and the 
19
in vitro clinical test— 
20
‘‘(A) is an eligible in vitro clinical test 
21
under subsection (b)(2); and 
22
‘‘(B) falls within the scope of a technology 
23
certification order issued under this section, 
24
and such order is in effect. 
25
01:17 Mar 17, 2020
H6102
82 
•HR 6102 IH
‘‘(b) ELIGIBILITY.— 
1
‘‘(1) ELIGIBLE PERSON.—In this section, the 
2
term ‘eligible person’ means an in vitro clinical test 
3
developer unless, at the time such person seeks or 
4
would seek technology certification order, the per-
5
son— 
6
‘‘(A) has been found to have committed a 
7
significant violation of section 353 of the Public 
8
Health Service Act, unless— 
9
‘‘(i) such violation occurred more than 
10
5 years prior to the date on which such 
11
technology certification order is or would 
12
be sought; 
13
‘‘(ii) such violation has been resolved; 
14
or 
15
‘‘(iii) such violation is not pertinent to 
16
any in vitro clinical test within the scope of 
17
the technology certification order that such 
18
person seeks or would seek; or 
19
‘‘(B) such person fails to maintain re-
20
quired certifications under section 353 of the 
21
Public Health Service Act; 
22
‘‘(C) has been found to have submitted in-
23
formation that— 
24
01:17 Mar 17, 2020
H6102
83 
•HR 6102 IH
‘‘(i) makes false or misleading state-
1
ments about a technology certification 
2
order previously issued or an application 
3
approved under section 587B; or 
4
‘‘(ii) violates any requirement of this 
5
subchapter related to technology certifi-
6
cation under this section or approval under 
7
section 587B, where such violation exposes 
8
persons to serious risk of illness, injury, or 
9
death. 
10
‘‘(2) ELIGIBLE IN VITRO CLINICAL TEST.—An 
11
in vitro clinical test is eligible under subsection 
12
(a)(2) for exemption from premarket review under 
13
section 587B unless— 
14
‘‘(A) such test is— 
15
‘‘(i) a component or part of an in 
16
vitro clinical test as described under sec-
17
tion 201(ss)(1)(B)(v); 
18
‘‘(ii) an instrument under section 
19
201(ss)(1)(B)(ii); 
20
‘‘(iii) a specimen receptacle under sec-
21
tion 201(ss)(1)(B)(iii); or 
22
‘‘(iv) an in vitro clinical test, including 
23
reagents used in such tests, intended for 
24
use for testing donors, donations, and re-
25
01:17 Mar 17, 2020
H6102
84 
•HR 6102 IH
cipients 
of 
blood, 
blood 
components, 
1
human cells, tissues, cellular-based prod-
2
ucts, or tissue-based products; or 
3
‘‘(B) unless otherwise permitted pursuant 
4
to section 587F, such test is— 
5
‘‘(i) a first-of-a-kind in vitro clinical 
6
test; 
7
‘‘(ii) a test system for home use; 
8
‘‘(iii) a high-risk in vitro clinical test; 
9
‘‘(iv) a cross-referenced in vitro clin-
10
ical test; or 
11
‘‘(v) a direct-to-consumer in vitro clin-
12
ical test. 
13
‘‘(c) PUBLIC MEETING AND INPUT.— 
14
‘‘(1) PUBLIC DOCKET.—Not later than 30 days 
15
after the date of enactment of the Verifying Accu-
16
rate Leading-edge IVCT Development Act of 2020, 
17
the Secretary shall establish a public docket to re-
18
ceive comments concerning recommendations for im-
19
plementation of this section, including criteria and 
20
procedures for subsections (e) through (j). The pub-
21
lic docket shall remain open for the duration of time 
22
that this section remains in effect. 
23
‘‘(2) PUBLIC
MEETING.—Not later than 180 
24
days after the date of enactment of the Verifying 
25
01:17 Mar 17, 2020
H6102
85 
•HR 6102 IH
Accurate Leading-edge IVCT Development Act of 
1
2020, the Secretary shall convene a public meeting 
2
to which stakeholders from organizations rep-
3
resenting patients and consumers, academia, and the 
4
in vitro clinical test industry are invited in order to 
5
discuss components of the technology certification 
6
process including application requirements, inspec-
7
tions, alignment with third-party accreditors, and 
8
the definition of ‘technology’ under section 587(17). 
9
The public meeting shall be assigned a docket num-
10
ber by the Commissioner of Food and Drugs and 
11
made available for the submission of public com-
12
ments. 
13
‘‘(d) GUIDANCE.—In accordance with section 5 of the 
14
Verifying Accurate Leading-edge IVCT Development Act 
15
of 2020, the Secretary shall issue a draft guidance on 
16
technology review including describing criteria or proce-
17
dures relating to technology review under this section, 
18
which shall be subject to public comment for a minimum 
19
of 60 days from issuance prior to finalizing such guidance 
20
documents after considering the comments received. The 
21
guidance shall include an outline of the application and 
22
recertification process, opportunities to meet with officials 
23
of the Food and Drug Administration, plans to streamline 
24
inspections, and a list of applicable technologies. The guid-
25
01:17 Mar 17, 2020
H6102
86 
•HR 6102 IH
ance shall be updated as appropriate, and not less fre-
1
quently than each time the Secretary identifies a unique 
2
technology. 
3
‘‘(e) APPLICATION
FOR
TECHNOLOGY
CERTIFI-
4
CATION.— 
5
‘‘(1) IN GENERAL.—A person seeking a tech-
6
nology certification order shall submit an application 
7
under this subsection, which shall contain the infor-
8
mation specified under paragraph (2). 
9
‘‘(2) CONTENT OF APPLICATION.—An applica-
10
tion for technology certification shall contain— 
11
‘‘(A) a statement identifying the scope of 
12
the proposed technology certification, which 
13
shall be no broader than a single technology in-
14
tended to be offered under the application; 
15
‘‘(B) information showing that the person 
16
seeking a technology certification order is an el-
17
igible person under subsection (b)(1); 
18
‘‘(C) information showing that the methods 
19
used in, and the facilities and controls used for, 
20
the development of eligible in vitro clinical tests 
21
covered by the scope of the technology certifi-
22
cation conform to the applicable quality require-
23
ments of section 587J; 
24
01:17 Mar 17, 2020
H6102
87 
•HR 6102 IH
‘‘(D) procedures for analytical validation, 
1
including all procedures for validation, verifica-
2
tion, and acceptance criteria, and an expla-
3
nation as to how such procedures, when used, 
4
provide a reasonable assurance of analytical va-
5
lidity of all eligible in vitro clinical tests within 
6
the proposed scope of technology certification 
7
order; 
8
‘‘(E) information showing that the person 
9
has an established clinical program, including 
10
procedures for clinical validation, including all 
11
procedures for validation, verification, and ac-
12
ceptance criteria, and an explanation as to how 
13
such procedures, when used, provide a reason-
14
able assurance of clinical validity of all eligible 
15
in vitro clinical tests within the proposed scope 
16
of technology certification order; 
17
‘‘(F) a notification under section 587I for 
18
each applicable in vitro clinical test that the de-
19
veloper plans to offer initially upon receiving a 
20
technology certification order and that would be 
21
introduced or delivered for introduction into 
22
interstate commerce upon the issuance of the 
23
technology certification order; 
24
01:17 Mar 17, 2020
H6102
88 
•HR 6102 IH
‘‘(G) information concerning one or more 
1
representative in vitro clinical tests, including— 
2
‘‘(i) one of the tests within the scope 
3
of the technology certification application 
4
with the greatest analytical complexity at 
5
the time of the filing of the application 
6
under this section that would be introduced 
7
or delivered for introduction into interstate 
8
commerce upon the issuance of the tech-
9
nology certification order to serve as the 
10
representative test and validate and run 
11
within the developer’s stated scope, and a 
12
rationale for such selection; 
13
‘‘(ii) the information specified in sub-
14
section (c) or (d) of section 587B for the 
15
representative in vitro clinical test or tests, 
16
except that raw data shall be provided for 
17
any such in vitro clinical test unless the 
18
Secretary determines otherwise; 
19
‘‘(iii) an explanation of the choice of 
20
the representative in vitro clinical test or 
21
tests for the technology certification appli-
22
cation and how such test adequately dem-
23
onstrates the range of procedures that the 
24
01:17 Mar 17, 2020
H6102
89 
•HR 6102 IH
developer includes in the application under 
1
subparagraphs (C), (D), (E), and (F); and 
2
‘‘(iv) a brief explanation of the ways 
3
in which the procedures included in the ap-
4
plication under subparagraphs (C), (D), 
5
(E), and (F) have been applied to the rep-
6
resentative in vitro clinical test or tests; 
7
‘‘(H) such other information relevant to 
8
the subject matter of the application as the Sec-
9
retary may require; and 
10
‘‘(I) a statement that the applicant believes 
11
to the best of the applicant’s knowledge that all 
12
data and information submitted to the Sec-
13
retary are truthful and accurate and that no 
14
material fact has been omitted. 
15
‘‘(f) ACTION ON AN APPLICATION FOR TECHNOLOGY 
16
CERTIFICATION.— 
17
‘‘(1) SECRETARY RESPONSE.— 
18
‘‘(A) IN GENERAL.—As promptly as prac-
19
ticable, and no later than 90 days after receipt 
20
of an application under subsection (c), the Sec-
21
retary shall— 
22
‘‘(i) issue a technology certification 
23
order granting the application, which shall 
24
specify the scope of the technology certifi-
25
01:17 Mar 17, 2020
H6102
90 
•HR 6102 IH
cation, if the Secretary finds that all of the 
1
grounds in paragraph (3) are met; or 
2
‘‘(ii) deny the application if the Sec-
3
retary finds (and sets forth the basis of 
4
such finding as part of or accompanying 
5
such denial) that one or more grounds for 
6
granting the application specified in para-
7
graph (3) are not met. 
8
‘‘(B) EXTENSION.—The timeline described 
9
in subparagraph (A) may be extended by mu-
10
tual agreement between the Secretary and the 
11
applicant. 
12
‘‘(2) DEFICIENT APPLICATIONS.—If, after re-
13
ceipt of an application under this section, the Sec-
14
retary determines that any portion of such applica-
15
tion is deficient, the Secretary, not later than 90 
16
days after receipt of such application, shall provide 
17
to the applicant a description of such deficiencies 
18
and identify the information required to correct such 
19
deficiencies. 
20
‘‘(3) APPROVAL.—The Secretary shall grant a 
21
technology certification order under this section if, 
22
on the basis of the information submitted to the Sec-
23
retary as part of the application and any other infor-
24
01:17 Mar 17, 2020
H6102
91 
•HR 6102 IH
mation with respect to such applicant, the Secretary 
1
finds that— 
2
‘‘(A) 
in 
accordance 
with 
subsection 
3
(e)(2)(D), there is a showing of reasonable as-
4
surance of analytical validity for all eligible in 
5
vitro clinical tests within the proposed scope of 
6
the technology certification, as evidenced by the 
7
procedures for analytical validation; 
8
‘‘(B) 
in 
accordance 
with 
subsection 
9
(e)(2)(E), there is a showing of reasonable as-
10
surance of clinical validity for all eligible in 
11
vitro clinical tests within the proposed scope of 
12
the technology certification, as evidenced by the 
13
clinical program, including procedures for clin-
14
ical validation; 
15
‘‘(C) the methods used in, or the facilities 
16
or controls used for, the development of eligible 
17
in vitro clinical tests covered by the proposed 
18
scope of the technology certification conform to 
19
the applicable requirements of section 587J; 
20
‘‘(D) based on a fair evaluation of all ma-
21
terial facts, the applicant’s proposed labeling 
22
and advertising is not false or misleading in any 
23
particular; 
24
01:17 Mar 17, 2020
H6102
92 
•HR 6102 IH
‘‘(E) the application does not contain a 
1
false statement of material fact; 
2
‘‘(F) there is a showing that the represent-
3
ative in vitro clinical test or tests— 
4
‘‘(i) meets the applicable standard for 
5
approval; and 
6
‘‘(ii) reasonably represent the range of 
7
procedures for analytical validation and 
8
clinical validation included in the applica-
9
tion, as applicable; and 
10
‘‘(G) the applicant permits authorized em-
11
ployees of the Food and Drug Administration 
12
or persons accredited under this Act an oppor-
13
tunity to inspect at a reasonable time and in a 
14
reasonable manner the facilities and all perti-
15
nent equipment, finished and unfinished mate-
16
rials, containers, and labeling therein, including 
17
all things (including records, files, papers, and 
18
controls) bearing on whether an in vitro clinical 
19
test is adulterated, misbranded, or otherwise in 
20
violation of this Act, and permits such author-
21
ized employees or persons accredited under this 
22
Act to view and to copy and verify all records 
23
pertinent to the application and the in vitro 
24
clinical test. 
25
01:17 Mar 17, 2020
H6102
93 
•HR 6102 IH
‘‘(4) REVIEW
OF
DENIALS.—An applicant 
1
whose application has been denied may, by petition 
2
filed on or before the date that is 30 calendar days 
3
after the date upon which such applicant receives 
4
notice of such denial, obtain review thereof in ac-
5
cordance with section 587O. 
6
‘‘(g) DURATION; SUBSEQUENT SUBMISSIONS.— 
7
‘‘(1) ORDER DURATION.—A technology certifi-
8
cation order shall remain in effect until the earlier 
9
of— 
10
‘‘(A) the expiration of such technology cer-
11
tification order under paragraph (2); or 
12
‘‘(B) the withdrawal of such technology 
13
certification order under subsection (j). 
14
‘‘(2) EXPIRATION.—An initial technology cer-
15
tification order issued under subsection (f)(3) shall 
16
expire on such date specified by the Secretary that 
17
is not later than 4 years after the date that such 
18
order is issued, except that if an application for re-
19
newal under paragraph (3) has been received not 
20
later than 30 days prior to the expiration of such 
21
order under this paragraph, such order shall expire 
22
on the date on which the Secretary has granted or 
23
denied the application for renewal. Any such subse-
24
quent renewal of a technology certification shall ex-
25
01:17 Mar 17, 2020
H6102
94 
•HR 6102 IH
pire on such date specified by the Secretary that is 
1
not later than 4 years after the date that such tech-
2
nology certification order is issued. 
3
‘‘(3) RENEWAL.— 
4
‘‘(A) IN
GENERAL.—Any person with a 
5
technology certification order in effect with re-
6
spect to development of in vitro clinical tests 
7
may seek renewal of such order provided that— 
8
‘‘(i) such person is an eligible person 
9
under subsection (b)(1); and 
10
‘‘(ii) none of the information specified 
11
in subsection (e)(2) has substantially 
12
changed, except as described in supple-
13
ments approved under paragraph (4). 
14
‘‘(B) CONTENT.—An application for re-
15
newal under this paragraph shall include infor-
16
mation concerning one or more representative 
17
in vitro clinical tests in accordance with sub-
18
section (e)(2)(G), except that such representa-
19
tive test or tests shall be different from the rep-
20
resentative test or tests relied upon as the rep-
21
resentative assay in any prior technology certifi-
22
cation that has not yet been reviewed, if appli-
23
cable. 
24
01:17 Mar 17, 2020
H6102
95 
•HR 6102 IH
‘‘(C) PROCESS.—The Secretary’s action on 
1
an application for renewal of technology certifi-
2
cation under this paragraph shall be conducted, 
3
to the extent practicable, in coordination with 
4
inspections conducted under section 353 of the 
5
Public Health Service Act, and any order re-
6
sulting from such renewal application shall be 
7
treated as a technology certification order for 
8
purposes of this subchapter. 
9
‘‘(4) SUPPLEMENTS AND REPORTS.— 
10
‘‘(A) SUPPLEMENTS.—Except as provided 
11
in subparagraph (B), any person with a tech-
12
nology certification order in effect may seek a 
13
supplement to such order upon a change or 
14
changes to the information provided in the ap-
15
plication for technology certification under sub-
16
paragraphs (C), (D), and (E) of subsection 
17
(e)(2), provided that— 
18
‘‘(i) such person is an eligible person 
19
under subsection (b)(1); and 
20
‘‘(ii) that such change does not ex-
21
pand the scope of the technology certifi-
22
cation unless the Secretary deems appro-
23
priate. 
24
01:17 Mar 17, 2020
H6102
96 
•HR 6102 IH
A supplement may contain only information rel-
1
evant to the change or changes. The Secretary’s 
2
action on a supplement shall be in accordance 
3
with subsection (f), and any order resulting 
4
from such supplement shall be treated as an 
5
amendment to a technology certification order 
6
that is in effect. 
7
‘‘(B) REPORTS.— 
8
‘‘(i) IN
GENERAL.—If a change de-
9
scribed in subparagraph (A) is made in 
10
order to address a potential risk to public 
11
health by adding a new specification or 
12
test method, the person may immediately 
13
implement such change or changes and 
14
shall report such changes or changes to the 
15
Secretary within 30 days. 
16
‘‘(ii) CONTENT.—Any report to the 
17
Secretary under this subparagraph shall 
18
include— 
19
‘‘(I) a summary of the relevant 
20
change or changes; 
21
‘‘(II) the rationale for imple-
22
menting such change or changes; and 
23
‘‘(III) a description of how the 
24
change or changes were evaluated. 
25
01:17 Mar 17, 2020
H6102
97 
•HR 6102 IH
‘‘(iii) 
SUPPLEMENTAL
REPORTS.— 
1
Upon review of such report and a finding 
2
that the relevant change or changes are in-
3
consistent with the standard specified 
4
under this subparagraph, the Secretary 
5
may require a supplement under subpara-
6
graph (A). 
7
‘‘(h) MAINTENANCE REQUIREMENTS.—For the dura-
8
tion of a technology certification order, a holder of a tech-
9
nology certification order shall— 
10
‘‘(1) use the procedures included in the relevant 
11
application, supplement, or report under subsections 
12
(b) and (e); 
13
‘‘(2) ensure compliance with any applicable 
14
mitigating measures; 
15
‘‘(3) maintain, and provide to the Secretary 
16
upon request, records related to any in vitro clinical 
17
test offered without premarket review under the 
18
technology certification order, where those records 
19
are necessary to demonstrate compliance with appli-
20
cable provisions of this subchapter; and 
21
‘‘(4) comply with the notification requirements 
22
under section 587I for each in vitro clinical test of-
23
fered without premarket review under the technology 
24
certification order. 
25
01:17 Mar 17, 2020
H6102
98 
•HR 6102 IH
‘‘(i) TEMPORARY HOLD.— 
1
‘‘(1) IN GENERAL.—Upon one or more findings 
2
under paragraph (4) and after promptly notifying 
3
the developer of such findings, the Secretary may 
4
issue a temporary hold prohibiting any holder of a 
5
technology certification order from introducing into 
6
interstate commerce an in vitro clinical test that was 
7
not previously the subject of a notification under 
8
section 587I. The temporary hold must identify the 
9
grounds for the temporary hold under paragraph (4) 
10
and the rationale for such finding. 
11
‘‘(2) NOTIFICATION TO THE DEVELOPER.—The 
12
Secretary shall not place a temporary hold under 
13
this subsection unless the Secretary has promptly 
14
notified the developer of such hold and provided 30 
15
calendar days for the developer to come into compli-
16
ance with or resolve the findings under paragraph 
17
(4). 
18
‘‘(3) WRITTEN
REQUESTS.—Any written re-
19
quest to the Secretary from the holder of a tech-
20
nology certification order that a temporary hold 
21
under paragraph (1) be removed shall receive a deci-
22
sion, in writing and specifying the reasons therefore, 
23
within 90 days after receipt of such request. Any 
24
01:17 Mar 17, 2020
H6102
99 
•HR 6102 IH
such request shall include information to support the 
1
removal of the temporary hold. 
2
‘‘(4) GROUNDS
FOR
TEMPORARY
HOLD.—A 
3
temporary hold under this subsection may be 
4
instated upon a finding or findings that the holder 
5
of a technology certification order— 
6
‘‘(A) is not in compliance with any mainte-
7
nance requirements under subsection (h); 
8
‘‘(B) labels or advertises one or more in 
9
vitro clinical tests with false or misleading 
10
claims; or 
11
‘‘(C) is no longer an eligible person under 
12
subsection (b)(1). 
13
‘‘(j) WITHDRAWAL.—The Secretary may, after due 
14
notice and opportunity for informal hearing, issue an 
15
order withdrawing a technology certification order if the 
16
Secretary finds that— 
17
‘‘(1) the application, supplement, or report 
18
under subsection (e) or (g) contains false or mis-
19
leading information or fails to reveal a material fact; 
20
‘‘(2) such holder fails to correct false or mis-
21
leading labeling or advertising upon the request of 
22
the Secretary; 
23
01:17 Mar 17, 2020
H6102
100 
•HR 6102 IH
‘‘(3) in connection with a technology certifi-
1
cation, the holder provides false or misleading infor-
2
mation to the Secretary; or 
3
‘‘(4) the holder of such technology certification 
4
order fails to correct the grounds for temporary hold 
5
within a timeframe specified in the temporary hold 
6
order. 
7
‘‘(k) REPORTS TO CONGRESS.— 
8
‘‘(1) IN GENERAL.—Not later than one year 
9
after the effective date, and annually for 4 years 
10
thereafter, the Secretary shall prepare and submit to 
11
the Committee on Energy and Commerce of the 
12
House of Representatives and the Committee on 
13
Health, Education, Labor, and Pensions of the Sen-
14
ate, and make publicly available, including through 
15
posting on the internet website of the Food and 
16
Drug Administration, a report containing the infor-
17
mation required under paragraph (2). 
18
‘‘(2) CONTENT.— 
19
‘‘(A) IN
GENERAL.—Each report under 
20
paragraph (1) shall address, at a minimum— 
21
‘‘(i) the total number and type of ap-
22
plications 
for 
technology 
certifications 
23
filed, granted, withdrawn or denied; 
24
01:17 Mar 17, 2020
H6102
101 
•HR 6102 IH
‘‘(ii) the total number of technology 
1
certification orders put on temporary hold 
2
under subsection (i) and the number of 
3
technology certification orders withdrawn 
4
under subsection (j); 
5
‘‘(iii) the types of technologies for 
6
which technology certification orders were 
7
granted; and 
8
‘‘(iv) the total number of laboratories 
9
and developers with technology certifi-
10
cation orders in effect. 
11
‘‘(B) FINAL
REPORT.—The fifth report 
12
submitted under paragraph (1) shall include a 
13
summary of, and responses to, comments raised 
14
in the meeting and docket. 
15
‘‘(C) PERFORMANCE
REPORTS.—The re-
16
ports required under this section may be issued 
17
as a component of performance reports as re-
18
quired under section 9 of the Verifying Accu-
19
rate Leading-edge IVCT Development Act of 
20
2020. 
21
‘‘SEC. 587E. MITIGATING MEASURES. 
22
‘‘(a) ESTABLISHMENT OF MITIGATING MEASURES.— 
23
‘‘(1) ESTABLISHING, 
CHANGING, 
OR
WITH-
24
DRAWING.— 
25
01:17 Mar 17, 2020
H6102
102 
•HR 6102 IH
‘‘(A) ESTABLISHMENT.—If the Secretary 
1
determines that the establishment of mitigating 
2
measures is necessary for either of the reasons 
3
described in clause (i) or (ii) of section 
4
587(15)(A) for any in vitro clinical test with 
5
the same indications for use, the Secretary may 
6
require that the in vitro clinical test comply 
7
with such mitigating measures. 
8
‘‘(B) 
PROCESS.—Notwithstanding 
sub-
9
chapter II of chapter 5 of title 5, United States 
10
Code, the Secretary may— 
11
‘‘(i) establish, change, or withdraw 
12
mitigating measures by— 
13
‘‘(I) publishing a proposed ad-
14
ministrative order in the Federal Reg-
15
ister; 
16
‘‘(II) providing an opportunity 
17
for public comment for a period of not 
18
less than 30 calendar days; and 
19
‘‘(III) after consideration of any 
20
comments submitted, publishing a 
21
final administrative order in the Fed-
22
eral Register; and 
23
‘‘(ii) may establish mitigating meas-
24
ures with respect to a category in a pre-
25
01:17 Mar 17, 2020
H6102
103 
•HR 6102 IH
market approval order or technology cer-
1
tification order. 
2
‘‘(2) IN
VITRO
CLINICAL
TESTS
PREVIOUSLY 
3
APPROVED, CLEARED, OR EXEMPTED AS DEVICES.— 
4
‘‘(A) IN GENERAL.—Any special controls 
5
or restrictions applicable to an in vitro clinical 
6
test with the same indications for use pursuant 
7
to section 587(10) based on prior regulation as 
8
a device approved under section 515, cleared or 
9
exempt under section 510(k), or classified 
10
under section 513(f)(2), including any such spe-
11
cial controls or restrictions established during 
12
the period beginning on the date of enactment 
13
of the Verifying Accurate Leading-edge IVCT 
14
Development Act of 2020 and ending on the ef-
15
fective date of such Act (as described in section 
16
5(b) of such Act)— 
17
‘‘(i) shall continue to apply to such 
18
approved, cleared, or exempted in vitro 
19
clinical test after such effective date; and 
20
‘‘(ii) are deemed to be mitigating 
21
measures as of the effective date of such 
22
approval, clearance, or exemption. 
23
‘‘(B) CHANGES.—The Secretary may es-
24
tablish, change, or withdraw mitigating meas-
25
01:17 Mar 17, 2020
H6102
104 
•HR 6102 IH
ures for such a test or indications for use the 
1
procedures under paragraph (1). 
2
‘‘(b) DOCUMENTATION.— 
3
‘‘(1) TESTS
SUBJECT
TO
PREMARKET
RE-
4
VIEW.—The developer of an in vitro clinical test sub-
5
ject to premarket review under section 587B and to 
6
which mitigating measures apply shall— 
7
‘‘(A) 
in 
accordance 
with 
section 
8
587B(c)(2)(G)(i), submit documentation to the 
9
Secretary as part of the application for the test 
10
under subsection (c) or (d) of section 587B 
11
demonstrating that such mitigating measures 
12
have been met; 
13
‘‘(B) if such application is approved, main-
14
tain documentation demonstrating that such 
15
mitigating measures continue to be met fol-
16
lowing a test modification by the developer; and 
17
‘‘(C) after responding to any informal com-
18
munications from the Secretary, make such 
19
documentation available to the Secretary upon 
20
request or inspection. 
21
‘‘(2) OTHER TESTS.—The developer of an in 
22
vitro clinical test that is marketed within the scope 
23
of a technology certification order or other exemp-
24
01:17 Mar 17, 2020
H6102
105 
•HR 6102 IH
tion from premarket review under section 587B and 
1
to which mitigating measures apply shall— 
2
‘‘(A) maintain documentation in accord-
3
ance with the applicable quality requirements 
4
under section 587J demonstrating that such 
5
mitigating measures continue to be met fol-
6
lowing a test modification by the developer; 
7
‘‘(B) after responding to any informal 
8
communications from the Secretary, make such 
9
documentation available to the Secretary upon 
10
request or inspection; and 
11
‘‘(C) include in the performance summary 
12
for such test a brief description of how such 
13
mitigating measures are met, if applicable. 
14
‘‘(c) MITIGATING
MEASURES
FOR
CROSS-REF-
15
ERENCED TESTS.—Not later than 1 year after the imple-
16
mentation of the Verifying Accurate Leading-edge IVCT 
17
Development Act of 2020, the Secretary shall issue miti-
18
gating measures for cross-referenced tests. 
19
‘‘SEC. 587F. REGULATORY PATHWAY REDESIGNATION. 
20
‘‘(a) TECHNOLOGY CERTIFICATION AND EXEMPTION 
21
DETERMINATIONS.— 
22
‘‘(1) IN GENERAL.—Based on new information, 
23
including the establishment of mitigating measures 
24
under section 587E, and after considering available 
25
01:17 Mar 17, 2020
H6102
106 
•HR 6102 IH
evidence respecting tests with the same indications 
1
for use pursuant to section 587(10), the Secretary 
2
may, upon the initiative of the Secretary or upon pe-
3
tition of an interested person— 
4
‘‘(A) revoke any exemption or requirement 
5
in effect under this subchapter with respect to 
6
such indications for use; or 
7
‘‘(B) determine that such indications for 
8
use are eligible for technology certification in 
9
accordance with section 587D(b)(2), or are oth-
10
erwise exempt from premarket review under 
11
section 587B. 
12
‘‘(2) PROCESS.—Any action under paragraph 
13
(1) shall be made by publication of a notice of such 
14
proposed action on the internet website of the Food 
15
and Drug Administration, the consideration of com-
16
ments to a public docket on such proposal, and pub-
17
lication of a final action on such internet website 
18
within 60 calendar days of the close of the comment 
19
period posted to such public docket, notwithstanding 
20
subchapter II of chapter 5 of title 5, United States 
21
Code. 
22
‘‘(b) REVOCATION.—The Secretary may revoke any 
23
exemption with respect to such test or indications for use 
24
pursuant to section 587(10), if— 
25
01:17 Mar 17, 2020
H6102
107 
•HR 6102 IH
‘‘(1) new clinical information indicates that the 
1
exemption of an in vitro clinical test or tests from 
2
premarket review under section 587B or exemption 
3
under section 587A has a reasonable probability of 
4
severe adverse health consequences, including the 
5
absence, delay, or discontinuation of appropriate 
6
medical treatment. 
7
‘‘(2) PROCESS.—Any action under this sub-
8
section shall be made by publication of a notice of 
9
such proposed action in the Federal Register, con-
10
sideration of comments to a public docket on such 
11
proposal, and publication of a final notice in the 
12
Federal Register, notwithstanding subchapter II of 
13
chapter 5 of title 5, United States Code. 
14
‘‘SEC. 587G. ADVISORY COMMITTEES. 
15
‘‘(a) IN GENERAL.—The Secretary may establish ad-
16
visory committees or use advisory committee panels of ex-
17
perts established before the date of enactment of this sec-
18
tion for the purposes of providing expert scientific advice 
19
and making recommendations related to— 
20
‘‘(1) the approval of an application for an in 
21
vitro clinical test submitted under this subchapter, 
22
including for evaluating, as applicable, the analytical 
23
validity, clinical validity, and safety of in vitro clin-
24
ical tests; 
25
01:17 Mar 17, 2020
H6102
108 
•HR 6102 IH
‘‘(2) the potential effectiveness of mitigating 
1
measures for a determination on the applicable regu-
2
latory pathway under section 587F or risk evalua-
3
tion for an in vitro clinical test or tests; 
4
‘‘(3) quality requirements under section 587J 
5
or applying such requirements to in vitro clinical 
6
tests developed or imported by developers; or 
7
‘‘(4) such other purposes as the Secretary de-
8
termines appropriate. 
9
‘‘(b) APPOINTMENTS.— 
10
‘‘(1) VOTING MEMBERS.—The Secretary shall 
11
appoint to each committee established under sub-
12
section (a), as voting members, individuals who are 
13
qualified by training and experience to evaluate in 
14
vitro clinical tests referred to the committee for the 
15
purposes specified in subsection (a), including indi-
16
viduals with, to the extent feasible, scientific exper-
17
tise in the development, manufacture, or utilization 
18
of such in vitro clinical tests, laboratory operations, 
19
and the use of in vitro clinical tests. The Secretary 
20
shall designate one member of each committee to 
21
serve as chair. 
22
‘‘(2) NONVOTING MEMBERS.—In addition to the 
23
individuals appointed pursuant to paragraph (1), the 
24
01:17 Mar 17, 2020
H6102
109 
•HR 6102 IH
Secretary shall appoint to each committee estab-
1
lished under subsection (a), as nonvoting members— 
2
‘‘(A) a representative of consumer inter-
3
ests; and 
4
‘‘(B) a representative of interests of in 
5
vitro clinical test developers not directly af-
6
fected by the matter to be brought before the 
7
committee. 
8
‘‘(3) LIMITATION.—No individual who is in the 
9
regular full-time employee of the United States and 
10
engaged in the administration of this Act may be a 
11
member of any advisory committee established under 
12
subsection (a). 
13
‘‘(4) EDUCATION
AND
TRAINING.—The Sec-
14
retary shall, as appropriate, provide education and 
15
training to each new committee member before such 
16
member participates in a committee’s activities, in-
17
cluding education regarding requirements under this 
18
Act and related regulations of the Secretary, and the 
19
administrative processes and procedures related to 
20
committee meetings. 
21
‘‘(5) MEETINGS.—The Secretary shall ensure 
22
that scientific advisory committees meet regularly 
23
and at appropriate intervals so that any matter to 
24
be reviewed by such a committee can be presented 
25
01:17 Mar 17, 2020
H6102
110 
•HR 6102 IH
to the committee not more than 60 calendar days 
1
after the matter is ready for such review. Meetings 
2
of the committee may be held using electronic com-
3
munication to convene the meetings. 
4
‘‘(6) COMPENSATION.—Members of an advisory 
5
committee established under subsection (a), while at-
6
tending meetings or conferences or otherwise en-
7
gaged in the business of the advisory committee— 
8
‘‘(A) shall be entitled to receive compensa-
9
tion at rates to be fixed by the Secretary, but 
10
not to exceed the daily equivalent of the rate in 
11
effect for positions classified above level GS–15 
12
of the General Schedule; and 
13
‘‘(B) may be allowed travel expenses as au-
14
thorized by section 5703 of title 5, United 
15
States Code, for employees serving intermit-
16
tently in the Government service. 
17
‘‘(c) GUIDANCE.—The Secretary may issue guidance 
18
on the policies and procedures governing advisory commit-
19
tees established under subsection (a). 
20
‘‘SEC. 587H. REQUEST FOR INFORMAL FEEDBACK. 
21
‘‘Before submitting a premarket application or tech-
22
nology certification application for an in vitro clinical 
23
test— 
24
01:17 Mar 17, 2020
H6102
111 
•HR 6102 IH
‘‘(1) the developer of the test may submit to the 
1
Secretary a written request for a meeting or con-
2
ference to discuss and provide information relating 
3
to the regulation of such in vitro clinical test which 
4
may include— 
5
‘‘(A) the submission process and the type 
6
and amount of evidence expected to dem-
7
onstrate the applicable standard; 
8
‘‘(B) which regulatory pathway is appro-
9
priate for an in vitro clinical test; and 
10
‘‘(C) an investigation plan for an in vitro 
11
clinical test, including a clinical protocol; and 
12
‘‘(2) upon receipt of such a request, the Sec-
13
retary shall— 
14
‘‘(A) within 60 calendar days after such 
15
receipt, or within such time period as may be 
16
agreed to by the developer, meet or confer with 
17
the developer submitting the request; and 
18
‘‘(B) within 15 calendar days after such 
19
meeting or conference, provide to the developer 
20
a written record or response describing the 
21
issues discussed and conclusions reached in the 
22
meeting or conference. 
23
01:17 Mar 17, 2020
H6102
112 
•HR 6102 IH
‘‘SEC. 587I. REGISTRATION AND LISTING. 
1
‘‘(a) REGISTRATION OF ESTABLISHMENTS FOR IN 
2
VITRO CLINICAL TESTS.— 
3
‘‘(1) IN GENERAL.—Each person described in 
4
subsection (b)(1), or an accredited person under sec-
5
tion 587P, acting on behalf of such a person, shall— 
6
‘‘(A) during the period beginning on Octo-
7
ber 1 and ending on December 31 of each year, 
8
register with the Secretary the name of such 
9
person, places of business of such person, all es-
10
tablishments engaged in the activities specified 
11
under this paragraph, the establishment reg-
12
istration number of each such establishment, 
13
and a point of contact for each such establish-
14
ment, including an electronic point of contact; 
15
and 
16
‘‘(B) submit an initial registration con-
17
taining the information required under subpara-
18
graph (A) not later than— 
19
‘‘(i) the date of implementation of this 
20
section if such establishment is engaged in 
21
any activity described in subsection (b)(1) 
22
on the date of enactment of this section, 
23
unless the Secretary establishes by guid-
24
ance a date later than such implementation 
25
01:17 Mar 17, 2020
H6102
113 
•HR 6102 IH
date for all or a category of such establish-
1
ments; or 
2
‘‘(ii) 30 days prior to engaging in any 
3
activity described in subsection (b)(1) after 
4
enactment of this section, if such establish-
5
ment is not engaged in any activity de-
6
scribed in this paragraph on the date of 
7
enactment of this section. 
8
‘‘(2) REGISTRATION NUMBERS.—The Secretary 
9
may assign a registration number to any person or 
10
an establishment registration number to any estab-
11
lishment registered in accordance with this section. 
12
Registration information shall be made publicly 
13
available by publication on the internet website 
14
maintained by the Food and Drug Administration, 
15
in accordance with subsection (d). 
16
‘‘(3) INSPECTION.—Every person or establish-
17
ment that is required to be registered with the Sec-
18
retary under this section shall be subject to inspec-
19
tion pursuant to section 704. 
20
‘‘(b) LISTING INFORMATION FOR IN VITRO CLINICAL 
21
TESTS.— 
22
‘‘(1) IN GENERAL.—Each person who— 
23
‘‘(A) is a developer, a contract manufac-
24
turer (including contract packaging), contract 
25
01:17 Mar 17, 2020
H6102
114 
•HR 6102 IH
sterilizer, repackager, relabeler, or distributor of 
1
an in vitro clinical test; and 
2
‘‘(B) introduces or proposes to begin the 
3
introduction or delivery for introduction into 
4
interstate commerce through an exemption 
5
under section 587A(f)(2)(b) or 587A(g) or 
6
through the filing of an application under sec-
7
tion 587B or 587D, 
8
shall submit a listing to the Secretary containing the 
9
information described in paragraph (2) in accord-
10
ance with the applicable schedule described under 
11
subsection (c). Such listing shall be prepared in such 
12
form and manner as the Secretary may specify in 
13
guidance. Listing information shall be submitted 
14
through the comprehensive test information system 
15
in accordance with section 587T, as appropriate. 
16
‘‘(2) SUBMISSIONS.—Each developer submitting 
17
a listing under paragraph (1) shall electronically 
18
submit to the comprehensive test information system 
19
under section 587T the following information for 
20
each in vitro clinical test for which such person is 
21
a developer in the form and manner prescribed by 
22
the Secretary: 
23
‘‘(A) Name of the establishment and its fa-
24
cility registration number. 
25
01:17 Mar 17, 2020
H6102
115 
•HR 6102 IH
‘‘(B) Contact information for the official 
1
correspondent for the listing. 
2
‘‘(C) Name (common name and trade 
3
name, if applicable) of the in vitro clinical test 
4
and its test listing number (when available). 
5
‘‘(D) CLIA certificate number for any lab-
6
oratory certified by the Secretary under section 
7
263a of title 42 that meets the requirements for 
8
performing high-complexity testing that is the 
9
developer of the in vitro clinical test, and CLIA 
10
certificate number for any laboratory under 
11
common ownership that is performing the test 
12
developed by such test developer. 
13
‘‘(E) Whether the in vitro clinical test is, 
14
as applicable, offered as a test approved under 
15
section 587B, offered under a technology cer-
16
tification order issued under section 587D, or 
17
offered as an in vitro clinical test under section 
18
587A. 
19
‘‘(F) Indications for use information under 
20
section 587(10). 
21
‘‘(G) Brief narrative description of the in 
22
vitro clinical test. 
23
01:17 Mar 17, 2020
H6102
116 
•HR 6102 IH
‘‘(H) A brief summary of the analytical 
1
and clinical performance of the in vitro clinical 
2
test, and as applicable, the lot release criteria. 
3
‘‘(I) A brief description of conformance 
4
with any applicable mitigating measures, re-
5
strictions, and standards. 
6
‘‘(J) Representative labeling for the in 
7
vitro clinical test, as appropriate. 
8
‘‘(K) A statement that the information 
9
submitted is truthful and accurate. 
10
‘‘(3) TEST LISTING NUMBER.—The Secretary 
11
may assign a test listing number to each in vitro 
12
clinical test that is the subject of a listing under this 
13
section. The process for assigning test listing num-
14
bers may be established through guidance, and may 
15
include the recognition of standards, formats, or 
16
conventions developed by a third-party organization. 
17
‘‘(4) ABBREVIATED LISTING.—A person who is 
18
not a developer but is otherwise required to register 
19
pursuant to subsection (a) shall submit an abbre-
20
viated listing to the Secretary containing the infor-
21
mation described in subparagraphs (A) through (C) 
22
of paragraph (2), and the name of the developer. 
23
The information shall be submitted in accordance 
24
with the applicable schedule described under sub-
25
01:17 Mar 17, 2020
H6102
117 
•HR 6102 IH
section (c). Such abbreviated listing shall be pre-
1
pared in such form and manner as the Secretary 
2
may specify in guidance. Listing information shall be 
3
submitted to the comprehensive test information sys-
4
tem in accordance with section 587T, as appro-
5
priate. 
6
‘‘(5) GRANDFATHERED TESTS.—A developer of 
7
an in vitro clinical test developer offering a test that 
8
is grandfathered under section 587A(c) shall submit 
9
listing information required under subparagraphs 
10
(A) through (I) of paragraph (2). 
11
‘‘(6) LOW-RISK TESTS.—A developer of a low 
12
risk in vitro clinical test shall notify and submit list-
13
ing information to the Secretary within one year of 
14
offering such test for clinical use. 
15
‘‘(7) EXEMPT
TESTS.—A developer of an in 
16
vitro clinical test who introduces or proposes to 
17
begin the introduction or delivery for introduction 
18
into interstate commerce pursuant to an exemption 
19
under section 587A may submit listing information 
20
under this subsection. 
21
‘‘(c) TIMELINES FOR SUBMISSION.— 
22
‘‘(1) IN GENERAL.—The timelines for submis-
23
sion of registration and listing under subsections (a) 
24
and (b) are as follows: 
25
01:17 Mar 17, 2020
H6102
118 
•HR 6102 IH
‘‘(A) For an in vitro clinical test that was 
1
listed as a device under section 510(j) prior to 
2
the date of enactment of this section, a person 
3
shall maintain a device listing under section 
4
510 until such time as the system for submit-
5
ting the notification information required under 
6
subsection (b) becomes available and thereafter 
7
shall submit the notification information no 
8
later than 1 year after the system for submit-
9
ting the notification under this section becomes 
10
available. 
11
‘‘(B) For an in vitro clinical test that is 
12
subject to the grandfathering provisions of sec-
13
tion 587A(c), a person shall submit the listing 
14
information required under subsection (b)(5) no 
15
later than 1 year after the system for submit-
16
ting the notification under this section becomes 
17
available. 
18
‘‘(C) For an in vitro clinical test that is 
19
not subject to subparagraph (A) or (B), a per-
20
son shall submit the required notification infor-
21
mation prior to offering, introducing, or mar-
22
keting the in vitro clinical test as follows: 
23
‘‘(i) For an in vitro clinical test that 
24
is not exempt from premarket approval 
25
01:17 Mar 17, 2020
H6102
119 
•HR 6102 IH
under section 587B, a person shall submit 
1
the required listing information no later 
2
than 30 business days after the date of ap-
3
proval of the premarket approval applica-
4
tion. 
5
‘‘(ii) For a developer who has received 
6
a technology certification order under sec-
7
tion 587D, a person shall submit the re-
8
quired listing information at least 30 busi-
9
ness days after receiving such technology 
10
certification order. 
11
‘‘(2) UPDATES.— 
12
‘‘(A) UPDATES
AFTER
CHANGES.—Each 
13
developer required to submit listing information 
14
under this section shall update such informa-
15
tion within 10 business days of any change that 
16
causes any previously notified information to be 
17
inaccurate or incomplete. 
18
‘‘(B) ANNUAL UPDATES.—Each developer 
19
required to submit listing information under 
20
this section shall update its information annu-
21
ally during the period beginning on October 1 
22
and ending on December 31 of each year as a 
23
component of the annual report submitted 
24
under sections 587B and 587D. 
25
01:17 Mar 17, 2020
H6102
120 
•HR 6102 IH
‘‘(d) PUBLIC AVAILABILITY OF NOTIFICATION IN-
1
FORMATION.— 
2
‘‘(1) IN
GENERAL.—Notification information 
3
submitted pursuant to this section shall be made 
4
publicly available on the website of the Food and 
5
Drug Administration in accordance with paragraph 
6
(3). 
7
‘‘(2) CONFIDENTIALITY.—Notification informa-
8
tion for an in vitro clinical test that is subject to 
9
premarket approval or technical certification shall 
10
remain confidential until such date as the in vitro 
11
clinical test receives the applicable premarket ap-
12
proval or the developer receives a technology certifi-
13
cation order. 
14
‘‘(3) EXCEPTIONS FROM PUBLIC AVAILABILITY 
15
REQUIREMENTS.—The registration and listing infor-
16
mation requirements described in subsections (a) 
17
and (b) shall not apply to the extent the Secretary 
18
determines that such information relates to— 
19
‘‘(A) trade secret or commercial confiden-
20
tial information; or 
21
‘‘(B) national security or countermeasures 
22
or is restricted from disclosure pursuant to an-
23
other provision of law. 
24
01:17 Mar 17, 2020
H6102
121 
•HR 6102 IH
‘‘(e) SUBMISSION OF INFORMATION BY ACCREDITED 
1
PERSONS.—If agreed upon by the developer, the informa-
2
tion required under this section may be submitted by an 
3
accredited person under section 587P. 
4
‘‘SEC. 587J. TEST DESIGN AND QUALITY REQUIREMENTS. 
5
‘‘(a) APPLICABILITY.— 
6
‘‘(1) IN GENERAL.—Each developer and each 
7
other person required to register under section 
8
587I(b)(1) shall establish and maintain quality re-
9
quirements in accordance with the applicable re-
10
quirements set forth in subsection (b), except as pro-
11
vided in section 587A. 
12
‘‘(2) 
CERTIFIED
LABORATORY
REQUIRE-
13
MENTS.—A developer that operates a clinical labora-
14
tory certified by the Secretary under section 353 of 
15
the Public Health Service Act that— 
16
‘‘(A) meets the requirements for per-
17
forming high-complexity testing; 
18
‘‘(B)(i) develops an vitro clinical test or in-
19
dications for use; or 
20
‘‘(ii) modifies another developer’s in vitro 
21
clinical test in that certified laboratory in a 
22
manner described in section 587(6); and 
23
‘‘(C) develops an in vitro clinical test or in-
24
dications for use that are for use only within 
25
01:17 Mar 17, 2020
H6102
122 
•HR 6102 IH
that certified laboratory or within another cer-
1
tified laboratory with common ownership, 
2
shall establish and maintain quality requirements 
3
that comply with the requirements set forth in sub-
4
section (b)(2). 
5
‘‘(3) APPLICABILITY
FOR
CERTAIN
IN
VITRO 
6
CLINICAL TESTS.—The applicable requirements set 
7
forth in subsection (b)(1) shall apply to any instru-
8
ment, specimen receptacle, or component or part 
9
that is developed for use by a clinical laboratory to 
10
which paragraph (2) applies. 
11
‘‘(4) REGULATIONS.—The Secretary may pro-
12
mulgate regulations to implement this section. In so 
13
promulgating regulations, the Secretary shall con-
14
sider whether and to what extent international har-
15
monization is appropriate. 
16
‘‘(b) QUALITY REQUIREMENTS.— 
17
‘‘(1) QUALITY
REQUIREMENTS
FOR
LABORA-
18
TORIES WITHOUT CLIA CERTIFICATION TO CONDUCT 
19
HIGH-COMPLEXITY
TESTS.—The quality require-
20
ments applicable under this section shall— 
21
‘‘(A) avoid duplication of regulations under 
22
section 353 of the Public Health Service Act; 
23
‘‘(B) apply only to the development, valida-
24
tion, production, preparation, propagation, or 
25
01:17 Mar 17, 2020
H6102
123 
•HR 6102 IH
assembly related to the design and associated 
1
manufacture and distribution of an in vitro clin-
2
ical test offered under this subchapter; 
3
‘‘(C) not apply with respect to laboratory 
4
operations; and 
5
‘‘(D) shall include the following, subject to 
6
paragraphs (2) and (3)— 
7
‘‘(i) management responsibility; 
8
‘‘(ii) quality audits; 
9
‘‘(iii) personnel; 
10
‘‘(iv) design controls; 
11
‘‘(v) document controls; 
12
‘‘(vi) purchasing controls; 
13
‘‘(vii) identification and traceability; 
14
‘‘(viii) production and process con-
15
trols; 
16
‘‘(ix) acceptance activities; 
17
‘‘(x) nonconforming product; 
18
‘‘(xi) corrective and preventive action; 
19
‘‘(xii) labeling and packaging controls; 
20
‘‘(xiii) handling, storage, distribution, 
21
and installation; 
22
‘‘(xiv) records; 
23
‘‘(xv) servicing; and 
24
‘‘(xvi) statistical techniques. 
25
01:17 Mar 17, 2020
H6102
124 
•HR 6102 IH
‘‘(2) QUALITY
REQUIREMENTS
FOR
LABORA-
1
TORIES CERTIFIED TO CONDUCT HIGH-COMPLEXITY 
2
TESTS.—Quality requirements applicable to the in 
3
vitro clinical tests and developers described in sub-
4
section (a)(2) shall— 
5
‘‘(A) avoid duplication of regulations under 
6
section 353 of the Public Health Service Act; 
7
and 
8
‘‘(B) consist of, as directed related to the 
9
design and development— 
10
‘‘(i) design controls; 
11
‘‘(ii) purchasing controls; 
12
‘‘(iii) acceptance activities; 
13
‘‘(iv) corrective and preventative ac-
14
tion; and 
15
‘‘(v) records. 
16
‘‘(3) QUALITY
REQUIREMENTS
FOR
CERTAIN 
17
LABORATORIES
DISTRIBUTING
IN
VITRO
CLINICAL 
18
TESTS OR TEST PROTOCOLS WITHIN ORGANIZATIONS 
19
OR PUBLIC HEALTH NETWORKS.— 
20
‘‘(A) IN GENERAL.—Quality requirements 
21
applicable to the developer who is distributing 
22
in vitro clinical test distributed as described in 
23
subparagraph (B) shall consist of the following: 
24
01:17 Mar 17, 2020
H6102
125 
•HR 6102 IH
‘‘(i) The requirements in paragraph 
1
(2). 
2
‘‘(ii) The labeling requirements in 
3
paragraph (1)(C)(xii). 
4
‘‘(iii) The requirement to maintain 
5
records of the laboratories to which the in 
6
vitro clinical test or test protocol is distrib-
7
uted. 
8
‘‘(B) DISTRIBUTING
LABORATORY.—Sub-
9
paragraph (A) shall apply to developers that 
10
meet the following conditions: 
11
‘‘(i) The laboratory distributing the 
12
test protocol is certified by the Secretary 
13
under section 353 of the Public Health 
14
Service Act and meets the requirements for 
15
performing high-complexity testing. 
16
‘‘(ii) The laboratory develops its own 
17
in vitro clinical test or modifies another de-
18
veloper’s in vitro clinical test in a manner 
19
described in section 587(6). 
20
‘‘(iii) The laboratory distributes the in 
21
vitro clinical test or test protocol for such 
22
test only to another laboratory that— 
23
‘‘(I) is certified by the Secretary 
24
under section 353 of the Public 
25
01:17 Mar 17, 2020
H6102
126 
•HR 6102 IH
Health Service Act and meets the re-
1
quirements for performing high-com-
2
plexity testing; 
3
‘‘(II) is within the same cor-
4
porate organization and having com-
5
mon ownership by the same parent 
6
corporation; or as applicable, is a lab-
7
oratory within a public health labora-
8
tory network coordinated or managed 
9
by the Centers for Disease Control 
10
and Prevention; and 
11
‘‘(III) implements the test pro-
12
tocol without further modification. 
13
‘‘(c) REGULATIONS.—In implementing quality re-
14
quirements for test developers under this section, the Sec-
15
retary shall— 
16
‘‘(1) for purposes of facilitating international 
17
harmonization, consider whether the developer par-
18
ticipates in an audit program in which the United 
19
States participates or the United States recognizes 
20
or conforms with standards recognized by the Sec-
21
retary; and 
22
‘‘(2) ensure a least burdensome approach de-
23
scribed in section 587B(j) by leveraging, to the ex-
24
tent applicable, the quality assurance requirements 
25
01:17 Mar 17, 2020
H6102
127 
•HR 6102 IH
applicable to developers certified by the Secretary 
1
under section 353 of the Public Health Service Act. 
2
‘‘SEC. 587K. LABELING REQUIREMENTS. 
3
‘‘(a) IN GENERAL.—An in vitro clinical test shall 
4
bear or be accompanied by labeling, and a label as applica-
5
ble, that meet the requirements set forth in subsections 
6
(b) and (c), unless such test is exempt as specified in sub-
7
section (d) or (e). 
8
‘‘(b) LABELS.— 
9
‘‘(1) IN GENERAL.—The label of an in vitro 
10
clinical test shall meet the requirements set forth in 
11
paragraph (2), except this requirement shall not 
12
apply to an in vitro clinical test that— 
13
‘‘(A) consists solely of a test protocol; or 
14
‘‘(B) is developed, manufactured, and used 
15
solely within a single laboratory certified by the 
16
Secretary under section 353 of the Public 
17
Health Service Act that meets the requirements 
18
for performing high-complexity testing. 
19
‘‘(2) REGULATIONS.—The label of an in vitro 
20
clinical test shall state the name and place of busi-
21
ness of its developer and meet the requirements set 
22
forth in regulations promulgated under this section. 
23
‘‘(c) LABELING.— 
24
01:17 Mar 17, 2020
H6102
128 
•HR 6102 IH
‘‘(1) IN GENERAL.—Labeling accompanying an 
1
in vitro clinical test, including labeling in the form 
2
of a package insert, standalone laboratory reference 
3
document, or other similar document except the la-
4
beling specified in paragraph (2), shall include ade-
5
quate directions for use and shall meet the require-
6
ments set forth in regulations promulgated under 
7
this section, except as provided in subsection (d) or 
8
(e). Labeling in the form of a package insert shall 
9
also include the information in subparagraph (A) or 
10
(B) of paragraph (2). 
11
‘‘(2) CONTENT.— 
12
‘‘(A) 
IN
GENERAL.—Labeling 
accom-
13
panying an in vitro clinical test that is in the 
14
form of a test report template or ordering infor-
15
mation shall include— 
16
‘‘(i) the test listing number that was 
17
provided to the developer at the time of 
18
listing; 
19
‘‘(ii) instructions for how and where 
20
to report an adverse event under section 
21
587L; 
22
‘‘(iii) instructions for how and where 
23
to access the performance summary data 
24
01:17 Mar 17, 2020
H6102
129 
•HR 6102 IH
displayed in the listing database for the 
1
test; 
2
‘‘(iv) the intended use of the in vitro 
3
clinical test; and 
4
‘‘(v) any warnings, contraindications, 
5
or limitations. 
6
‘‘(B) PUBLIC AVAILABILITY OF INFORMA-
7
TION.—The Secretary shall make all of the in-
8
formation described in subparagraph (A) with 
9
respect to each in vitro clinical test available to 
10
the public, as applicable, in accordance with 
11
section 587T, except to the extent that the Sec-
12
retary determines that such information is— 
13
‘‘(i) trade secret or commercial con-
14
fidential information; or 
15
‘‘(ii) national security or counter-
16
measures or is restricted from disclosure 
17
pursuant to another provision of law. 
18
‘‘(3) ADDITIONAL
REQUIREMENTS.—Labeling 
19
for an in vitro clinical test used for immunohematol-
20
ogy testing shall meet the following applicable re-
21
quirements set forth in part 660 of the Code of Fed-
22
eral Regulations (or any successor regulation), re-
23
lated to the labeling of blood grouping reagents, rea-
24
gent red blood cells, and anti-human globulin. 
25
01:17 Mar 17, 2020
H6102
130 
•HR 6102 IH
‘‘(d) EXEMPTIONS
AND ALTERNATIVE REQUIRE-
1
MENTS.— 
2
‘‘(1) IN GENERAL.— 
3
‘‘(A) IN GENERAL.—With respect to an in 
4
vitro clinical test that meets the criteria of sub-
5
paragraph (B), the ‘state in one place’ regula-
6
tions under section 809.10(b) of title 21 of the 
7
Code of Federal Regulations (or any successor 
8
regulations) may be satisfied by the laboratory 
9
posting such information on its website or in 
10
multiple documents, if such documents are 
11
maintained and accessible in one place. 
12
‘‘(B) APPLICABLE
TESTS.—An in vitro 
13
clinical test meets the criteria of this subpara-
14
graph if such test is— 
15
‘‘(i) designed and manufactured by a 
16
laboratory certified by the Secretary under 
17
section 353 of the Public Health Service 
18
Act that meets the requirements for per-
19
forming high-complexity testing; and 
20
‘‘(ii) performed in the same laboratory 
21
in which it was developed or by another 
22
such laboratory certified by the Secretary 
23
under section 353 of the Public Health 
24
Service Act that meets the requirements 
25
01:17 Mar 17, 2020
H6102
131 
•HR 6102 IH
for performing high complexity testing and 
1
is under common ownership with the lab-
2
oratory that designed and manufactured 
3
the test. 
4
‘‘(2) TEST INSTRUMENT LABELING.—The label-
5
ing for an instrument is not required to bear the in-
6
formation indicated in paragraphs (3), (4), (5), (7), 
7
(8), (9), (10), (11), (12), and (13) of section 
8
809.10(b) of title 21 of the Code of Federal Regula-
9
tions, as it appears on the date of enactment of this 
10
subchapter and amended thereafter. 
11
‘‘(3) REAGENT
LABELING.—For purposes of 
12
compliance with subsection (c)(1), the labeling for a 
13
reagent intended for use as a replacement in an in 
14
vitro clinical test may be limited to that information 
15
necessary to identify the reagent adequately and to 
16
describe its proper use in the system. 
17
‘‘(4) LAB
RESEARCH
OR
INVESTIGATIONAL 
18
USE.—A shipment or other delivery of an in vitro 
19
clinical test for research or investigational use pur-
20
suant to section 587A(m) shall be exempt from the 
21
labeling requirements of subsections (b) and (c)(1) 
22
and from any standard promulgated through regula-
23
tions, except as required under section 353 of the 
24
01:17 Mar 17, 2020
H6102
132 
•HR 6102 IH
Public Health Service Act or section 587R of this 
1
Act. 
2
‘‘(5) GENERAL
PURPOSE
LABORATORY
RE-
3
AGENTS.—The labeling of general purpose labora-
4
tory reagents (such as hydrochloric acid) whose uses 
5
are generally known by persons trained in their use 
6
need not bear the directions for use required by sub-
7
section (b) and subsection (c)(1). 
8
‘‘(6) ANALYTE SPECIFIC REAGENTS.—The la-
9
beling for analyte specific reagents shall bear the fol-
10
lowing statement: ‘This product is intended solely 
11
for further development of an in vitro clinical test 
12
and is exempt from most FDA regulation. This 
13
product must be evaluated by the in vitro clinical 
14
test developer in accordance with applicable require-
15
ments.’. If the labeling of an analyte specific reagent 
16
bears the information set forth in this paragraph, it 
17
need not bear the information required by subsection 
18
(c)(1). 
19
‘‘(7) OVER-THE-COUNTER TEST SAMPLE COL-
20
LECTION
SYSTEMS
LABELING.—The labeling for 
21
over-the-counter test sample collection systems for 
22
drugs of abuse testing shall bear the name and place 
23
of business of the developer included in the registra-
24
tion listing under section 587I, in language appro-
25
01:17 Mar 17, 2020
H6102
133 
•HR 6102 IH
priate for the intended users. If the labeling of such 
1
over-the-counter test sample collection system bears 
2
the information set forth in this paragraph (4)(G), 
3
it need not bear the information required by sub-
4
section (c)(1). 
5
‘‘(e) TESTS IN THE STRATEGIC NATIONAL STOCK-
6
PILE.— 
7
‘‘(1) IN GENERAL.—The Secretary may grant 
8
an exception or alternative to any provision listed in 
9
this section, unless explicitly required by a statutory 
10
provision outside this section, for specified lots, 
11
batches, or other units of an in vitro clinical test, if 
12
the Secretary determines that compliance with such 
13
labeling requirement could adversely affect the safe-
14
ty, effectiveness, or availability of such products that 
15
are or will be included in the Strategic National 
16
Stockpile. 
17
‘‘(2) REGULATIONS.—The Secretary may issue 
18
regulations amending section 809.11 of title 21 of 
19
the Code of Federal Regulations or any successor 
20
regulation to apply in full or in part to in vitro clin-
21
ical tests and in vitro clinical test developers. 
22
‘‘(f) GUIDANCE.—The Secretary may, in collabora-
23
tion with developers, issue guidance on standardized, gen-
24
eral content and format for in vitro clinical test labeling 
25
01:17 Mar 17, 2020
H6102
134 
•HR 6102 IH
to help ensure compliance with applicable requirements in 
1
this subsection. 
2
‘‘SEC. 587L. ADVERSE EVENT REPORTING. 
3
‘‘(a) APPLICABILITY.— 
4
‘‘(1) IN GENERAL.—Each in vitro clinical test 
5
developer shall establish and maintain a system for 
6
reporting adverse events in accordance with sub-
7
section (b), except as provided in section 587A. 
8
‘‘(2) REGULATIONS.—The Secretary shall pro-
9
mulgate regulations to implement this section, in-
10
cluding information necessary to be reported to en-
11
sure the analytical and clinical validity of in vitro 
12
clinical tests, and the safety of articles for taking or 
13
deriving specimens from the human body. 
14
‘‘(b) 
ADVERSE
EVENT
REPORTING
REQUIRE-
15
MENTS.—Each developer shall report to the Secretary 
16
whenever information that reasonably suggests that one 
17
of the developer’s in vitro clinical tests is associated with 
18
an adverse event becomes known to the developer. 
19
‘‘(c) REPORTS.—Reports required under this section 
20
shall be submitted as follows: 
21
‘‘(1) An individual adverse event report shall be 
22
submitted for the following events not later than— 
23
‘‘(A) 5 calendar days after an in vitro clin-
24
ical test developer receives or otherwise becomes 
25
01:17 Mar 17, 2020
H6102
135 
•HR 6102 IH
aware of information that reasonably suggests 
1
the adverse event involves a patient death; or 
2
‘‘(B) 5 calendar days after an in vitro clin-
3
ical test developer receives or otherwise becomes 
4
aware of information that reasonably suggests 
5
the event presents an imminent threat to public 
6
health. 
7
‘‘(2) Quarterly reports shall be submitted for all 
8
other adverse events, if any, and no later than the 
9
end of the quarter following the quarter in which the 
10
adverse event information was received by the in 
11
vitro clinical test developer. 
12
‘‘(d) DEFINITIONS.—In this section— 
13
‘‘(1) the term ‘adverse event’— 
14
‘‘(A) means— 
15
‘‘(i) death of, or serious injury to, a 
16
specific patient or user for which it is rea-
17
sonably believed that an in vitro clinical 
18
test error contributed to such death or se-
19
rious injury; or 
20
‘‘(ii) an in vitro clinical test error that 
21
may have reasonable likelihood to cause se-
22
rious injury or death; and 
23
‘‘(B) excludes laboratory errors that are 
24
subject to the requirements of section 353 of 
25
01:17 Mar 17, 2020
H6102
136 
•HR 6102 IH
the Public Health Service Act and corrective or 
1
preventive actions to prevent such errors; 
2
‘‘(2) the term ‘in vitro clinical test error’— 
3
‘‘(A) means a failure in an in vitro clinical 
4
test to meet the analytical or clinical validity 
5
standard or otherwise perform as intended by 
6
the developer; and 
7
‘‘(B) includes an inaccurate false result 
8
that reaches a health care provider, patient, or 
9
consumer, except that such term excludes any 
10
such event or error related to laboratory oper-
11
ations pursuant to section 353 of the Public 
12
Health Service Act; and 
13
‘‘(3) the term ‘serious injury’ means— 
14
‘‘(A) a significant delay in a critical diag-
15
nosis or causing the absence, delay, or dis-
16
continuation of critical medical treatment or 
17
that irreversibly or seriously and negatively al-
18
ters the course of the disease or condition; or 
19
‘‘(B) an injury that— 
20
‘‘(i) is life threatening; 
21
‘‘(ii) results in permanent impairment 
22
of a body function or permanent damage 
23
to a body structure; or 
24
01:17 Mar 17, 2020
H6102
137 
•HR 6102 IH
‘‘(iii) necessitates medical or surgical 
1
intervention to preclude permanent impair-
2
ment of a body function or permanent 
3
damage to a body structure. 
4
‘‘SEC. 587M. CORRECTIONS AND REMOVALS. 
5
‘‘(a) IN GENERAL.—The Secretary shall promulgate 
6
regulations to implement this section, including informa-
7
tion necessary to be reported to ensure the analytical and 
8
clinical validity of in vitro clinical tests, and the safety of 
9
specimen receptacles. 
10
‘‘(b) REPORTS OF REMOVALS AND CORRECTIONS.— 
11
‘‘(1) IN GENERAL.—Each in vitro clinical test 
12
developer or importer shall report to the Secretary 
13
any correction or removal of an in vitro clinical test 
14
undertaken by such developer or importer if the re-
15
moval or correction was undertaken— 
16
‘‘(A) to reduce the risk to health posed by 
17
the in vitro clinical test; or 
18
‘‘(B) to remedy a violation of this Act 
19
caused by the in vitro clinical test which may 
20
present a risk to health. 
21
‘‘(2) EXCEPTION.—No report of the correction 
22
or removal of an in vitro clinical test is required 
23
under paragraph (1) if a report of the correction or 
24
01:17 Mar 17, 2020
H6102
138 
•HR 6102 IH
removal is required under, and has been submitted 
1
under, section 587L. 
2
‘‘(c) TIMING.—A developer or importer shall submit 
3
any report required under this subsection to the Secretary 
4
within 15 business days of initiating such correction or 
5
removal. 
6
‘‘(d) RECORDKEEPING.—A developer or importer of 
7
an in vitro clinical test who undertakes a correction or re-
8
moval of an in vitro clinical test which is not required to 
9
be reported under this subsection shall keep a record of 
10
such correction or removal. 
11
‘‘(e) RECALL
COMMUNICATIONS.—Upon the vol-
12
untary reporting of a correction or removal by the devel-
13
oper— 
14
‘‘(1) the Secretary shall classify such correction 
15
or removal under this section within 15 calendar 
16
days; and 
17
‘‘(2) not later than 45 calendar days after the 
18
developer or other responsible party notifies the Sec-
19
retary that it has completed a recall action, the Sec-
20
retary shall provide the developer or other respon-
21
sible party with a written statement closing the re-
22
call action or stating the reasons the Secretary can-
23
not close the recall at that time. 
24
01:17 Mar 17, 2020
H6102
139 
•HR 6102 IH
‘‘(f) LIMITATION.—The developer is not required to 
1
report a correction or removal of an in vitro clinical test 
2
based solely on an adverse event report under section 
3
587L that captures an error within the approved perform-
4
ance standards for such test. 
5
‘‘(g) DEFINITIONS.—For purposes of this section— 
6
‘‘(1) the term ‘correction’ means the repair, 
7
modification, adjustment, relabeling, destruction, or 
8
inspection (including patient monitoring) of an in 
9
vitro clinical test without its physical removal from 
10
its point of use to another location, and does not in-
11
clude routine servicing; and 
12
‘‘(2) the term ‘removal’ means the physical re-
13
moval of an in vitro clinical test from its point of use 
14
to another location for repair, modification, adjust-
15
ment, relabeling, destruction, or inspection, and does 
16
not include routine servicing. 
17
‘‘SEC. 587N. RESTRICTED IN VITRO CLINICAL TESTS. 
18
‘‘(a) APPLICABILITY.— 
19
‘‘(1) IN GENERAL.—The Secretary, in issuing 
20
an approval of an in vitro clinical test under section 
21
587B of a category described in paragraph (3) may 
22
require that such test be restricted to sale, distribu-
23
tion, or use upon such conditions as the Secretary 
24
may prescribe under paragraph (2). 
25
01:17 Mar 17, 2020
H6102
140 
•HR 6102 IH
‘‘(2) CONDITIONS
PRESCRIBED
BY
THE
SEC-
1
RETARY.—The conditions prescribed by the Sec-
2
retary under this paragraph, with respect to an in 
3
vitro clinical test described in paragraph (3), are 
4
those conditions which the Secretary determines due 
5
to the potentiality for harmful effect of such test (in-
6
cluding any resulting absence, delay, or discontinu-
7
ation of appropriate medical treatment), are nec-
8
essary to assure the analytical or clinical validity of 
9
the test, or the safety of a specimen receptacle. 
10
‘‘(3) IN VITRO CLINICAL TESTS SUBJECT TO 
11
RESTRICTIONS.—The restrictions authorized under 
12
this section may be applied by the Secretary to any 
13
high-risk in vitro clinical test, prescription home-use 
14
in vitro clinical test, direct-to-consumer in vitro clin-
15
ical test, or over-the-counter in vitro clinical test. 
16
‘‘(b) LABELING AND ADVERTISING OF A RESTRICTED 
17
IN VITRO CLINICAL TEST.—The label, labeling, and ad-
18
vertising of an in vitro clinical test to which restrictions 
19
apply under subsection (a) shall bear such appropriate 
20
statements of the restrictions as the Secretary may pre-
21
scribe in the approval, provisional approval, technology 
22
certification, or regulation, as applicable. 
23
‘‘(c) REQUIREMENTS PRIOR TO ENACTMENT.—An in 
24
vitro clinical test that was offered, sold, or distributed as 
25
01:17 Mar 17, 2020
H6102
141 
•HR 6102 IH
a restricted device prior to the enactment date of this sub-
1
chapter shall continue to comply with the applicable re-
2
strictions imposed under section 515 or section 520(e) 
3
until the effective date of restrictions issued under sub-
4
section (a). 
5
‘‘SEC. 587O. APPEALS. 
6
‘‘(a) SIGNIFICANT DECISION.— 
7
‘‘(1) IN GENERAL.—The Secretary shall provide 
8
a substantive summary of the scientific and regu-
9
latory rationale for any significant decision of the 
10
Center for Devices and Radiological Health regard-
11
ing submission of an application for, or a review of, 
12
an in vitro clinical test under section 587B or sec-
13
tion 587D or regarding an exemption under section 
14
587A, including documentation of significant con-
15
troversies or differences of opinion and the resolu-
16
tion of such controversies or differences of opinion. 
17
‘‘(2) PROVISION
OF
DOCUMENTATION.—Upon 
18
request, the Secretary shall furnish a substantive 
19
summary described in paragraph (1) to the person 
20
who has made, or is seeking to make, a submission 
21
described in such paragraph. 
22
‘‘(3) APPLICATION OF LEAST BURDENSOME RE-
23
QUIREMENTS.—The substantive summary required 
24
under this subsection shall include a brief statement 
25
01:17 Mar 17, 2020
H6102
142 
•HR 6102 IH
regarding how the least burdensome requirements 
1
were considered and applied consistent with section 
2
587B(j), as applicable. 
3
‘‘(b) REVIEW OF SIGNIFICANT DECISIONS.— 
4
‘‘(1) REQUEST FOR SUPERVISORY REVIEW OF 
5
SIGNIFICANT DECISION.—Any person may request a 
6
supervisory review of the significant decision de-
7
scribed in subsection (a)(1). Such review may be 
8
conducted at the next supervisory level or higher 
9
above the agency official who made the significant 
10
decision. 
11
‘‘(2) SUBMISSION OF REQUEST.—A person re-
12
questing a supervisory review under paragraph (1) 
13
shall submit such request to the Secretary not later 
14
than 30 days after the decision for which the review 
15
is requested and shall indicate in the request wheth-
16
er such person seeks an in-person meeting or a tele-
17
conference review. 
18
‘‘(3) TIMEFRAME.—The Secretary shall sched-
19
ule an in-person or teleconference review, if so re-
20
quested, not later than 30 days after such request 
21
is made. The Secretary shall issue a decision to the 
22
person requesting a review under this subsection not 
23
later than 45 days after the request is made under 
24
paragraph (1), or, in the case of a person who re-
25
01:17 Mar 17, 2020
H6102
143 
•HR 6102 IH
quests an in-person meeting or teleconference, 30 
1
days after such meeting or teleconference. 
2
‘‘(c) ADVISORY PANELS.—The process established 
3
under subsection (a) shall permit the appellant to request 
4
review by an advisory committee established under section 
5
513 or 587G. The Secretary shall provide a response to 
6
an appellant under this subsection not later than 45 days 
7
after the requested advisory committee is convened. 
8
‘‘SEC. 587P. ACCREDITED PERSONS. 
9
‘‘(a) IN GENERAL.— 
10
‘‘(1) REVIEW OF APPLICATIONS.— 
11
‘‘(A) ACCREDITATION
FOR
APPLICATION 
12
REVIEW.—Subject to subparagraph (C), during 
13
the period beginning on the date of enactment 
14
of the Verifying Accurate Leading-edge IVCT 
15
Development Act of 2020 and ending 2 years 
16
after the date of enactment of such Act, the 
17
Secretary shall accredit persons for any of the 
18
following purposes: 
19
‘‘(i) Reviewing applications for pre-
20
market approval under section 587B and 
21
applications for technology certification 
22
under section 587D. 
23
‘‘(ii) Making recommendations to the 
24
Secretary with respect to an approval of an 
25
01:17 Mar 17, 2020
H6102
144 
•HR 6102 IH
application under section 587B or issuance 
1
of a technology certification order under 
2
section 587D. 
3
‘‘(B) REQUIREMENT
REGARDING
REVIEW 
4
RECOMMENDATIONS.— 
5
‘‘(i) IN GENERAL.—In making a rec-
6
ommendation to the Secretary under this 
7
section, an accredited person shall notify 
8
the Secretary in writing of the reasons for 
9
the recommendation concerning the appli-
10
cation. 
11
‘‘(ii) TIME
PERIOD
FOR
REVIEW.— 
12
Not later than 30 calendar days after the 
13
date on which the Secretary is notified of 
14
a recommendation under this section with 
15
respect to an application for premarket ap-
16
proval or technology certification, the Sec-
17
retary shall make a determination with re-
18
spect to the application. 
19
‘‘(C) LACK OF APPLICATIONS WITHIN 2- 
20
YEAR TIMEFRAME.—If the Secretary does not 
21
receive applications from persons that meet the 
22
criteria under subsection (c) within such period, 
23
the Secretary— 
24
01:17 Mar 17, 2020
H6102
145 
•HR 6102 IH
‘‘(i) may accredit persons under this 
1
paragraph after the 2-year period de-
2
scribed in subparagraph (A); and 
3
‘‘(ii) shall issue a public notice on the 
4
internet website of the Food and Drug Ad-
5
ministration calling for applications for 
6
such accreditation. 
7
‘‘(2) INSPECTIONS.— 
8
‘‘(A) ACCREDITATION FOR INSPECTIONS.— 
9
Subject to subparagraph (B), during the period 
10
beginning on the date of enactment of the 
11
Verifying Accurate Leading-edge IVCT Devel-
12
opment Act of 2020 and ending 2 years after 
13
the date of enactment of such Act, the Sec-
14
retary shall accredit persons for the purpose of 
15
conducting inspections of in vitro clinical test 
16
developers and other persons required to reg-
17
ister pursuant to section 587I. 
18
‘‘(B) LACK OF APPLICATIONS WITHIN 2- 
19
YEAR TIMEFRAME.—If no persons who meet the 
20
criteria for such accreditation apply during the 
21
2-year period described in subparagraph (A), 
22
the Secretary— 
23
‘‘(i) may accredit persons under this 
24
subparagraph after such period; and 
25
01:17 Mar 17, 2020
H6102
146 
•HR 6102 IH
‘‘(ii) shall issue a public notice on the 
1
internet website of the Food and Drug Ad-
2
ministration calling for applications for 
3
such accreditation. 
4
‘‘(C) EFFECT OF ACCREDITATION.— 
5
‘‘(i) IN GENERAL.—Persons accredited 
6
under subparagraph (A) to conduct inspec-
7
tions, when conducting such inspections, 
8
shall record in writing their specific obser-
9
vations and shall present their observations 
10
to the designated representative of the in-
11
spected establishment. 
12
‘‘(ii) INSPECTION
REPORT
REQUIRE-
13
MENTS.—Each person accredited under 
14
this paragraph shall prepare and submit to 
15
the Secretary an inspection report in a 
16
form and manner designated by the Sec-
17
retary for conducting inspections, taking 
18
into consideration the goals of inter-
19
national harmonization of quality systems 
20
standards. Any official classification of the 
21
inspection shall be determined by the Sec-
22
retary. Any statement or representation 
23
made by an employee or agent of an estab-
24
lishment to a person accredited to conduct 
25
01:17 Mar 17, 2020
H6102
147 
•HR 6102 IH
inspections shall be subject to section 1001 
1
of title 18, United States Code. 
2
‘‘(D) SAVINGS CLAUSE.—Nothing in this 
3
section affects the authority of the Secretary to 
4
inspect any in vitro clinical test developer or 
5
other person registered under section 587I. 
6
‘‘(E) INSPECTION LIMITATIONS.—The Sec-
7
retary shall ensure that inspections carried out 
8
under this section are not duplicative of inspec-
9
tions carried out under section 353 of the Pub-
10
lic Health Service Act. Inspections under this 
11
section shall be limited to the data and informa-
12
tion necessary— 
13
‘‘(i) for routine surveillance activities 
14
associated with applications under sections 
15
587B and 587D; or 
16
‘‘(ii) to meet the requirements to re-
17
ceive premarket approval under section 
18
587B or a technology certification order 
19
under section 587D, as applicable. 
20
‘‘(b) ACCREDITATION.— 
21
‘‘(1) ACCREDITATION PROGRAM.— 
22
‘‘(A) IN
GENERAL.—The Secretary may 
23
provide for accreditation under this section 
24
through programs administered by the Food 
25
01:17 Mar 17, 2020
H6102
148 
•HR 6102 IH
and Drug Administration, by other non-Federal 
1
government agencies, or by qualified nongovern-
2
mental organizations. A person may be accred-
3
ited for the review of both applications sub-
4
mitted under sections 587B and 587D as de-
5
scribed in subsection (a)(1)(A) and to conduct 
6
inspection activities under subsection (a)(2)(A), 
7
or for a subset of such review or activities. 
8
‘‘(B) ELIGIBLE PERSONS.—Not later than 
9
180 days after the date of enactment of the 
10
Verifying Accurate Leading-edge IVCT Devel-
11
opment Act of 2020, the Secretary shall issue 
12
draft guidance on the criteria that the Sec-
13
retary will use to accredit or deny accreditation 
14
to a person who requests such accreditation 
15
under subsection (a), and not later than one 
16
year after the close of the comment period for 
17
the draft guidance issued in this section, issue 
18
final guidance. 
19
‘‘(C) REQUIREMENTS.— 
20
‘‘(i) IN
GENERAL.—The Secretary 
21
shall not accredit or maintain accreditation 
22
for a person unless such person meets the 
23
minimum qualifications required under 
24
subsection (c). 
25
01:17 Mar 17, 2020
H6102
149 
•HR 6102 IH
‘‘(ii) SCOPE
OF
ACCREDITATION.— 
1
The accreditation of a person under this 
2
section shall specify the particular activi-
3
ties under subsection (a) for which such 
4
person is accredited. 
5
‘‘(D) PUBLIC LIST.—The Secretary shall 
6
publish on the internet website of the Food and 
7
Drug Administration a list of persons who are 
8
accredited under this section. Such list shall be 
9
updated on at least a monthly basis. The list 
10
shall specify the particular activity or activities 
11
under this section for which the person is ac-
12
credited. 
13
‘‘(2) ACCREDITATION PROCESS.— 
14
‘‘(A) 
ACCREDITATION
PROCESS
GUID-
15
ANCE.—The Secretary shall— 
16
‘‘(i) not later than 180 days after the 
17
date of enactment of the Verifying Accu-
18
rate Leading-edge IVCT Development Act 
19
of 2020, issue draft guidance specifying 
20
the process for submitting a request for 
21
each type of accreditation and reaccredita-
22
tion under this section, including the form 
23
and content of information to be submitted 
24
in such a request; and 
25
01:17 Mar 17, 2020
H6102
150 
•HR 6102 IH
‘‘(ii) not later than 1 year after the 
1
close of the comment period for the draft 
2
guidance, issue final guidance. 
3
‘‘(B) RESPONSE TO REQUEST.—The Sec-
4
retary shall respond to a request for accredita-
5
tion or reaccreditation within 60 calendar days 
6
of the receipt of the request. The Secretary’s 
7
response may be to accredit or reaccredit the 
8
person, to deny accreditation, or to request ad-
9
ditional information in support of the request. 
10
If the Secretary requests additional informa-
11
tion, the Secretary shall respond within 60 cal-
12
endar days of receipt of such additional infor-
13
mation to accredit or deny the accreditation. 
14
‘‘(C) TYPE OF ACCREDITATION.—The ac-
15
creditation or reaccreditation of a person shall 
16
specify the particular activity or activities under 
17
subsection (a) for which such person is accred-
18
ited, and shall include any limitation to certain 
19
eligible in vitro clinical tests. 
20
‘‘(D) AUDIT.—The Secretary may audit 
21
the performance of persons accredited under 
22
this section for purposes of ensuring that such 
23
persons continue to meet the published criteria 
24
for accreditation, and may modify the scope or 
25
01:17 Mar 17, 2020
H6102
151 
•HR 6102 IH
particular activities for which a person is ac-
1
credited if the Secretary determines that such 
2
person fails to meet one or more criteria for ac-
3
creditation. 
4
‘‘(E) SUSPENSION OR WITHDRAWAL.—The 
5
Secretary may suspend or withdraw accredita-
6
tion of any person accredited under this section, 
7
after providing notice and an opportunity for an 
8
informal hearing, when such person is substan-
9
tially not in compliance with the requirements 
10
of this section or the published criteria for ac-
11
creditation, or poses a threat to public health, 
12
or fails to act in a manner that is consistent 
13
with the purposes of this section. 
14
‘‘(F) REACCREDITATION.—Accredited per-
15
sons may be initially accredited for up to 4 
16
years. After expiration of such initial period, 
17
persons may be reaccredited for unlimited addi-
18
tional 4-year periods, as determined by the Sec-
19
retary. 
20
‘‘(c) QUALIFICATIONS OF ACCREDITED PERSONS.— 
21
‘‘(1) ELIGIBILITY.—An accredited person, at a 
22
minimum, shall— 
23
‘‘(A) not be an employee of the Federal 
24
Government; 
25
01:17 Mar 17, 2020
H6102
152 
•HR 6102 IH
‘‘(B) not engage in the activities of a de-
1
veloper, as defined in section 587(7); 
2
‘‘(C) not be a person required to register 
3
under section 587I, unless such person has es-
4
tablished sufficient processes and protocols to 
5
separate activities to develop in vitro clinical 
6
tests and the activities for which such person 
7
would be accredited under subsection (a) and 
8
discloses applicable information under this sec-
9
tion; 
10
‘‘(D) not be owned or controlled by, and 
11
shall have no organizational, material or finan-
12
cial affiliation with, an in vitro clinical test de-
13
veloper or other person required to register 
14
under section 587I; 
15
‘‘(E) be a legally constituted entity per-
16
mitted to conduct the activities for which it 
17
seeks accreditation; 
18
‘‘(F) ensure that the operations of such 
19
person are in accordance with generally accept-
20
ed professional and ethical business practices; 
21
and 
22
‘‘(G) include in its request for accredita-
23
tion a commitment to, at the time of accredita-
24
01:17 Mar 17, 2020
H6102
153 
•HR 6102 IH
tion and at any time it is performing activities 
1
pursuant to this section— 
2
‘‘(i) certify that the information re-
3
ported to the Secretary accurately reflects 
4
the data or protocol reviewed, and the doc-
5
umented inspection findings, as applicable; 
6
‘‘(ii) limit work to that for which com-
7
petence and capacity are available; 
8
‘‘(iii) treat information received or 
9
learned, records, reports, and recommenda-
10
tions as proprietary information of the per-
11
son submitting such information; and 
12
‘‘(iv) in conducting the activities for 
13
which the person is accredited in respect to 
14
a particular in vitro clinical test, protect 
15
against the use of any employee or consult-
16
ant who has a financial conflict of interest 
17
regarding that in vitro clinical test. 
18
‘‘(2) WAIVER.—The Secretary may waive any 
19
requirements in subparagraph (A), (B), (C), or (D) 
20
of paragraph (1) upon making a determination that 
21
such person has implemented other appropriate con-
22
trols sufficient to ensure a competent and impartial 
23
review. 
24
‘‘(d) COMPENSATION OF ACCREDITED PERSONS.— 
25
01:17 Mar 17, 2020
H6102
154 
•HR 6102 IH
‘‘(1) IN
GENERAL.—Compensation of an ac-
1
credited person who reviews an application for pre-
2
market approval submitted under section 587B or 
3
an application for technical certification submitted 
4
under section 587D shall be determined by agree-
5
ment between the accredited person and the person 
6
who engages the services of the accredited person, 
7
and shall be paid by the person who engages such 
8
services. 
9
‘‘(2) INSPECTION ACCREDITATION.—Compensa-
10
tion of an accredited person who is conducting an 
11
inspection under section 704 shall be determined by 
12
agreement between the accredited person and the 
13
person who engages the services of the accredited 
14
person, and shall be paid by the person who engages 
15
such services. 
16
‘‘(e) COOPERATIVE AGREEMENTS.—The Secretary is 
17
authorized to enter into cooperative arrangements with of-
18
ficials of foreign countries to ensure that adequate and 
19
effective means are available for purposes of determining, 
20
from time to time, whether in vitro clinical tests intended 
21
for use in the United States by a person whose facility 
22
is located outside the United States shall be refused ad-
23
mission on any of the grounds set forth in section 801(a). 
24
01:17 Mar 17, 2020
H6102
155 
•HR 6102 IH
‘‘(f) INFORMATION SHARING AGREEMENTS.—An ac-
1
credited person may enter into an agreement with a test 
2
developer to provide information to the comprehensive test 
3
information system under section 587T, including any re-
4
quirements under section 587I. 
5
‘‘SEC. 587Q. RECOGNIZED STANDARDS. 
6
‘‘(a) IN GENERAL.—The Secretary may by order es-
7
tablish performance standards for an in vitro clinical test 
8
or tests with the same indication for use to provide reason-
9
able assurance of the analytical validity, clinical validity, 
10
or as applicable safety, of that in vitro clinical test or tests 
11
with the same indications for use. 
12
‘‘(b) OTHER STANDARDS.—The Secretary may recog-
13
nize all or part of appropriate standards established by 
14
nationally or internationally recognized standard develop-
15
ment organizations for which a person may submit a dec-
16
laration of conformity in order to meet a requirement 
17
under this subchapter to which that standard is applicable. 
18
In recognizing a standard, any person requesting recogni-
19
tion of a standard or seeking to use a recognized standard, 
20
the Secretary shall follow the processes and requirements, 
21
in accordance with section 514(c). Standards for in vitro 
22
diagnostic devices previously recognized under section 
23
514(c) shall be considered recognized standards under this 
24
section. The application of any such consensus standard 
25
01:17 Mar 17, 2020
H6102
156 
•HR 6102 IH
shall only apply prospectively. The Secretary shall issue 
1
guidance establishing the criteria and process for such rec-
2
ognition and adoption. 
3
‘‘(c) ORDER PROCESS.—In establishing a standard 
4
under subsection (a), the Secretary shall issue a draft 
5
order proposing to establish a standard and shall provide 
6
for a comment period of not less than 60 calendar days. 
7
The Secretary may choose to seek the recommendation of 
8
an advisory committee under section 587G concerning a 
9
proposed standard either prior to or after issuance of a 
10
proposed order. After considering the comments and with-
11
in 90 days of the close of the comment period, the Sec-
12
retary shall issue a final order adopting the proposed 
13
standard, adopting a modification of the proposed stand-
14
ard or terminating the proceeding. 
15
‘‘(d) AMENDMENT PROCESS.—The procedures estab-
16
lished in this section or in guidance issued under this sec-
17
tion shall apply to amendment of an existing standard. 
18
‘‘SEC. 587R. INVESTIGATIONAL USE. 
19
‘‘(a) IN GENERAL.—Except as provided in subsection 
20
(c), an in vitro clinical test for investigational use shall 
21
be exempt from the requirements of this subchapter other 
22
than sections 587A, 587O, and 587U. 
23
‘‘(b) REGULATIONS.—Not later than 2 years after 
24
the date of enactment of the Verifying Accurate Leading- 
25
01:17 Mar 17, 2020
H6102
157 
•HR 6102 IH
edge IVCT Development Act of 2020, the Secretary shall 
1
promulgate regulations to implement this section. 
2
‘‘(c) APPLICATION FOR INVESTIGATIONAL USE.— 
3
‘‘(1) IN GENERAL.—The following shall apply 
4
with respect to in vitro clinical tests for investiga-
5
tional use: 
6
‘‘(A) STREAMLINING
APPLICATIONS
SUB-
7
MITTED UNDER THIS SECTION.—Requirements 
8
with respect to such tests shall be completed in 
9
accordance with current investigational use re-
10
quirements for institutional review boards and 
11
current processes for any analytical or clinical 
12
validation. 
13
‘‘(B) VARIATION.—The requirements in 
14
the regulations promulgated under this section 
15
shall take into account variations based on— 
16
‘‘(i) the scope and duration of clinical 
17
testing to be conducted under investigation 
18
that is the subject of such application; 
19
‘‘(ii) the number of human subjects 
20
that are to be involved in such testing; 
21
‘‘(iii) the need to permit changes to be 
22
made in the in vitro clinical test involved 
23
during testing conducted in accordance 
24
01:17 Mar 17, 2020
H6102
158 
•HR 6102 IH
with a plan required under paragraph 
1
(3)(B); or 
2
‘‘(iv) whether the clinical testing of 
3
such in vitro clinical test is for the purpose 
4
of developing data to obtain approval to 
5
offer such test. 
6
‘‘(C) SIGNIFICANT RISK STUDIES.—In the 
7
case of an in vitro clinical test the investiga-
8
tional use of which poses a significant risk, a 
9
sponsor of an investigation of such a test seek-
10
ing an investigational use exemption shall sub-
11
mit to the Secretary an investigational use ap-
12
plication with respect to the test in accordance 
13
with paragraphs (2) and (3). For purposes of 
14
this subparagraph, the term ‘significant risk’ 
15
means, with respect to an in vitro clinical test 
16
that is a high-risk test, and that the use of the 
17
test— 
18
‘‘(i) is a use of substantial importance 
19
in performing an activity or activities de-
20
scribed in subsection (ss)(1)(A) for, a seri-
21
ous or life-threatening disease or condition 
22
without confirmation of the diagnosis by a 
23
medically established means; 
24
01:17 Mar 17, 2020
H6102
159 
•HR 6102 IH
‘‘(ii) requires an invasive sampling 
1
procedure that presents a significant risk 
2
to the human subject; or 
3
‘‘(iii) otherwise presents a reasonably 
4
foreseeable serious risk to the health of a 
5
human subject. 
6
‘‘(D) NON-SIGNIFICANT
RISK
TESTS.—In 
7
the case of an in vitro clinical test, the inves-
8
tigational use of which does not pose a signifi-
9
cant risk— 
10
‘‘(i) the sponsor of such investigation 
11
shall— 
12
‘‘(I) conduct such investigation in 
13
compliance with an investigational 
14
plan specified in paragraph (5) and 
15
labeling 
specified 
in 
paragraph 
16
(3)(A)(ii); 
17
‘‘(II) ensure each investigator ob-
18
tains informed consent under part 50 
19
of title 21, Code of Federal Regula-
20
tions (or any successor regulations), 
21
subject to the exceptions set forth in 
22
paragraphs (5)(A)(iii) and (5)(B); 
23
‘‘(III) submit a listing to the Sec-
24
retary of such investigation; and 
25
01:17 Mar 17, 2020
H6102
160 
•HR 6102 IH
‘‘(IV) maintain records with re-
1
spect to all requirements in this sub-
2
paragraph; and 
3
‘‘(ii) the sponsor may rely on any ex-
4
ception or exemption identified in para-
5
graph (5)(B) or as established by the Sec-
6
retary in regulations issued under sub-
7
section (b). 
8
‘‘(2) APPLICATION
CONTENT.—An investiga-
9
tional use application shall be submitted in such 
10
time and manner and contain such information as 
11
the Secretary may require in regulation, and shall 
12
include an investigational plan for proposed clinical 
13
testing and assurances that the sponsor submitting 
14
the application will— 
15
‘‘(A) establish and maintain records rel-
16
evant to the investigation of such in vitro clin-
17
ical test; and 
18
‘‘(B) submit to the Secretary annual re-
19
ports of data obtained as a result of the inves-
20
tigational use of the in vitro clinical test during 
21
the period covered by the exemption that the 
22
Secretary reasonably determines will enable the 
23
Secretary— 
24
01:17 Mar 17, 2020
H6102
161 
•HR 6102 IH
‘‘(i) to ensure compliance with the 
1
conditions for approval specified in para-
2
graph (3); 
3
‘‘(ii) to review the progress of the in-
4
vestigation involved; and 
5
‘‘(iii) to evaluate the analytical valid-
6
ity and clinical validity of such test. 
7
‘‘(3) CONDITIONS OF APPROVAL.— 
8
‘‘(A) IN GENERAL.—An investigational use 
9
application with respect to significant risk tests 
10
shall only be approved if each of the following 
11
conditions is met: 
12
‘‘(i) The risks to the subjects of the in 
13
vitro clinical test are outweighed by the an-
14
ticipated benefits to the subjects and the 
15
importance of the knowledge to be gained, 
16
and adequate assurance of informed con-
17
sent is provided in accordance with para-
18
graph (5)(A)(iii). 
19
‘‘(ii) The proposed labeling for the in 
20
vitro clinical test involved clearly and con-
21
spicuously states ‘For investigational use’. 
22
‘‘(iii) Such other requirements the 
23
Secretary determines to be necessary for 
24
the protection of the public health and 
25
01:17 Mar 17, 2020
H6102
162 
•HR 6102 IH
safety as long as the requirements do not 
1
unduly delay investigation after finding 
2
that the results of such investigation estab-
3
lish sufficient data to support clinical or 
4
analytical validity. 
5
‘‘(B) CERTAIN SIGNIFICANT RISK IN VITRO 
6
CLINICAL TESTS FOR AN UNMET NEED.—As a 
7
condition of approval under this paragraph, the 
8
Secretary shall not impose a limit on the sam-
9
ple size for a significant risk in vitro clinical 
10
test that meets the requirements of section 
11
587C, as long as such test is developed within 
12
a laboratory that is certified to conduct high- 
13
complexity testing under section 353 of the 
14
Public Health Service Act. 
15
‘‘(4) COORDINATION
WITH
INVESTIGATIONAL 
16
NEW
DRUG
APPLICATIONS.—Any requirement for 
17
the submission of a report to the Secretary pursuant 
18
to an investigational new drug application involving 
19
an in vitro clinical test shall supersede the reporting 
20
requirement in paragraph (2)(B), but only to the ex-
21
tent the requirement with respect to the investiga-
22
tional new drug application is duplicative of the re-
23
porting requirement under such paragraph. 
24
‘‘(5) INVESTIGATION PLAN REQUIREMENTS.— 
25
01:17 Mar 17, 2020
H6102
163 
•HR 6102 IH
‘‘(A) IN GENERAL.—With respect to an in-
1
vestigational plan submitted under paragraph 
2
(2)(A), the sponsor submitting such plan 
3
shall— 
4
‘‘(i) in the case of such a plan sub-
5
mitted to an institutional review com-
6
mittee, promptly notify the Secretary of 
7
the approval or the suspension or termi-
8
nation of the approval of such plan by an 
9
institutional review committee; 
10
‘‘(ii) in the case of an in vitro clinical 
11
test made available to investigators for 
12
clinical testing, assurance that all inves-
13
tigators will comply with this section, regu-
14
lations promulgated or revised under this 
15
section, and applicable human subjects reg-
16
ulations; and 
17
‘‘(iii) submit an assurance to the Sec-
18
retary that informed consent will be ob-
19
tained from each human subject (or the 
20
representative of such subject) of proposed 
21
clinical testing involving such in vitro clin-
22
ical test, except in the case that— 
23
‘‘(I) there is a life-threatening 
24
situation involving the human subject 
25
01:17 Mar 17, 2020
H6102
164 
•HR 6102 IH
of such testing which necessitates the 
1
use of such in vitro clinical test; 
2
‘‘(II) it is not feasible to obtain 
3
informed consent from the subject; 
4
and 
5
‘‘(III) there is not sufficient time 
6
to obtain such consent from a rep-
7
resentative of such subject. 
8
‘‘(B) EXCEPTION.—The informed consent 
9
of human subjects shall not be required with re-
10
spect to clinical testing conducted as part of an 
11
investigation, if— 
12
‘‘(i) the clinical testing uses remnants 
13
of specimens collected for routine clinical 
14
care or analysis that would have been dis-
15
carded, leftover specimens that were pre-
16
viously collected for other research pur-
17
poses, or specimens obtained from speci-
18
men repositories; 
19
‘‘(ii) the identity of the subject of the 
20
specimen is not known to, and may not 
21
readily be ascertained by, the investigator 
22
or any other individual associated with the 
23
investigation, including the sponsor; 
24
01:17 Mar 17, 2020
H6102
165 
•HR 6102 IH
‘‘(iii) any clinical information that ac-
1
companies the specimens does not make 
2
the specimen source identifiable to the in-
3
vestigator or any other individual associ-
4
ated with the investigation, including the 
5
sponsor; 
6
‘‘(iv) the individuals caring for the 
7
human subjects as patients are different 
8
from, and do not share information about 
9
the patient with, the individuals conducting 
10
the investigation; and 
11
‘‘(v) the specimens are provided to the 
12
investigators without personally identifiable 
13
information and the supplier of the speci-
14
mens has established policies and proce-
15
dures to prevent the release of personally 
16
identifiable information. 
17
‘‘(d) REVIEW OF APPLICATIONS.— 
18
‘‘(1) IN GENERAL.—The Secretary may issue 
19
an order approving an investigation as proposed, ap-
20
proving it with conditions or modifications, or dis-
21
approving it. 
22
‘‘(2) FAILURE TO ACT.—Unless the Secretary, 
23
not later than the date that is 30 calendar days 
24
after the date of the submission of an investigational 
25
01:17 Mar 17, 2020
H6102
166 
•HR 6102 IH
use application that meets the requirements of sub-
1
section (c)(2), issues an order under subsection 
2
(d)(1) and notifies the sponsor submitting the appli-
3
cation, the application shall be treated as approved 
4
as of such date without further action by the Sec-
5
retary. 
6
‘‘(3) DISAPPROVAL.—The Secretary may dis-
7
approve an investigational use application submitted 
8
under this subsection if the Secretary determines 
9
that the investigation with respect to which the ap-
10
plication is submitted does not conform to the re-
11
quirements of subsection (c)(3). A listing of such 
12
disapproval submitted to the sponsor with respect to 
13
such an application shall contain the order of dis-
14
approval and a complete statement of the reasons 
15
for the Secretary’s disapproval of the application. 
16
‘‘(e) WITHDRAWAL OF APPROVAL.— 
17
‘‘(1) IN GENERAL.—The Secretary may, by ad-
18
ministrative order, withdraw the approval of an ex-
19
emption granted under this section with respect to 
20
an in vitro clinical test, including an exemption 
21
granted based on the Secretary’s failure to act pur-
22
suant to subsection (d)(2), if the Secretary deter-
23
mines that the test does not meet the applicable con-
24
ditions under subsection (c)(3) for such approval. 
25
01:17 Mar 17, 2020
H6102
167 
•HR 6102 IH
‘‘(2) OPPORTUNITY TO BE HEARD.— 
1
‘‘(A) IN
GENERAL.—Subject to subpara-
2
graph (B), an order withdrawing the approval 
3
of an exemption granted under this section may 
4
be issued only after the Secretary provides the 
5
applicant or sponsor of the test with an oppor-
6
tunity for an informal hearing. 
7
‘‘(B) EXCEPTION.—An order referred to in 
8
subparagraph (A) with respect to an exemption 
9
granted under this subsection may be issued on 
10
a preliminary basis before the provision of an 
11
opportunity for an informal hearing if the Sec-
12
retary determines that the continuation of test-
13
ing under the exemption will result in an unrea-
14
sonable risk to the public health. The Secretary 
15
will provide an opportunity for an informal 
16
hearing promptly following any preliminary ac-
17
tion under this subparagraph. 
18
‘‘(f) CHANGES.— 
19
‘‘(1) IN
GENERAL.—The regulations promul-
20
gated under subsection (b) shall provide, with re-
21
spect to an in vitro clinical test for which an exemp-
22
tion under this subsection is in effect, procedures 
23
and conditions under which the changes to the test 
24
are allowed without the additional approval of an ap-
25
01:17 Mar 17, 2020
H6102
168 
•HR 6102 IH
plication for an exemption or the approval of a sup-
1
plement to such an application. Such regulations 
2
shall provide that such a change may be made if— 
3
‘‘(A) the sponsor or applicant determines, 
4
on the basis of credible information (as defined 
5
by the Secretary) that the change meets the 
6
conditions specified in paragraph (2); and 
7
‘‘(B) the sponsor or applicant submits to 
8
the Secretary, not later than 5 calendar days 
9
after making the change, a notice of the 
10
change. 
11
‘‘(2) CONDITIONS.—The conditions specified in 
12
this paragraph are that— 
13
‘‘(A) in the case of developmental changes 
14
to an in vitro clinical test (including manufac-
15
turing changes), the changes— 
16
‘‘(i) do not constitute a significant 
17
change in design or in basic principles of 
18
operation; 
19
‘‘(ii) do not affect the rights, safety, 
20
or welfare of the human subjects (if any) 
21
involved in the investigation; and 
22
‘‘(iii) are made in response to infor-
23
mation gathered during the course of an 
24
investigation; and 
25
01:17 Mar 17, 2020
H6102
169 
•HR 6102 IH
‘‘(B) in the case of changes to clinical pro-
1
tocols applicable to the test, the changes do not 
2
affect— 
3
‘‘(i) the validity of data or information 
4
resulting from the completion of an ap-
5
proved clinical protocol; 
6
‘‘(ii) the scientific soundness of a plan 
7
submitted under subsection (c)(5); or 
8
‘‘(iii) the rights, safety, or welfare of 
9
the human subjects (if any) involved in the 
10
investigation. 
11
‘‘(g) CLINICAL HOLD.— 
12
‘‘(1) IN GENERAL.—At any time, the Secretary 
13
may impose a clinical hold with respect to an inves-
14
tigation of an in vitro clinical test if the Secretary 
15
makes a determination described in paragraph (2). 
16
The Secretary shall, in imposing such clinical hold, 
17
specify the basis for the clinical hold, including the 
18
specific information available to the Secretary which 
19
served as the basis for such clinical hold, and con-
20
firm such determination in writing. The applicant or 
21
sponsor may immediately appeal any such deter-
22
mination pursuant to section 587O. 
23
‘‘(2) DETERMINATION.—For purposes of para-
24
graph (1), a determination described in this sub-
25
01:17 Mar 17, 2020
H6102
170 
•HR 6102 IH
paragraph with respect to a clinical hold is a deter-
1
mination that— 
2
‘‘(A) the in vitro clinical test involved rep-
3
resents an unreasonable risk to the safety of 
4
the persons who are the subjects of the clinical 
5
investigation, taking into account the qualifica-
6
tions of the clinical investigators, information 
7
about the in vitro clinical test, the design of the 
8
clinical investigation, the condition for which 
9
the in vitro clinical test is to be investigated, 
10
and the health status of the subjects involved; 
11
‘‘(B) the clinical hold should be issued for 
12
such other reasons as the Secretary may by 
13
regulation establish; or 
14
‘‘(C) any written request to the Secretary 
15
from the sponsor of an investigation that a clin-
16
ical hold be removed shall receive a decision, in 
17
writing and specifying the reasons therefor, 
18
within 30 days after receipt of such request. 
19
Any such request shall include sufficient infor-
20
mation to support the removal of such clinical 
21
hold. 
22
‘‘SEC. 587S. COLLABORATIVE COMMUNITIES FOR IN VITRO 
23
CLINICAL TESTS. 
24
‘‘(a) IN GENERAL.— 
25
01:17 Mar 17, 2020
H6102
171 
•HR 6102 IH
‘‘(1) For the purposes of facilitating community 
1
solutions and decision making with respect to in 
2
vitro clinical tests, the Secretary may participate in 
3
collaborative communities comprised of public and 
4
private participants that may provide recommenda-
5
tions and other advice to the Secretary on the devel-
6
opment and regulation of in vitro clinical tests. 
7
‘‘(2) A collaborative community under this sec-
8
tion shall have broad representation of interested 
9
private and public-sector stakeholder communities 
10
and may include patients, care partners, academics, 
11
healthcare professionals, healthcare systems, payers, 
12
Federal and State agencies, entities responsible for 
13
accrediting clinical laboratories, international regu-
14
latory bodies, test developers, or other interested en-
15
tities or communities. 
16
‘‘(b) GUIDANCE.—The Secretary shall issue a draft 
17
guidance not later than 180 days after the date of enact-
18
ment of the Verifying Accurate Leading-edge IVCT Devel-
19
opment Act of 2020, addressing the participation process 
20
and framework to build consensus, and how the Secretary 
21
may consider, review, and implement recommendations 
22
under subsection (c). 
23
01:17 Mar 17, 2020
H6102
172 
•HR 6102 IH
‘‘(c) RECOMMENDATIONS.—A collaborative commu-
1
nity for in vitro clinical tests may make recommendations 
2
to the Secretary on matters including— 
3
‘‘(1) mitigating measures for in vitro clinical 
4
tests; 
5
‘‘(2) standards development activities and per-
6
formance standards for in vitro clinical tests or 
7
groups of such tests; 
8
‘‘(3) scientific and clinical evidence to support 
9
new claims for in vitro clinical tests; 
10
‘‘(4) new technologies and methodologies re-
11
lated to in vitro clinical tests; 
12
‘‘(5) stakeholder communication and engage-
13
ment; and 
14
‘‘(6) development of effective policies and proc-
15
esses, including to develop tests, and to regulate 
16
such tests in accordance with least burdensome prin-
17
cipals under this Act. 
18
‘‘(d) USE BY SECRETARY.— 
19
‘‘(1) IN GENERAL.—The Secretary may adopt 
20
recommendations made under subsection (b), or oth-
21
erwise incorporate the feedback from collaborative 
22
communities 
into 
regulatory 
decision 
making, 
23
through rulemaking or guidance, as appropriate. 
24
01:17 Mar 17, 2020
H6102
173 
•HR 6102 IH
‘‘(2) CLARIFICATION.—The Secretary is not re-
1
quired to adopt recommendations submitted by col-
2
laborative communities. 
3
‘‘(e) TRANSPARENCY.—The Secretary shall— 
4
‘‘(1) publish on the internet website of the Food 
5
and Drug Administration matters for which it is 
6
seeking comments or recommendations, in a timely 
7
manner; 
8
‘‘(2) maintain a list of all collaborative commu-
9
nities in which the Secretary participates and make 
10
such list available on the internet website of the 
11
Food and Drug Administration; and 
12
‘‘(3) post on the internet website of the Food 
13
and Drug Administration at least once every year a 
14
report on the recommendations it has adopted and 
15
recommendations it has not adopted from collabo-
16
rative communities. 
17
‘‘(f) PARTICIPATION.—The Secretary may participate 
18
in a collaborative community only if such community re-
19
quires members to disclose conflicts of interest and has 
20
established a process to address conflicts of interest. 
21
‘‘(g) EXCEPTION.—The Federal Advisory Committee 
22
Act in the appendix to title 5 shall not apply to collabo-
23
rative communities established and used in accordance 
24
with this section. 
25
01:17 Mar 17, 2020
H6102
174 
•HR 6102 IH
‘‘SEC. 587T. COMPREHENSIVE TEST INFORMATION SYSTEM. 
1
‘‘(a) PURPOSE.—For the purposes of improving the 
2
transparency of information on in vitro clinical tests and 
3
allowing patients and health care providers better access 
4
to information about in vitro clinical tests, the Secretary 
5
shall establish a comprehensive test information system. 
6
‘‘(b) ESTABLISHMENT.—Not later than 2 years after 
7
the date of enactment of the Verifying Accurate Leading- 
8
edge IVCT Development Act of 2020, the Secretary shall 
9
make available a comprehensive test information system 
10
for in vitro clinical tests that is designed to— 
11
‘‘(1) provide a transparent interface on the 
12
internet website of the Food and Drug Administra-
13
tion for stakeholders, to the extent permitted by ap-
14
plicable law, to access the— 
15
‘‘(A) regulatory pathway designation infor-
16
mation for each in vitro clinical test or tests 
17
with the same indications for use; 
18
‘‘(B) registration and listing information 
19
provided by developers under section 587I, in-
20
cluding the use of a link for labels; 
21
‘‘(C) adverse event reports submitted 
22
under section 587L; 
23
‘‘(D) reports of corrections and removals 
24
submitted under section 587M; and 
25
01:17 Mar 17, 2020
H6102
175 
•HR 6102 IH
‘‘(E) other information pertaining to an in 
1
vitro clinical test or tests with the same indica-
2
tions for use, as the Secretary determines ap-
3
propriate; and 
4
‘‘(2) provide a secure portal for electronic sub-
5
mission, including applications and other in vitro 
6
clinical test submissions, registration and listing in-
7
formation, and adverse event reports. 
8
‘‘(c) SUBMISSION FUNCTION.—The comprehensive 
9
test information system shall serve as the electronic sub-
10
mission service for test developers submitting information 
11
for applications under sections 587B and 587D. 
12
‘‘SEC. 587U. PREEMPTION. 
13
‘‘(a) IN GENERAL.—No State, tribal, or local govern-
14
ment (or political subdivision thereof) may establish or 
15
continue in effect any requirement related to the develop-
16
ment, manufacture, labeling, distribution, sale, or use of 
17
an in vitro clinical test that is different from, or in addi-
18
tion to, the requirements of this subchapter. 
19
‘‘(b) EXCEPTIONS.—Subsection (a) shall not be con-
20
strued to affect the authority of a State, tribal, or local 
21
government— 
22
‘‘(1) to license laboratory personnel, health care 
23
practitioners, or health care facilities or to regulate 
24
01:17 Mar 17, 2020
H6102
176 
•HR 6102 IH
any aspect of a health care practitioner-patient rela-
1
tionship; or 
2
‘‘(2) to enforce laws of general applicability, 
3
such as zoning laws, environmental laws, labor laws, 
4
and general business laws. 
5
‘‘(c) CLARIFICATION.—This section shall not be con-
6
strued to shift liability to health care practitioners or other 
7
users. 
8
‘‘SEC. 587V. ADULTERATION. 
9
‘‘An in vitro clinical test shall be deemed to be adul-
10
terated: 
11
‘‘(1) If it consists in whole or in part of any 
12
filthy, putrid, or decomposed substance. 
13
‘‘(2) If it has been developed, prepared, packed, 
14
or held under insanitary conditions whereby it may 
15
have been contaminated with filth, or whereby it 
16
may have been rendered injurious to health. 
17
‘‘(3) If its container or package is composed, in 
18
whole or in part, of any poisonous or deleterious 
19
substance which may render the contents injurious 
20
to health. 
21
‘‘(4) If it bears or contains, for purposes of 
22
coloring only, a color additive which is unsafe within 
23
the meaning of section 721(a). 
24
01:17 Mar 17, 2020
H6102
177 
•HR 6102 IH
‘‘(5) If its analytical or clinical validity, or with 
1
respect to a specimen receptacle, its safety, or its 
2
strength, purity, or quality, differs from or falls 
3
below that which it purports or is represented to 
4
possess. 
5
‘‘(6) If it is required to be, declared to be, pur-
6
ports to be, or is represented as being, in conformity 
7
with any performance standard established or recog-
8
nized under section 587Q and is not in all respects 
9
in conformity with such standard. 
10
‘‘(7) If it is required to be in conformity with 
11
a mitigating measure established under section 
12
587E and is not in all respects in conformity with 
13
such mitigating measure. 
14
‘‘(8) If it fails to have an approved premarket 
15
application under section 587B unless such in vitro 
16
clinical test can be lawfully offered— 
17
‘‘(A) for clinical use pursuant to an exemp-
18
tion under section 587A; 
19
‘‘(B) for emergency use pursuant to an au-
20
thorization under section 564; or 
21
‘‘(C) for investigational use pursuant to 
22
section 587R. 
23
‘‘(9) If it is not in conformity with any condi-
24
tion established under section 587B, 587D, or 564. 
25
01:17 Mar 17, 2020
H6102
178 
•HR 6102 IH
‘‘(10) If it purports to be an in vitro clinical 
1
test that is offered for clinical use subject to an ex-
2
emption under section 587A and it fails to meet or 
3
maintain any criteria, condition, or requirement of 
4
such exemption. 
5
‘‘(11) If it has been granted an exemption 
6
under section 587R for investigational use, and the 
7
person granted such exemption or any investigator 
8
who uses such in vitro clinical test under such ex-
9
emption fails to comply with a requirement pre-
10
scribed by or under such section. 
11
‘‘(12) If it fails to meet the quality require-
12
ments prescribed in or established under section 
13
587J (as applicable), or the methods used in, or fa-
14
cilities or controls used for, its development, manu-
15
facture, packing, storage, or installation are not in 
16
conformity with applicable requirements established 
17
under such section. 
18
‘‘(13) If it has been developed, manufactured, 
19
processed, packed or held in any establishment, fac-
20
tory, or warehouse and the owner, operator or agent 
21
of such establishment, factory, or warehouse delays, 
22
denies, or limits an inspection, or refuses to permit 
23
entry or inspection. 
24
01:17 Mar 17, 2020
H6102
179 
•HR 6102 IH
‘‘(14) If it is not in compliance with any restric-
1
tion required under section 587N. 
2
‘‘SEC. 587W. MISBRANDING. 
3
‘‘An in vitro clinical test shall be deemed to be mis-
4
branded: 
5
‘‘(1) If its labeling is false or misleading in any 
6
particular. 
7
‘‘(2) If in a package form unless it bears a label 
8
containing— 
9
‘‘(A) the name and place of business of the 
10
test developer, manufacturer, packer, or dis-
11
tributor; and 
12
‘‘(B) an accurate statement of the quantity 
13
of contents in terms of weight, measure, or nu-
14
merical count with respect to small packages, 
15
unless an exemption is granted by the Secretary 
16
by the issuance of guidance. 
17
‘‘(3) If any word, statement, or other informa-
18
tion required by or under authority of this Act to 
19
appear on the label or labeling, including a test re-
20
port, is not prominently placed thereon with such 
21
conspicuousness (as compared with other words, 
22
statements, designs, or devices, in the labeling) and 
23
in such terms as to render it likely to be read and 
24
01:17 Mar 17, 2020
H6102
180 
•HR 6102 IH
understood by the ordinary individual under cus-
1
tomary conditions of purchase and use. 
2
‘‘(4) Unless its labeling bears adequate direc-
3
tions for use and such adequate warnings as are 
4
necessary for the protection of users of the in vitro 
5
clinical test and recipients of the results of such in 
6
vitro clinical test, including patients, consumers, do-
7
nors, and related health care professionals. Required 
8
labeling for in vitro clinical tests intended for use in 
9
health care facilities or by a health care professional 
10
may be made available solely by electronic means, 
11
provided that the labeling complies with all applica-
12
ble requirements of law, and that the test developer, 
13
manufacturer, or distributor affords such users the 
14
opportunity to request the labeling in paper form, 
15
and after such request, promptly provides the re-
16
quested information without additional cost. 
17
‘‘(5) If it causes serious or adverse health con-
18
sequences or death, including through absence, 
19
delay, or discontinuation in diagnosis or treatment, 
20
when used in the manner prescribed, recommended, 
21
or suggested in the labeling thereof. 
22
‘‘(6) If it was developed or manufactured in an 
23
establishment not duly registered under section 587I 
24
or it was not included in a listing under section 
25
01:17 Mar 17, 2020
H6102
181 
•HR 6102 IH
587I, in accordance with timely reporting require-
1
ments under this subchapter. 
2
‘‘(7) In the case of any in vitro clinical test sub-
3
ject to restrictions under section 587N, (1) if its ad-
4
vertising is false or misleading in any particular, (2) 
5
if it is offered for clinical use, sold, distributed, or 
6
used in violation of such restrictions, or (3) unless 
7
the test developer, manufacturer, or distributor in-
8
cludes in all advertisements and other descriptive 
9
printed matter that such person issues or causes to 
10
be issued, a brief statement of the intended uses of 
11
the in vitro clinical test and relevant warnings, pre-
12
cautions, side effects, and contraindications. This 
13
subsection shall not be applicable to any printed 
14
matter that the Secretary determines to be labeling 
15
as defined in section 201(m) or section 587K. 
16
‘‘(8) If it was subject to a mitigating measure 
17
established under section 587E, unless it bears such 
18
labeling as may be prescribed in such mitigating 
19
measure. 
20
‘‘(9) If it was subject to a standard established 
21
under section 587Q, unless it bears such labeling as 
22
may be prescribed in such standard. 
23
01:17 Mar 17, 2020
H6102
182 
•HR 6102 IH
‘‘(10) Unless it bears such labeling as may be 
1
prescribed by or established under an applicable la-
2
beling requirement under this Act. 
3
‘‘(11) If there was a failure or refusal to comply 
4
with any requirement prescribed under section 587I 
5
or 587X, or to comply with a requirement under sec-
6
tion 587Y, or to provide any report, material, or in-
7
formation required under this subchapter. 
8
‘‘SEC. 587X. POSTMARKET SURVEILLANCE. 
9
‘‘(a) IN GENERAL.— 
10
‘‘(1) IN GENERAL.—In addition to other appli-
11
cable requirements under this Act, the Secretary 
12
may issue an order requiring a developer to conduct 
13
postmarket surveillance of a single in vitro clinical 
14
test as a condition of approval under section 587B. 
15
‘‘(2) EXEMPT
TESTS.—The Secretary may 
16
order postmarket surveillance for tests exempt pur-
17
suant to section 587A for which the failure of the 
18
in vitro clinical test to meet the applicable standard 
19
for approval is likely to result in serious or adverse 
20
health consequences or death from use of the single 
21
in vitro clinical test. 
22
‘‘(3) CONSIDERATION.—In determining whether 
23
to require a developer to conduct postmarket surveil-
24
lance of an in vitro clinical test, the Secretary shall 
25
01:17 Mar 17, 2020
H6102
183 
•HR 6102 IH
take into consideration the benefits and risks for the 
1
patient and the least burdensome principles under 
2
section 587B. 
3
‘‘(b) SURVEILLANCE APPROVAL.— 
4
‘‘(1) Each developer required to conduct a sur-
5
veillance of an in vitro clinical test shall submit, 
6
within 30 days of receiving an order from the Sec-
7
retary, a plan for the required surveillance. The Sec-
8
retary, within 60 days of the receipt of such plan, 
9
shall determine if the person designated to conduct 
10
the surveillance has the appropriate qualifications 
11
and experience to undertake such surveillance and if 
12
the plan will result in useful data that can reveal un-
13
foreseen adverse events or other information nec-
14
essary to protect the health of patients or the public. 
15
‘‘(2) The developer shall commence surveillance 
16
under this section not later than 15 months after 
17
the day on which the Secretary orders such postmar-
18
ket surveillance, unless the Secretary determines 
19
more time is needed to commence surveillance. 
20
‘‘(3) The Secretary may order a prospective 
21
surveillance period of up to 3 years. Any determina-
22
tion by the Secretary that a longer period is nec-
23
essary shall be made by mutual agreement between 
24
the Secretary and the manufacturer or, if no agree-
25
01:17 Mar 17, 2020
H6102
184 
•HR 6102 IH
ment can be reached, after the completion of a dis-
1
pute resolution process. 
2
‘‘SEC. 587Y. ELECTRONIC FORMAT FOR SUBMISSIONS. 
3
‘‘(a) IN GENERAL.—All presubmissions and submis-
4
sions to the Food and Drug Administration with respect 
5
to an in vitro clinical test shall include an electronic copy 
6
of such presubmission or submission, and, with respect to 
7
the information required under sections 587B and 587D, 
8
shall utilize the system described in section 587T. 
9
‘‘(b) ELECTRONIC FORMAT.—Beginning on such date 
10
as the Secretary specifies in final guidance issued under 
11
subsection (c), presubmissions and submissions for in vitro 
12
clinical tests (and any appeals of action taken by the Sec-
13
retary with respect to such presubmissions and submis-
14
sions) shall be submitted solely in such electronic format 
15
as specified by the Secretary in such guidance. 
16
‘‘(c) GUIDANCE.—The Secretary shall issue guidance 
17
implementing this section. In such guidance, the Secretary 
18
may— 
19
‘‘(1) provide standards for the electronic copy 
20
required under subsection (a) or the submission in 
21
electronic format required under subsection (b); 
22
‘‘(2) set forth criteria for waivers of or exemp-
23
tions from the requirements of subsection (a) or (b); 
24
and 
25
01:17 Mar 17, 2020
H6102
185 
•HR 6102 IH
‘‘(3) provide any other information for the effi-
1
cient implementation and enforcement of this sec-
2
tion. 
3
‘‘SEC. 587Z. POSTMARKET REMEDIES. 
4
‘‘(a) SAFETY NOTICE.— 
5
‘‘(1) IN GENERAL.—If the Secretary determines 
6
that an in vitro clinical test presents an unreason-
7
able risk of substantial harm to the public health, 
8
and notification under this subsection is necessary to 
9
eliminate the unreasonable risk of such harm and no 
10
more practicable means is available under the provi-
11
sions of this Act (other than this section) to elimi-
12
nate the risk, the Secretary may issue such order as 
13
may be necessary to ensure that adequate safety no-
14
tice is provided in an appropriate form, by the per-
15
sons and means best suited under the circumstances, 
16
to all health care professionals who prescribe, order, 
17
or use the in vitro clinical test and to any other per-
18
son (including developers, manufacturers, importers, 
19
distributors, retailers, and users) who should prop-
20
erly receive such notice. 
21
‘‘(2) NOTICE
TO
INDIVIDUALS.—An order 
22
under this subsection shall require that the individ-
23
uals subject to the risk with respect to which the 
24
order is to be issued be included in the persons to 
25
01:17 Mar 17, 2020
H6102
186 
•HR 6102 IH
be notified of the risk unless the Secretary deter-
1
mines that notice to such individuals would present 
2
a greater danger to the health of such individuals 
3
than no such notice. If the Secretary makes such a 
4
determination with respect to such individuals, the 
5
order shall advise the health care professionals who 
6
prescribed, ordered, or used the in vitro clinical test 
7
provide notification to the individuals for whom the 
8
health professionals prescribed, ordered, or used 
9
such test, of the risk presented by such in vitro clin-
10
ical test and of any action which may be taken by 
11
or on behalf of such individuals to eliminate or re-
12
duce such risk. Before issuing an order under this 
13
subsection, the Secretary shall consult with the per-
14
sons required to give notice under the order. 
15
‘‘(b) REPAIR, REPLACEMENT, OR REFUND.— 
16
‘‘(1) DETERMINATION
AFTER
AN
INFORMAL 
17
HEARING.— 
18
‘‘(A) IN GENERAL.—If, after affording op-
19
portunity for an informal hearing, the Secretary 
20
determines that— 
21
‘‘(i) an in vitro clinical test presents 
22
an unreasonable risk of substantial harm 
23
to the public health; 
24
01:17 Mar 17, 2020
H6102
187 
•HR 6102 IH
‘‘(ii) there are reasonable grounds to 
1
believe that the in vitro clinical test was 
2
not properly developed or manufactured 
3
considering the state of the art as it ex-
4
isted at the time of its development or 
5
manufacture; 
6
‘‘(iii) there are reasonable grounds to 
7
believe that the unreasonable risk was not 
8
caused by failure of a person other than a 
9
developer, manufacturer, importer, dis-
10
tributor, or retailer of the in vitro clinical 
11
test to exercise due care in the installation, 
12
maintenance, repair, or use of the in vitro 
13
clinical test; and 
14
‘‘(iv) the notice authorized by sub-
15
section (a) would not by itself be sufficient 
16
to eliminate the unreasonable risk and ac-
17
tion described in paragraph (2) of this sub-
18
section is necessary to eliminate such risk, 
19
the Secretary may order the developer, manu-
20
facturer, importer, or any distributor of such in 
21
vitro clinical test, or any combination of such 
22
persons, to submit to him within a reasonable 
23
time a plan for taking one or more of the ac-
24
tions described in paragraph (2). An order 
25
01:17 Mar 17, 2020
H6102
188 
•HR 6102 IH
issued under the preceding sentence which is di-
1
rected to more than one person shall specify 
2
which person may decide which action shall be 
3
taken under such plan and the person specified 
4
shall be the person who the Secretary deter-
5
mines bears the principal, ultimate financial re-
6
sponsibility for action taken under the plan un-
7
less the Secretary cannot determine who bears 
8
such responsibility or the Secretary determines 
9
that the protection of the public health requires 
10
that such decision be made by a person (includ-
11
ing a health professional or user of the in vitro 
12
clinical test) other than the person the Sec-
13
retary determines bears such responsibility. 
14
‘‘(B) SECRETARY APPROVAL OF PLAN.— 
15
Within 30 calendar days of issuing an order 
16
under subparagraph (A), the Secretary shall ap-
17
prove a plan submitted pursuant to an order 
18
issued under subparagraph (A) unless the Sec-
19
retary determines (after affording opportunity 
20
for an informal hearing) that the action or ac-
21
tions to be taken under the plan or the manner 
22
in which such action or actions are to be taken 
23
under the plan will not assure that the unrea-
24
sonable risk with respect to which such order 
25
01:17 Mar 17, 2020
H6102
189 
•HR 6102 IH
was issued will be eliminated. If the Secretary 
1
disapproves a plan, the Secretary shall order a 
2
revised plan to be submitted within a reason-
3
able time. If the Secretary determines (after af-
4
fording opportunity for an informal hearing) 
5
that the revised plan is unsatisfactory or if no 
6
revised plan or no initial plan has been sub-
7
mitted to the Secretary within the prescribed 
8
time, the Secretary shall (i) prescribe a plan to 
9
be carried out by the person or persons to 
10
whom the order issued under subparagraph (A) 
11
was directed, or (ii) after affording an oppor-
12
tunity for an informal hearing, by order pre-
13
scribe a plan to be carried out by a person who 
14
is a manufacturer, importer, distributor, or re-
15
tailer of the in vitro clinical test with respect to 
16
which the order was issued but to whom the 
17
order under subparagraph (A) was not directed. 
18
‘‘(2) ACTIONS ON A PLAN.—The actions which 
19
may be taken under a plan submitted under an 
20
order issued under paragraph (1) are as follows: 
21
‘‘(A) To repair the in vitro clinical test so 
22
that it does not present the unreasonable risk 
23
of substantial harm with respect to which the 
24
order under paragraph (1)(A) was issued. 
25
01:17 Mar 17, 2020
H6102
190 
•HR 6102 IH
‘‘(B) To replace the in vitro clinical test 
1
with a like or equivalent test which is in con-
2
formity with all applicable requirements of this 
3
Act. 
4
‘‘(C) To refund the purchase price of the 
5
in vitro clinical test (less a reasonable allowance 
6
for use if such in vitro clinical test has been in 
7
the possession of the user for one year or more 
8
at the time of notice ordered under subsection 
9
(a), or at the time the user receives actual no-
10
tice of the unreasonable risk with respect to 
11
which the order was issued under paragraph 
12
(1)(A), whichever occurs first). 
13
‘‘(3) NO CHARGE.—No charge shall be made to 
14
any person (other than a developer, manufacturer, 
15
importer, distributor or retailer) for using a remedy 
16
described in paragraph (2) and provided under an 
17
order issued under paragraph (1), and the person 
18
subject to the order shall reimburse each person 
19
(other than a developer, manufacturer, importer, 
20
distributor, or retailer) who is entitled to such a 
21
remedy for any reasonable and foreseeable expenses 
22
actually incurred by such person in availing himself 
23
of such remedy. 
24
01:17 Mar 17, 2020
H6102
191 
•HR 6102 IH
‘‘(c) REIMBURSEMENT.—An order issued under sub-
1
section (b)(1)(A) with respect to an in vitro clinical test 
2
may require any person who is a developer, manufacturer, 
3
importer, distributor, or retailer of the in vitro clinical test 
4
to reimburse any other person who is a developer, manu-
5
facturer, importer, distributor, or retailer of such in vitro 
6
clinical test for such other person’s expenses actually in-
7
curred in connection with carrying out the order if the 
8
Secretary determines such reimbursement is required for 
9
the protection of the public health. Any such requirement 
10
shall not affect any rights or obligations under any con-
11
tract to which the person receiving reimbursement or the 
12
person making such reimbursement is a party. 
13
‘‘(d) RECALL AUTHORITY.— 
14
‘‘(1) IN GENERAL.—If the Secretary finds that 
15
there is a reasonable probability that an in vitro 
16
clinical test approved under section 587B would 
17
cause serious, adverse health consequences or death, 
18
including by the absence, delay, or discontinuation of 
19
appropriate medical treatment, the Secretary shall 
20
issue an order requiring the appropriate person (in-
21
cluding the developers, manufacturers, importers, 
22
distributors, or retailers of the in vitro clinical 
23
test)— 
24
01:17 Mar 17, 2020
H6102
192 
•HR 6102 IH
‘‘(A) to immediately cease distribution of 
1
such in vitro clinical test; and 
2
‘‘(B) to immediately notify health profes-
3
sionals and user facilities of the order and to 
4
instruct such professionals and facilities to 
5
cease use of such in vitro clinical test. 
6
‘‘(2) INFORMAL
HEARING.—The order issued 
7
under paragraph (1)(A), shall provide the person 
8
subject to the order with an opportunity for an in-
9
formal hearing, to be held not later than 10 calendar 
10
days after the date of the issuance of the order, on 
11
the actions required by the order and on whether the 
12
order should be amended to require a recall of such 
13
in vitro clinical test. If, after providing an oppor-
14
tunity for such a hearing, the Secretary determines 
15
that inadequate grounds exist to support the actions 
16
required by the order, the Secretary shall vacate the 
17
order. 
18
‘‘(3) AMENDED ORDER.— 
19
‘‘(A) IN GENERAL.—If, after providing an 
20
opportunity for an informal hearing under 
21
paragraph (2), the Secretary determines that 
22
the order should be amended to include a recall 
23
of the in vitro clinical test with respect to which 
24
the order was issued, the Secretary shall, except 
25
01:17 Mar 17, 2020
H6102
193 
•HR 6102 IH
as provided in subparagraph (B), amend the 
1
order to require a recall. The Secretary shall 
2
specify a timetable in which the recall will occur 
3
and shall require periodic reports describing the 
4
progress of the recall. 
5
‘‘(B) REQUIREMENTS.—An amended order 
6
under subparagraph (A)— 
7
‘‘(i) shall not include recall of the in 
8
vitro clinical test from individuals; 
9
‘‘(ii) shall not include recall of an in 
10
vitro clinical test from test user facilities if 
11
the Secretary determines that the risk of 
12
recalling such in vitro clinical test from the 
13
facilities presents a greater health risk 
14
than the health risk of not recalling the in 
15
vitro clinical test from use; and 
16
‘‘(iii) shall provide for notice to indi-
17
viduals subject to the risks associated with 
18
the use of such in vitro clinical test. In 
19
providing the notice required by this 
20
clause, the Secretary may use the assist-
21
ance of health professionals who pre-
22
scribed, ordered, or used such an in vitro 
23
clinical test for individuals. 
24
01:17 Mar 17, 2020
H6102
194 
•HR 6102 IH
‘‘(4) CLARIFICATION.—The remedy provided by 
1
this subsection shall be in addition to remedies pro-
2
vided by subsections (b) and (c).’’. 
3
SEC. 4. ENFORCEMENT AND OTHER PROVISIONS. 
4
(a) PROHIBITED ACTS.—Section 301 of the Federal 
5
Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amend-
6
ed— 
7
(1) in paragraphs (a), (b), (c), (g), (k), (q), (r), 
8
and (y), by inserting ‘‘in vitro clinical test,’’ after 
9
‘‘device,’’ each place it appears; 
10
(2) in paragraph (y) by inserting ‘‘or 587P’’ 
11
after ‘‘section 523’’ each place it appears; and 
12
(3) by adding at the end, the following: 
13
‘‘(fff)(1) The introduction or delivery for introduction 
14
into interstate commerce of an in vitro clinical test in vio-
15
lation of section 587B(a). 
16
‘‘(2) The false, fraudulent, or deceptive claiming for 
17
an in vitro clinical test of an exemption from the pre-
18
market review required under section 587B. 
19
‘‘(3) When claiming an exemption under section 
20
587A from the premarket review required under section 
21
587B, the failure to maintain complete and accurate docu-
22
mentation for the exemption as required under section 
23
587A or the failure to provide labeling required under sec-
24
tion 587A. 
25
01:17 Mar 17, 2020
H6102
195 
•HR 6102 IH
‘‘(4) With respect to an in vitro clinical test, the sub-
1
mission of any report that is required by or under this 
2
Act that is false or misleading in any material respect. 
3
‘‘(5) The making of a false, fraudulent, or materially 
4
deceptive analytical or clinical claim for an in vitro clinical 
5
test— 
6
‘‘(A) in any application, report, or notification 
7
submitted to the Secretary under this Act; or 
8
‘‘(B) in the labeling or advertising of an in vitro 
9
clinical test. 
10
‘‘(6) The failure to comply with a condition of ap-
11
proval, performance standard, mitigating measure, or re-
12
striction established in an order approving an application 
13
or supplement under section 587B; the failure to perform 
14
a risk analysis required by section 587B; the failure to 
15
submit an annual report required under section 587B(k); 
16
or the failure to complete postmarket studies required 
17
under section 587V. 
18
‘‘(7) The marketing of an in vitro clinical test in vio-
19
lation of— 
20
‘‘(A) an order issued by the Secretary under 
21
section 587A; or 
22
‘‘(B) any requirement under section 587A. 
23
‘‘(8) With respect to technology certification under 
24
section 587D, the refusal to permit, or unreasonable delay 
25
01:17 Mar 17, 2020
H6102
196 
•HR 6102 IH
in permitting, an inspection authorized under section 
1
587D(f)(3)(G); the failure to comply with applicable re-
2
quirements to submit an application or report under sec-
3
tion 587D(e); or the failure to comply with applicable 
4
maintenance requirements under section 587D(h). 
5
‘‘(9) The failure to comply with an applicable miti-
6
gating measure established under section 587E or to 
7
maintain the documentation required under section 
8
587E(b); or the failure to comply with a performance 
9
standard established under section 587Q. 
10
‘‘(10) The failure to register in accordance with sec-
11
tion 587I, the failure to provide information required 
12
under section 587I(b), or the failure to maintain or submit 
13
information required under section 587I(c). 
14
‘‘(11) The failure to submit a report required under 
15
section 587L or 587M; the failure to comply with a re-
16
striction imposed under section 587N; or the failure to 
17
comply with labeling and advertising requirements under 
18
section 587N(b). 
19
‘‘(12) The failure to comply with the requirements 
20
of section 587P (relating to accredited persons). 
21
‘‘(13) The failure to comply with any requirement 
22
prescribed or established under section 587R; the failure 
23
to furnish any notification, information, material, or re-
24
01:17 Mar 17, 2020
H6102
197 
•HR 6102 IH
port required under section 587R; or the failure to comply 
1
with an order issued under section 587R.’’. 
2
(b) PENALTIES.—Section 303(f)(1) of the Federal 
3
Food, Drug, and Cosmetic Act (21 U.S.C. 333(f)(1)) is 
4
amended— 
5
(1) in subparagraph (A), by inserting ‘‘or in 
6
vitro clinical tests’’ after ‘‘devices’’; and 
7
(2) in subparagraph (B)(i)— 
8
(A) by inserting ‘‘, or 587J or 587L,’’ 
9
after ‘‘520(f)’’; and 
10
(B) by inserting ‘‘, or who violates section 
11
587M(b) with respect to a correction report’’ 
12
after ‘‘risk to public health’’. 
13
(c) SEIZURE.—Section 304 of the Federal Food, 
14
Drug, and Cosmetic Act (21 U.S.C. 334) is amended— 
15
(1) in subsection (a)(2)— 
16
(A) by striking ‘‘and’’ before ‘‘(E) Any’’; 
17
and 
18
(B) by inserting ‘‘, and (F) Any adulter-
19
ated or misbranded in vitro clinical test’’ after 
20
‘‘tobacco product’’; 
21
(2) in subsection (d)(1), by inserting ‘‘in vitro 
22
clinical test,’’ after ‘‘device,’’; and 
23
(3) in subsection (g)— 
24
01:17 Mar 17, 2020
H6102
198 
•HR 6102 IH
(A) in paragraph (1), by inserting ‘‘, in 
1
vitro clinical test,’’ after ‘‘device’’ each place it 
2
appears; and 
3
(B) in paragraph (2)— 
4
(i) in subparagraph (A), by inserting 
5
‘‘, in vitro clinical test,’’ after ‘‘device’’; 
6
and 
7
(ii) in subparagraph (B), by inserting 
8
‘‘or in vitro clinical test’’ after ‘‘device’’ 
9
each place it appears. 
10
(d) DEBARMENT, TEMPORARY
DENIAL
OF
AP-
11
PROVAL, AND SUSPENSION.—Section 306 of the Federal 
12
Food, Drug, and Cosmetic Act (21 U.S.C. 335a) is 
13
amended by adding at the end the following: 
14
‘‘(n) IN VITRO CLINICAL TESTS; MANDATORY DE-
15
BARMENT REGARDING THIRD-PARTY INSPECTIONS AND 
16
REVIEWS.— 
17
‘‘(1) IN GENERAL.—If the Secretary finds that 
18
a person has been convicted of a felony under sec-
19
tion 301(gg), 301(fff)(2), 301(fff)(5), or 301(fff)(8), 
20
the Secretary shall debar such person from being ac-
21
credited under section 587P and from carrying out 
22
activities under an agreement described in section 
23
803(b). 
24
01:17 Mar 17, 2020
H6102
199 
•HR 6102 IH
‘‘(2) DEBARMENT
PERIOD.—The Secretary 
1
shall debar a person under paragraph (1) for the fol-
2
lowing periods: 
3
‘‘(A) The period of debarment of a person 
4
(other than an individual) shall not be less than 
5
1 year or more than 10 years, but if an act 
6
leading to a subsequent debarment under such 
7
paragraph occurs within 10 years after such 
8
person has been debarred under such para-
9
graph, the period of debarment shall be perma-
10
nent. 
11
‘‘(B) The debarment of an individual shall 
12
be permanent. 
13
‘‘(3) TERMINATION OF DEBARMENT; JUDICIAL 
14
REVIEW; OTHER MATTERS.—Subsections (c)(3), (d), 
15
(e), (i), (j), and (l)(1) apply with respect to a person 
16
(other than an individual) or an individual who is 
17
debarred under paragraph (1) to the same extent 
18
and in the same manner as such subsections apply 
19
with respect to a person who is debarred under sub-
20
section (a)(1), or an individual who is debarred 
21
under subsection (a)(2), respectively.’’. 
22
(e) JUDICIAL REVIEW.—Section 517(a) of the Fed-
23
eral Food, Drug, and Cosmetic Act (21 U.S.C. 360g(a)) 
24
is amended— 
25
01:17 Mar 17, 2020
H6102
200 
•HR 6102 IH
(1) in paragraph (8), by striking ‘‘or’’ at the 
1
end; 
2
(2) in paragraph (9), by inserting ‘‘or’’ after 
3
the comma at the end; and 
4
(3) before the matter that follows paragraph 
5
(9), by inserting the following: 
6
‘‘(10) an order issued pursuant to section 
7
587B, 587D, 587R, or 587S,’’. 
8
(f) EXPANDED ACCESS TO UNAPPROVED THERAPIES 
9
AND DIAGNOSTICS.—Section 561 of the Federal Food, 
10
Drug, and Cosmetic Act (21 U.S.C. 360bbb) is amend-
11
ed— 
12
(1) in subsections (a) through (d)— 
13
(A) by striking ‘‘or investigational devices’’ 
14
each place it appears and inserting ‘‘, investiga-
15
tional devices, or investigational in vitro clinical 
16
tests’’; and 
17
(B) by striking ‘‘or investigational device’’ 
18
each place it appears (other than the second 
19
such place in paragraph (3)(A)) and inserting 
20
‘‘, investigational device, or investigational in 
21
vitro clinical test’’; 
22
(2) in subsection (b)(4) by striking ‘‘or 520(g)’’ 
23
and inserting ‘‘, 520(g), or 587R’’ each place it ap-
24
pears; 
25
01:17 Mar 17, 2020
H6102
201 
•HR 6102 IH
(3) in subsection (c)— 
1
(A) by amending the subsection heading to 
2
read: ‘‘TREATMENT
INVESTIGATIONAL
NEW 
3
DRUG APPLICATIONS, TREATMENT INVESTIGA-
4
TIONAL DEVICE EXEMPTIONS, AND TREAT-
5
MENT INVESTIGATIONAL
IN VITRO CLINICAL 
6
TEST EXEMPTIONS’’; 
7
(B) in paragraph (3)(A), by striking ‘‘or 
8
investigational device exemption in effect under 
9
section 520(g)’’ and inserting ‘‘, investigational 
10
device exemption in effect under section 520(g), 
11
or investigational in vitro clinical test exemption 
12
under section 587R’’; 
13
(C) by striking ‘‘or treatment investiga-
14
tional device exemption’’ each place it appears 
15
and inserting ‘‘, treatment investigational device 
16
exemption, or treatment investigational in vitro 
17
clinical test exemption’’; and 
18
(D) in the matter following paragraph (7) 
19
by striking ‘‘or 520(g)’’ each place it appears 
20
and inserting ‘‘, 520(g) or 587R’’; and 
21
(4) by amending subsection (e) to read as fol-
22
lows: 
23
‘‘(e) DEFINITIONS.—In this section, the terms ‘inves-
24
tigational drug’, ‘investigational device’, ‘investigational in 
25
01:17 Mar 17, 2020
H6102
202 
•HR 6102 IH
vitro clinical test’, ‘treatment investigational new drug ap-
1
plication’, ‘treatment investigational device exemption’, 
2
and ‘treatment investigational in vitro clinical test exemp-
3
tion’ shall have the meanings given the terms in regula-
4
tions prescribed by the Secretary.’’. 
5
(g) OPTIMIZING GLOBAL CLINICAL TRIALS.—Section 
6
569A(b) of the Federal Food, Drug, and Cosmetic Act (21 
7
U.S.C. 360bbb–8a(b)) is amended by inserting ‘‘an in 
8
vitro clinical test, as defined in subsection (ss) of such sec-
9
tion,’’ before ‘‘or a biological product’’. 
10
(h) PATIENT PARTICIPATION IN MEDICAL PRODUCT 
11
DISCUSSION.—The heading of subsection (a) of section 
12
569C of the Federal Food, Drug, and Cosmetic Act (21 
13
U.S.C. 360bbb–8c) is amended by striking ‘‘DRUGS AND 
14
DEVICES’’ and inserting ‘‘DRUGS, DEVICES, AND IN 
15
VITRO CLINICAL TESTS’’. 
16
(i) 
REGULATIONS
AND
HEARINGS.—Section 
17
701(h)(1)(C)(ii) of the Federal Food, Drug, and Cosmetic 
18
Act (21 U.S.C. 371(h)(1)(C)(ii)) is amended by inserting 
19
‘‘and in vitro clinical tests’’ after ‘‘devices’’. 
20
(j) FACTORY INSPECTION.—Section 704 of the Fed-
21
eral Food, Drug, and Cosmetic Act (21 U.S.C. 374) (other 
22
than subsection (g)) is amended— 
23
01:17 Mar 17, 2020
H6102
203 
•HR 6102 IH
(1) by striking ‘‘drugs or devices’’ each place it 
1
appears and inserting ‘‘drugs, devices, or in vitro 
2
clinical tests’’; 
3
(2) in subsection (a)(1), in the third sentence, 
4
by striking ‘‘or chapter IX’’ and inserting ‘‘section 
5
587R or chapter IX’’; 
6
(3) in subsection (a)(2)(B)— 
7
(A) by inserting ‘‘or in vitro clinical tests’’ 
8
after ‘‘prescribe or use devices’’; and 
9
(B) by inserting ‘‘or in vitro clinical tests’’ 
10
after ‘‘process devices’’; 
11
(4) by inserting ‘‘in vitro clinical test,’’ after 
12
‘‘device,’’ each place it appears; 
13
(5) after making the amendments in para-
14
graphs (1) and (2), by inserting ‘‘in vitro clinical 
15
tests,’’ after ‘‘devices,’’ each place it appears; 
16
(6) in subsection (e), by inserting ‘‘, or section 
17
587L, 587M, or 587R,’’ after ‘‘section 519 or 
18
520(g)’’; and 
19
(7) in subsection (f)(3)— 
20
(A) in subparagraph (A), by striking ‘‘or’’ 
21
at the end; 
22
(B) in subparagraph (B), by striking the 
23
period at the end and inserting ‘‘; or’’; and 
24
01:17 Mar 17, 2020
H6102
204 
•HR 6102 IH
(C) after subparagraph (B), by inserting 
1
the following: 
2
‘‘(C) is accredited under section 587P.’’. 
3
(k) PUBLICITY.—Section 705(b) of the Federal Food, 
4
Drug, and Cosmetic Act (21 U.S.C. 375(b)) is amended 
5
by inserting ‘‘in vitro clinical tests,’’ after ‘‘devices,’’. 
6
(l) PRESUMPTION.—Section 709 of the Federal Food, 
7
Drug, and Cosmetic Act (21 U.S.C. 379a) is amended by 
8
inserting ‘‘in vitro clinical test,’’ after ‘‘device,’’. 
9
(m) IMPORTS AND EXPORTS.—Section 801 of the 
10
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381) 
11
is amended— 
12
(1) in subsection (a)— 
13
(A) by inserting ‘‘in vitro clinical tests,’’ 
14
after ‘‘devices,’’ each place it appears; and 
15
(B) by inserting ‘‘in the case of an in vitro 
16
clinical test, the test does not conform to the 
17
applicable requirements of section 587J, or’’ 
18
after ‘‘requirements of section 520(f), or’’; 
19
(2) in subsection (d)(3)— 
20
(A) in subparagraph (A)— 
21
(i) in the matter preceding clause (i), 
22
by inserting ‘‘and no component of an in 
23
vitro clinical test or other article of in vitro 
24
01:17 Mar 17, 2020
H6102
205 
•HR 6102 IH
clinical test that requires further proc-
1
essing,’’ after ‘‘health-related purposes’’; 
2
(ii) in clause (i), by striking ‘‘drug or 
3
device’’ and inserting ‘‘drug, device, or in 
4
vitro clinical test’’; and 
5
(iii) in clause (i)(I), by inserting ‘‘in 
6
vitro clinical test,’’ after ‘‘device,’’; and 
7
(B) in subparagraph (B), by inserting ‘‘in 
8
vitro clinical test,’’ after ‘‘device,’’; and 
9
(3) in subsection (e)(1), by inserting ‘‘in vitro 
10
clinical test,’’ after ‘‘device,’’. 
11
(n) OFFICE OF INTERNATIONAL RELATIONS.—Sec-
12
tion 803 of the Federal Food, Drug, and Cosmetic Act 
13
(21 U.S.C. 383) is amended— 
14
(1) in subsection (b)— 
15
(A) in the matter preceding paragraph (1), 
16
by inserting ‘‘and in vitro clinical tests’’ after 
17
‘‘devices’’; and 
18
(B) in paragraph (1), by inserting ‘‘quality 
19
requirements established under section 587J; 
20
and’’ at the end; and 
21
(2) in subsection (c)— 
22
(A) in paragraph (2), by inserting ‘‘in vitro 
23
clinical tests,’’ after ‘‘devices,’’; and 
24
01:17 Mar 17, 2020
H6102
206 
•HR 6102 IH
(B) in paragraph (4), by inserting ‘‘or in 
1
vitro clinical tests’’ after ‘‘devices’’. 
2
(o) RECOGNITION OF FOREIGN GOVERNMENT IN-
3
SPECTIONS.—Section 809(a)(1) of the Federal Food, 
4
Drug, and Cosmetic Act (21 U.S.C. 384e(a)(1)) is amend-
5
ed by inserting ‘‘, or section 587I’’ after ‘‘510(h)’’. 
6
(p) FOOD
AND DRUG ADMINISTRATION.—Section 
7
1003(b)(2) of the Federal Food, Drug, and Cosmetic Act 
8
(21 U.S.C. 393(b)(2)) is amended— 
9
(1) in subparagraph (D), by striking ‘‘and’’ at 
10
the end; 
11
(2) in subparagraph (E), by striking the semi-
12
colon at the end and inserting ‘‘; and’’; and 
13
(3) by adding at the end the following: 
14
‘‘(F) in vitro clinical tests are analytically 
15
and clinically valid;’’. 
16
(q) OFFICE OF WOMEN’S HEALTH.—Section 1011(b) 
17
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
18
399b(b)) is amended— 
19
(1) in paragraph (1), by inserting ‘‘in vitro clin-
20
ical tests,’’ after ‘‘devices,’’; and 
21
(2) in paragraph (4), by striking ‘‘and device 
22
manufacturers’’ and inserting ‘‘device manufactur-
23
ers, and in vitro clinical test developers,’’. 
24
01:17 Mar 17, 2020
H6102
207 
•HR 6102 IH
(r) 
COUNTERMEASURE
PROVISIONS
OF
THE 
1
PHSA.—Title III of the PHSA is amended— 
2
(1) in section 319F–2(c)(1)(B) (42 U.S.C. 
3
247d–6b(c)(1)(B)) is amended— 
4
(A) by striking ‘‘or device’’ and inserting 
5
‘‘device’’; and 
6
(B) by inserting ‘‘or an in vitro clinical 
7
test (as that term is defined in section 201(ss) 
8
of the Federal Food, Drug, and Cosmetic Act 
9
(21 U.S.C. 321(ss)))’’ after ‘‘Act (21 U.S.C. 
10
321(h)))’’; 
11
(2) in section 319F–1(a)(2) (42 U.S.C. 247d– 
12
6a(a)(2)), by inserting ‘‘an in vitro clinical tests (as 
13
that term is defined in section 201(ss) of the Fed-
14
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
15
321(ss))),’’ before ‘‘or device’’; and 
16
(3) in section 319F–3(i)(7) (42 U.S.C. 247d– 
17
6d(i)(7)), by inserting ‘‘an in vitro clinical tests (as 
18
that term is defined in section 201(ss) of the Fed-
19
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
20
321(ss))),’’ before ‘‘or device’’. 
21
SEC. 5. TRANSITION. 
22
(a) IMPLEMENTATION.— 
23
(1) IN
GENERAL.—Except as otherwise pro-
24
vided in this section, the amendments made by this 
25
01:17 Mar 17, 2020
H6102
208 
•HR 6102 IH
Act apply beginning on the first day of the fourth 
1
fiscal year that begins after the date of enactment 
2
of this Act (in this section and in subchapter J of 
3
chapter V of the Federal Food, Drug, and Cosmetic 
4
Act, as added by this Act, referred to in this section 
5
as the ‘‘effective date of this Act’’), except that the 
6
Secretary of Health and Human Services (in this 
7
section referred to as the ‘‘Secretary’’) may take the 
8
actions described in paragraph (2) as described in 
9
such paragraph, and may take such other actions, 
10
and expend such funds, as the Secretary determines 
11
necessary to ensure an orderly transition. 
12
(2) ACTIONS.—The Secretary shall, prior to the 
13
date on which the amendments made by this Act 
14
generally apply pursuant to paragraph (1)— 
15
(A) within 2 years of the date of enact-
16
ment of this Act hold the public meetings de-
17
scribed in subchapter J of chapter V of the 
18
Federal Food, Drug, and Cosmetic Act, as 
19
added by section 3; 
20
(B) within 2 years of the date of enact-
21
ment of this Act promulgate regulations re-
22
quired under sections 587L, 587M, 587V, and 
23
587W; 
24
01:17 Mar 17, 2020
H6102
209 
•HR 6102 IH
(C) issue final guidance on premarket re-
1
view requirements under section 587B, tech-
2
nology certification review requirements under 
3
section 587D, and applicability under section 
4
587A; and 
5
(D) promulgate additional regulations re-
6
quired by such amendments made by this Act. 
7
(3) APPLICABILITY
OF
REGULATIONS.—Not-
8
withstanding the date on which guidance or regula-
9
tions are issued under paragraph (2), no guidance or 
10
regulations issued pursuant to the amendments 
11
made by this Act shall take effect until the effective 
12
date of this Act, as described in paragraph (1), ex-
13
cept as otherwise provided for transitional tests. 
14
(b) APPLICATION
OF AUTHORITIES
TO IN VITRO 
15
CLINICAL TESTS UNTIL AND AFTER EFFECTIVE DATE 
16
OF THIS ACT.—Except as provided in subsection (d), for 
17
any product or test that is an in vitro clinical test as de-
18
fined in section 201(ss) of the Federal Food, Drug, and 
19
Cosmetic Act, as added by this Act, the following authori-
20
ties shall apply: 
21
(1) TESTS OFFERED PRIOR TO ENACTMENT.— 
22
An in vitro clinical test that meets the criteria for 
23
a grandfathered test as set forth in section 
24
587A(c)(2) of the Federal Food, Drug, and Cos-
25
01:17 Mar 17, 2020
H6102
210 
•HR 6102 IH
metic Act, as added by section 3, may continue to 
1
be offered for clinical use and shall be subject only 
2
to applicable provisions of section 353 of the Public 
3
Health Service Act and section 587A(a)(4) of the 
4
Federal Food, Drug, and Cosmetic Act, as added by 
5
section 3. 
6
(2) TESTS OFFERED ON OR AFTER ENACTMENT 
7
BUT BEFORE IMPLEMENTATION.—Before any prod-
8
uct or test that is an in vitro clinical test as defined 
9
in section 201(ss) of the Federal Food, Drug, and 
10
Cosmetic Act, as added by this Act, is first offered, 
11
sold, or distributed after the date of enactment of 
12
this Act, but prior to 90 days before the effective 
13
date of this Act, such product or test shall be con-
14
sidered a transitional test as described under sub-
15
section (d) and comply with the applicable device 
16
provisions of the Federal Food, Drug, and Cosmetic 
17
Act (21 U.S.C. 301 et seq.) and the Public Health 
18
Service Act (42 U.S.C. 201 et seq.). 
19
(3) TESTS UNDER REVIEW BEGINNING ON OR 
20
AFTER THE DATE OF ENACTMENT OF THIS ACT BUT 
21
PRIOR TO IMPLEMENTATION.—For any product or 
22
test that is an in vitro clinical test as defined in sec-
23
tion 201(ss) of the Federal Food, Drug, and Cos-
24
metic Act, as added by this Act, for which a submis-
25
01:17 Mar 17, 2020
H6102
211 
•HR 6102 IH
sion for marketing authorization under section 515, 
1
clearance under section 510(k), authorization under 
2
section 513(f)(2), approval under section 520(m), or 
3
emergency use authorization under section 564 of 
4
the Federal Food, Drug, and Cosmetic Act (21 
5
U.S.C. 360e, 360(k), 360c(f)(2), 360j(m), 360bbb– 
6
3) or approval under the Public Health Service Act 
7
(42 U.S.C. 201 et seq.) is pending on the effective 
8
date of this Act, the Secretary may review and take 
9
action on such submission after the effective date of 
10
this Act according to the statutory provision under 
11
which such submission was submitted. 
12
(c) APPLICATION
OF
AUTHORITIES
TO
TRANSI-
13
TIONAL
AND
GRANDFATHERED
IN
VITRO
CLINICAL 
14
TESTS.— 
15
(1) DEFINITION.—For purposes of this para-
16
graph, the term ‘‘transitional in vitro clinical test’’ 
17
means an in vitro clinical test, as defined in section 
18
201(ss) of the Federal Food, Drug, and Cosmetic 
19
Act, as added by this Act, that— 
20
(A) was developed by a clinical laboratory 
21
certified by the Secretary under section 353 of 
22
the Public Health Service Act (42 U.S.C. 263a) 
23
that meets the requirements for performing 
24
high-complexity testing for use only within that 
25
01:17 Mar 17, 2020
H6102
212 
•HR 6102 IH
certified laboratory or another laboratory within 
1
the organization under common ownership; 
2
(B) does not have an approval under sec-
3
tion 515, a clearance under section 510(k), an 
4
authorization under section 513(f)(2), an ap-
5
proval under section 520(m), or an emergency 
6
use authorization under section 564 of the Fed-
7
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
8
360e, 360(k), 360c(f)(2), 360j(m), 360bbb–3) 
9
or approval under the Public Health Service 
10
Act (42 U.S.C. 201 et seq.); and 
11
(C) is first offered for clinical use during 
12
the period beginning on the date of enactment 
13
of this Act and ending on the implementation 
14
date of this Act. 
15
(2) CONTINUED
OFFERING.—Notwithstanding 
16
subsection (c), a transitional in vitro clinical test 
17
may continue to be offered for clinical use until the 
18
effective date of this Act, as described in subsection 
19
(b)(1), except that the Secretary retains authority to 
20
enforce the device provisions of the Federal Food, 
21
Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and 
22
the Public Health Service Act (42 U.S.C. 201 et 
23
seq.) for any specific transitional in vitro clinical 
24
test, or any type of transitional in vitro clinical test, 
25
01:17 Mar 17, 2020
H6102
213 
•HR 6102 IH
as the Secretary determines necessary to protect the 
1
public from a serious risk to health. 
2
(3) PREMARKET REVIEW OR TECHNOLOGY CER-
3
TIFICATION.—A transitional in vitro clinical test 
4
that is the subject of an application for premarket 
5
review under section 587B of the Federal Food, 
6
Drug, and Cosmetic Act or technology certification 
7
application under section 587D of such Act, as 
8
added by this Act, that is submitted within 90 days 
9
of the effective date of this Act may continue to be 
10
offered, sold, or distributed until completion of the 
11
Secretary’s review of the premarket application or 
12
technology certification application. 
13
(d) CONVERSION.— 
14
(1) DEEMED PREMARKET APPROVAL.—Any in 
15
vitro clinical test (as defined in section 201(ss) of 
16
the Federal Food, Drug, and Cosmetic Act, as 
17
added by this Act) with a premarket approval under 
18
section 515, a clearance under section 510(k), an 
19
authorization under section 513(f), or a licensure 
20
under section 351 of the Public Health Service Act 
21
(42 U.S.C. 262) is deemed to have an approved ap-
22
plication under section 587B of the Federal Food, 
23
Drug, and Cosmetic Act, as added by this Act, be-
24
ginning on the later of— 
25
01:17 Mar 17, 2020
H6102
214 
•HR 6102 IH
(A) the effective date of this Act; or 
1
(B) such other date, not later than 3 years 
2
after such effective date, as the person respon-
3
sible for the device selects. 
4
(2) 
DEEMED
INVESTIGATIONAL
USE
AP-
5
PROVAL.—Any in vitro clinical test (as defined in 
6
section 201(ss) of the Federal Food, Drug, and Cos-
7
metic Act, as added by this Act) that has an ap-
8
proved investigational device exemption under sec-
9
tion 520(g) of the Federal Food, Drug, and Cos-
10
metic Act (21 U.S.C. 360j(g)) is deemed to have an 
11
approved investigational use under section 587Q of 
12
such Act, as added by this Act, beginning on the ef-
13
fective date of this Act. 
14
(e) INSTRUMENTS.—An instrument (as defined in 
15
section 587 of the Federal Food, Drug, and Cosmetic Act, 
16
as added by this Act) that was purchased prior to the date 
17
of enactment of this Act and was not cleared, authorized, 
18
or approved by the Food and Drug Administration or part 
19
of an instrument family that was cleared, authorized, or 
20
approved by the Food and Drug Administration at the 
21
time of purchase may continue to be used by the purchaser 
22
to develop and introduce into interstate commerce an in 
23
vitro clinical test during the period beginning on the date 
24
of enactment of this Act and ending 5 years after such 
25
01:17 Mar 17, 2020
H6102
215 
•HR 6102 IH
date of enactment. Beginning at the end of such period, 
1
any new in vitro clinical test that is developed and intro-
2
duced into interstate commerce shall be based on an in-
3
strument (as defined in section 587(11) of the Federal 
4
Food, Drug, and Cosmetic Act, as added by section 3) 
5
that complies with the requirements of the Federal Food, 
6
Drug, and Cosmetic Act, as amended by this Act. 
7
(f) RELATION TO IN VITRO CLINICAL TEST PROVI-
8
SION.—This section applies notwithstanding section 
9
587A(a)(1)(C) of the Federal Food, Drug, and Cosmetic 
10
Act, as added by this Act. 
11
SEC. 6. EMERGENCY USE AUTHORIZATION. 
12
Section 564 of the Federal Food, Drug, and Cosmetic 
13
Act (21 U.S.C. 360bbb–3) is amended— 
14
(1) in paragraphs (1) and (4)(C) of subsection 
15
(a), by inserting ‘‘in vitro clinical test,’’ before ‘‘or 
16
biological product’’ each place such term appears; 
17
and 
18
(2) in subsection (e)(3)— 
19
(A) in subparagraph (B), by striking 
20
‘‘and’’ at the end; 
21
(B) in subparagraph (C), by striking the 
22
period and inserting ‘‘; and’’; and 
23
(C) by adding at the end the following: 
24
01:17 Mar 17, 2020
H6102
216 
•HR 6102 IH
‘‘(D) quality system requirements (with re-
1
spect to in vitro clinical tests) under section 
2
587J.’’. 
3
SEC. 7. ANTIMICROBIAL SUSCEPTIBILITY TESTS. 
4
Section 511A of the Federal Food, Drug, and Cos-
5
metic Act (21 U.S.C. 360a–2) is amended— 
6
(1) in subsection (a)(1)(C)— 
7
(A) by striking ‘‘or approve under section 
8
515’’ and inserting ‘‘approve under section 515, 
9
or approve, exempt, or issue a technology cer-
10
tification order under subchapter J’’; and 
11
(B) by striking ‘‘testing devices’’ and in-
12
serting ‘‘tests’’; 
13
(2) in subsection (c)(5), by striking ‘‘drug or 
14
device’’ each place it appears and inserting ‘‘drug, 
15
device, or in vitro clinical test’’; 
16
(3) in subsection (e)— 
17
(A) in the heading, by striking ‘‘TESTING 
18
DEVICES’’ and inserting ‘‘IN VITRO CLINICAL 
19
TESTS’’; 
20
(B) in paragraph (1)— 
21
(i) by striking ‘‘and 515,’’ and insert-
22
ing ‘‘515, 587B, and 587D’’; 
23
(ii) by striking ‘‘antimicrobial suscep-
24
tibility testing device’’ and inserting ‘‘anti-
25
01:17 Mar 17, 2020
H6102
217 
•HR 6102 IH
microbial susceptibility in vitro clinical 
1
test’’; and 
2
(iii) by striking ‘‘such device’’ and in-
3
serting ‘‘such test’’; 
4
(C) in paragraph (2)— 
5
(i) in the heading, by striking ‘‘TEST-
6
ING
DEVICES’’ and inserting ‘‘IN
VITRO 
7
CLINICAL TESTS’’; and 
8
(ii) by amending subparagraph (C) to 
9
read as follows: 
10
‘‘(C) The antimicrobial susceptibility in 
11
vitro clinical test meets all other requirements 
12
to be approved under section 587B or exempted 
13
from premarket review under section 587D.’’; 
14
and 
15
(D) after making the amendments in sub-
16
paragraphs (B)(ii), (B)(iii), and (C)(ii), by 
17
striking ‘‘device’’ each place it appears and in-
18
serting ‘‘in vitro clinical test’’; 
19
(4) in subsection (f), by amending paragraph 
20
(1) to read as follows: 
21
‘‘(1) The term ‘antimicrobial susceptibility in 
22
vitro clinical test’ means an in vitro clinical test that 
23
utilizes susceptibility test interpretive criteria to de-
24
01:17 Mar 17, 2020
H6102
218 
•HR 6102 IH
termine and report the in vitro susceptibility of cer-
1
tain microorganisms to a drug (or drugs).’’; and 
2
(5) in subsection (g)(2)— 
3
(A) by amending the matter preceding sub-
4
paragraph (A) to read as follows: 
5
‘‘(2) with respect to clearing under section 
6
510(k), classifying under section 513(f)(2), approv-
7
ing under section 515 or section 587B, or exempting 
8
from approval requirements under section 587D—’’; 
9
and 
10
(B) in subparagraph (A)— 
11
(i) by striking ‘‘device’’ and inserting 
12
‘‘in vitro clinical test’’; and 
13
(ii) by striking ‘‘antimicrobial suscep-
14
tibility testing device’’ and inserting ‘‘anti-
15
microbial susceptibility in vitro clinical 
16
test’’. 
17
SEC. 8. COMBINATION PRODUCTS. 
18
(a) IN GENERAL.—Section 503(g) of the Federal 
19
Food, Drug, and Cosmetic Act (21 U.S.C. 353(g)) is 
20
amended— 
21
(1) in paragraph (1)— 
22
(A) in subparagraph (A)— 
23
(i) by inserting ‘‘(except for a com-
24
bination product constituted of a device 
25
01:17 Mar 17, 2020
H6102
219 
•HR 6102 IH
and an in vitro clinical test)’’ after ‘‘agency 
1
center,’’; and 
2
(ii) by inserting ‘‘in vitro clinical 
3
test,’’ before ‘‘or biological product’’; and 
4
(B) in subparagraph (D)— 
5
(i) in the matter preceding clause (i), 
6
by striking ‘‘. If the Secretary determines’’ 
7
and inserting ‘‘, except for a combination 
8
product constituted of a device and an in 
9
vitro clinical test. For other combination 
10
products, if the Secretary determines’’; and 
11
(ii) in clause (ii)— 
12
(I) by inserting ‘‘or in vitro clin-
13
ical test’’ after ‘‘device’’; and 
14
(II) by inserting ‘‘and in vitro 
15
clinical tests’’ before ‘‘shall’’; 
16
(2) in paragraph (3), by striking ‘‘safety and 
17
effectiveness or substantial equivalence’’ and insert-
18
ing ‘‘safety and effectiveness, substantial equiva-
19
lence, or analytical validity and clinical validity’’ be-
20
fore ‘‘for the approved constituent part’’; 
21
(3) in paragraph (4)— 
22
(A) in subparagraph (A), by striking ‘‘or 
23
513(f)(2) (submitted in accordance with para-
24
graph (5))’’ and inserting ‘‘513(f)(2) (sub-
25
01:17 Mar 17, 2020
H6102
220 
•HR 6102 IH
mitted in accordance with paragraph (5)), 
1
587B, or an exempt test under section 587A, as 
2
applicable’’; and 
3
(B) in subparagraph (B), by inserting ‘‘or 
4
587B’’ after ‘‘section 515’’; 
5
(4) in paragraph (5)(A), by striking ‘‘or 
6
510(k)’’ and inserting ‘‘, 510(k), or 587B’’; 
7
(5) in paragraph (7), by striking ‘‘or substan-
8
tial equivalence’’ and inserting ‘‘, substantial equiva-
9
lence, or analytical validity and clinical validity’’; 
10
(6) in paragraph (8), by adding at the end the 
11
following: 
12
‘‘(I) This paragraph shall not apply to a 
13
combination product constituted of a device and 
14
an in vitro clinical test.’’; and 
15
(7) in paragraph (9)— 
16
(A) in subparagraph (C)(i), by striking ‘‘or 
17
520(g)’’ and inserting ‘‘520(g), or 587B’’; and 
18
(B) in subparagraph (D), by striking ‘‘or 
19
520’’ and inserting ‘‘520, or 587B’’. 
20
(b) CLASSIFICATION OF PRODUCTS.—Section 563 of 
21
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
22
360bbb–2) is amended by adding at the end the following: 
23
01:17 Mar 17, 2020
H6102
221 
•HR 6102 IH
‘‘(d) EXEMPTION.—This section shall not apply to a 
1
combination product constituted of a device and an in 
2
vitro clinical test.’’. 
3
SEC. 9. RESOURCES. 
4
(a) FINDINGS.—Congress finds that the fees author-
5
ized by this section will be dedicated to meeting the goals 
6
identified in the letters from the Secretary of Health and 
7
Human Services to the Committee on Health, Education, 
8
Labor, and Pensions of the Senate and the Committee on 
9
Energy and Commerce of the House of Representatives, 
10
as set forth in the Congressional Record. 
11
(b) ESTABLISHMENT OF USER FEE PROGRAM.— 
12
(1) DEVELOPMENT
OF
USER
FEES
FOR
IN 
13
VITRO CLINICAL TESTS.— 
14
(A) IN
GENERAL.—Beginning not later 
15
than October 1, 2020, the Secretary of Health 
16
and Human Services (in this section referred to 
17
as the ‘‘Secretary’’) shall develop recommenda-
18
tions to present to Congress with respect to the 
19
goals, and plans for meeting the goals, for the 
20
process of the review of in vitro clinical test ap-
21
plications submitted under subchapter J of 
22
chapter V of the Federal Food, Drug, and Cos-
23
metic Act, as added by this Act, for the first 5 
24
fiscal years after fiscal year 2021. In developing 
25
01:17 Mar 17, 2020
H6102
222 
•HR 6102 IH
such recommendations, the Secretary shall con-
1
sult with— 
2
(i) the Committee on Energy and 
3
Commerce of the House of Representa-
4
tives; 
5
(ii) the Committee on Health, Edu-
6
cation, Labor, and Pensions of the Senate; 
7
(iii) scientific and academic experts; 
8
(iv) health care professionals; 
9
(v) representatives of patient and con-
10
sumer advocacy groups; and 
11
(vi) the regulated industry. 
12
(B) PRIOR PUBLIC INPUT.—Prior to begin-
13
ning negotiations with the regulated industry 
14
on the authorization of such subchapter J, the 
15
Secretary shall— 
16
(i) publish a notice in the Federal 
17
Register requesting public input on the au-
18
thorization of user fees; 
19
(ii) hold a public meeting at which the 
20
public may present its views on the author-
21
ization, including specific suggestions for 
22
the recommendations submitted under sub-
23
paragraph (E); 
24
01:17 Mar 17, 2020
H6102
223 
•HR 6102 IH
(iii) provide a period of 30 days after 
1
the public meeting to obtain written com-
2
ments from the public suggesting changes 
3
to such subchapter J; and 
4
(iv) publish any comments received 
5
under clause (iii) on the internet website of 
6
the Food and Drug Administration. 
7
(C) PERIODIC
CONSULTATION.—Not less 
8
frequently than once every month during nego-
9
tiations with the regulated industry, the Sec-
10
retary shall hold discussions with representa-
11
tives of patient and consumer advocacy groups 
12
to continue discussions of the authorization 
13
under such subchapter J and to solicit sugges-
14
tions to be included in the recommendations 
15
transmitted to Congress under subparagraph 
16
(E). 
17
(D) PUBLIC
REVIEW
OF
RECOMMENDA-
18
TIONS.—After negotiations with the regulated 
19
industry, the Secretary shall— 
20
(i) present the recommendations de-
21
veloped under subparagraph (A) to the 
22
Committee on Health, Education, Labor, 
23
and Pensions of the Senate and the Com-
24
01:17 Mar 17, 2020
H6102
224 
•HR 6102 IH
mittee on Energy and Commerce of the 
1
House of Representatives; 
2
(ii) publish such recommendations in 
3
the Federal Register; 
4
(iii) provide for a period of 30 days 
5
for the public to provide written comments 
6
on such recommendations; 
7
(iv) hold a meeting at which the pub-
8
lic may present its views on such rec-
9
ommendations; and 
10
(v) after consideration of such public 
11
views and comments, revise such rec-
12
ommendations as necessary. 
13
(E) 
TRANSMITTAL
OF
RECOMMENDA-
14
TIONS.— 
15
(i) IN
GENERAL.—Not later than 
16
June 1, 2021, the Secretary shall transmit 
17
to Congress the revised recommendations 
18
under subparagraph (A), a summary of the 
19
views and comments received under such 
20
subparagraph, and any changes made to 
21
the recommendations in response to such 
22
views and comments. 
23
01:17 Mar 17, 2020
H6102
225 
•HR 6102 IH
(ii) 
RECOMMENDATION
REQUIRE-
1
MENTS.—The 
recommendations 
trans-
2
mitted under this subparagraph shall— 
3
(I) include the number of full- 
4
time equivalent employees per fiscal 
5
year that are agreed to be hired to 
6
carry out the goals included in such 
7
recommendations for each year of the 
8
5-year period; 
9
(II) provide that the amount of 
10
operating reserve balance in the user 
11
fee program established under this 
12
section is not more than the equiva-
13
lent of 10 weeks of operating reserve; 
14
(III) require the development of 
15
a strategic plan for any surplus within 
16
the operating reserve account above 
17
the 10-week operating reserve within 
18
2 years of the establishment of the 
19
program; 
20
(IV) include an operating reserve 
21
adjustment such that, if the Secretary 
22
has an operating reserve balance in 
23
excess of 10 weeks of such operating 
24
reserves, the Secretary shall decrease 
25
01:17 Mar 17, 2020
H6102
226 
•HR 6102 IH
such fee revenue and fees to provide 
1
for not more than 10 weeks of such 
2
operating reserves; 
3
(V) if an adjustment is made as 
4
described in subclause (IV), provide 
5
the rationale for the amount of the 
6
decrease in fee revenue and fees shall 
7
be contained in the Federal Register; 
8
and 
9
(VI) provide that the fees as-
10
sessed and collected for the full-time 
11
equivalent employees at the Center for 
12
Devices and Radiological Health, with 
13
respect to which the majority of time 
14
reporting data indicates are dedicated 
15
to the review of in vitro clinical tests, 
16
are not supported by the funds au-
17
thorized to be collected and assessed 
18
under section 738 of the Federal 
19
Food, Drug, and Cosmetic Act (21 
20
U.S.C. 379j). 
21
(F) 
PUBLICATION
OF
RECOMMENDA-
22
TIONS.—The Secretary shall publish on the 
23
internet website of the Food and Drug Admin-
24
istration the revised recommendations under 
25
01:17 Mar 17, 2020
H6102
227 
•HR 6102 IH
subparagraph (A), a summary of the views and 
1
comments received under subparagraphs (B) 
2
through (D), and any changes made to the rec-
3
ommendations originally proposed by the Sec-
4
retary in response to such views and comments. 
5
(G) MINUTES
OF
NEGOTIATION
MEET-
6
INGS.— 
7
(i) 
PUBLIC
AVAILABILITY.—Before 
8
transmitting the recommendations devel-
9
oped under subparagraphs (A) through (F) 
10
to Congress, the Secretary shall make pub-
11
licly available, on the internet website of 
12
the Food and Drug Administration, min-
13
utes of all negotiation meetings conducted 
14
under this subsection between the Food 
15
and Drug Administration and the regu-
16
lated industry. 
17
(ii) 
CONTENT.—The 
minutes 
de-
18
scribed under clause (i) shall summarize 
19
any substantive proposal made by any 
20
party to the negotiations, any significant 
21
controversies or differences of opinion dur-
22
ing the negotiations, and the resolution of 
23
any such controversy or difference of opin-
24
ion. 
25
01:17 Mar 17, 2020
H6102
228 
•HR 6102 IH
(2) ESTABLISHMENT
OF
USER
FEE
PRO-
1
GRAM.—Effective on October 1, 2021, provided that 
2
the Secretary transmits the recommendations under 
3
paragraph (1)(E), the Secretary is authorized to col-
4
lect user fees relating to the submission of in vitro 
5
clinical test applications submitted under subchapter 
6
J of chapter V of the Federal Food, Drug, and Cos-
7
metic Act, as added by this Act. Fees under such 
8
program shall be assessed and collected only if the 
9
requirements under paragraph (4) are met. 
10
(3) AUDIT.— 
11
(A) IN GENERAL.—On the date that is 2 
12
years after first receiving a user fee applicable 
13
to submission of an in vitro clinical test applica-
14
tion submitted under subchapter J of chapter V 
15
of the Federal Food, Drug, and Cosmetic Act, 
16
as added by this Act, and on a biennial basis 
17
thereafter until October 1, 2027, the Secretary 
18
shall perform an audit of the costs of reviewing 
19
such applications under such subchapter J. 
20
Such an audit shall compare the costs of re-
21
viewing such applications under such sub-
22
chapter J to the amount of the user fee applica-
23
ble to such applications. 
24
01:17 Mar 17, 2020
H6102
229 
•HR 6102 IH
(B) ALTERATION OF USER FEE.—If the 
1
audit performed under subparagraph (A) indi-
2
cates that the user fees applicable to applica-
3
tions submitted under such subchapter J exceed 
4
30 percent of the costs of reviewing such appli-
5
cations, the Secretary shall alter the user fees 
6
applicable to applications submitted under such 
7
subchapter J such that the user fees do not ex-
8
ceed such percentage. 
9
(C) ACCOUNTING STANDARDS.—The Sec-
10
retary shall perform an audit under subpara-
11
graph (A) in conformance with the accounting 
12
principles, standards, and requirements pre-
13
scribed by the Comptroller General of the 
14
United States under section 3511 of title 31, 
15
United States Code, to ensure the validity of 
16
any potential variability. 
17
(4) CONDITIONS.—The user fee program de-
18
scribed in this subsection shall take effect only if the 
19
Food and Drug Administration issues draft guidance 
20
related to the review requirements for in vitro diag-
21
nostic tests that would be subject to premarket re-
22
view under section 587B of the Federal Food, Drug, 
23
and Cosmetic Act, as added by section 3, the review 
24
requirements for test categories eligible for tech-
25
01:17 Mar 17, 2020
H6102
230 
•HR 6102 IH
nology certification under section 587D of such Act, 
1
as added by section 3, and the parameters for the 
2
test categories that would be exempt from any re-
3
view under subchapter J of chapter V of such Act. 
4
(5) USER FEE PROGRAM DEFINITIONS AND RE-
5
SOURCE REQUIREMENTS.— 
6
(A) IN GENERAL.—The term ‘‘process for 
7
the review of in vitro clinical test applications’’ 
8
means the following activities of the Secretary 
9
with respect to the review of premarket applica-
10
tions under section 587B of the Federal Food, 
11
Drug, and Cosmetic Act (as added by section 
12
3), technology certification applications under 
13
section 587D of such Act (as added by section 
14
3), and supplements for such applications: 
15
(i) The activities necessary for the re-
16
view of premarket applications, premarket 
17
reports, and supplements to such applica-
18
tions. 
19
(ii) The issuance of action letters that 
20
allow the marketing of in vitro clinical 
21
tests or which set forth in detail the spe-
22
cific deficiencies in such applications, re-
23
ports, supplements, or submissions and, 
24
01:17 Mar 17, 2020
H6102
231 
•HR 6102 IH
where appropriate, the actions necessary to 
1
place them in condition for approval. 
2
(iii) The inspection of manufacturing 
3
establishments and other facilities under-
4
taken as part of the Secretary’s review of 
5
pending premarket applications, technology 
6
certifications, and supplements. 
7
(iv) Monitoring of research conducted 
8
in connection with the review of such appli-
9
cations, supplements, and submissions. 
10
(v) Review of in vitro clinical test ap-
11
plications subject to section 351 of the 
12
Public Health Service Act (42 U.S.C. 
13
262), investigational new drug applications 
14
under section 505(i) of the Federal Food, 
15
Drug, and Cosmetic Act (21 U.S.C. 
16
355(i)), or investigational test exemptions 
17
under section 587A(m) of the Federal 
18
Food, Drug, and Cosmetic Act (as added 
19
by section 3), and activities conducted in 
20
anticipation of the submission of such ap-
21
plications under section 505(i) of the Fed-
22
eral Food, Drug, and Cosmetic Act or in-
23
vestigational use under section 587R of the 
24
01:17 Mar 17, 2020
H6102
232 
•HR 6102 IH
Federal Food, Drug, and Cosmetic Act (as 
1
added by section 3). 
2
(vi) The development of guidance, pol-
3
icy documents, or regulations to improve 
4
the process for the review of premarket ap-
5
plications, technology certification applica-
6
tions, and supplements. 
7
(vii) The development of voluntary 
8
test methods, consensus standards, or 
9
mandatory performance standards in con-
10
nection with the review of such applica-
11
tions, supplements, or submissions and re-
12
lated activities. 
13
(viii) The provision of technical assist-
14
ance to in vitro clinical test developers in 
15
connection with the submission of such ap-
16
plications, reports, supplements, or submis-
17
sions. 
18
(ix) Any activity undertaken in con-
19
nection with the initial classification or re-
20
classification of an in vitro clinical test in 
21
connection with any requirement for ap-
22
proval of an in vitro clinical test. 
23
(x) Evaluation of postmarket studies 
24
required as a condition of an approval of 
25
01:17 Mar 17, 2020
H6102
233 
•HR 6102 IH
a premarket application of an in vitro clin-
1
ical test. 
2
(xi) Compiling, developing, and re-
3
viewing information on relevant in vitro 
4
clinical tests to identify issues with the ap-
5
plicable standard for premarket applica-
6
tions, technology certification applications, 
7
and supplements. 
8
(B) RESOURCE REQUIREMENTS.—Fees col-
9
lected and assessed under this section shall be 
10
used for the process for the review of in vitro 
11
clinical test applications, as described in sub-
12
paragraph (A), and shall— 
13
(i) be subject to the limitation under 
14
section 738(g)(3) of the Federal Food, 
15
Drug, and Cosmetic Act (21 U.S.C. 
16
379j(g)(3)), in the same manner that fees 
17
collected 
and 
assessed 
under 
section 
18
737(9)(C) 
of 
such 
Act 
(21 
U.S.C. 
19
379i(9)(C)) are subject to such limitation; 
20
(ii) include travel expenses for officers 
21
and employees of the Food and Drug Ad-
22
ministration only if the Secretary deter-
23
mines that such travel is directly related to 
24
01:17 Mar 17, 2020
H6102
234 
•HR 6102 IH
an activity described in subparagraph (A); 
1
and 
2
(iii) not be allocated to purposes de-
3
scribed under section 722(a) of the Con-
4
solidated Appropriations Act, 2018 (Public 
5
Law 115–141). 
6
(c) REPORTS.— 
7
(1) PERFORMANCE REPORT.— 
8
(A) IN GENERAL.— 
9
(i) GENERAL
REQUIREMENTS.—Be-
10
ginning with fiscal year 2021, for each fis-
11
cal year for which fees are collected under 
12
this section, the Secretary shall prepare 
13
and submit to the Committee on Health, 
14
Education, Labor, and Pensions of the 
15
Senate and the Committee on Energy and 
16
Commerce of the House of Representatives 
17
annual reports concerning the progress of 
18
the Food and Drug Administration in 
19
achieving the goals identified in the rec-
20
ommendations transmitted to Congress by 
21
the Secretary pursuant to subsection 
22
(b)(1)(E) during such fiscal year and the 
23
future plans of the Food and Drug Admin-
24
istration for meeting the goals. 
25
01:17 Mar 17, 2020
H6102
235 
•HR 6102 IH
(ii) ADDITIONAL INFORMATION.—Be-
1
ginning with fiscal year 2021, the annual 
2
report under this subparagraph shall in-
3
clude the progress of the Food and Drug 
4
Administration in achieving the goals, and 
5
future plans for meeting the goals, includ-
6
ing— 
7
(I) the number of premarket ap-
8
plications filed under section 587B of 
9
the Federal Food, Drug, and Cos-
10
metic Act during the applicable fiscal 
11
year; 
12
(II) the number of technology 
13
certification 
applications 
submitted 
14
under section 587D of the Federal 
15
Food, Drug, and Cosmetic Act during 
16
the applicable fiscal year for each re-
17
view division; and 
18
(III) the number of breakthrough 
19
designations under section 587C of 
20
the Federal Food, Drug, and Cos-
21
metic Act during the applicable fiscal 
22
year. 
23
(iii) REAL-TIME REPORTING.— 
24
01:17 Mar 17, 2020
H6102
236 
•HR 6102 IH
(I) IN GENERAL.—Not later than 
1
30 calendar days after the end of the 
2
second quarter of fiscal year 2021, 
3
and not later than 30 calendar days 
4
after the end of each quarter of each 
5
fiscal year thereafter, the Secretary 
6
shall post the data described in sub-
7
clause (II) on the internet website of 
8
the Food and Drug Administration 
9
for such quarter and on a cumulative 
10
basis for such fiscal year, and may re-
11
move duplicative data from the annual 
12
report under this subparagraph. 
13
(II) DATA.—The Secretary shall 
14
post the following data in accordance 
15
with subclause (I): 
16
(aa) The number and titles 
17
of draft and final guidance on 
18
topics related to the process for 
19
the review of in vitro clinical 
20
tests, and whether such guid-
21
ances were issued as required by 
22
statute or pursuant to the rec-
23
ommendations 
transmitted 
to 
24
01:17 Mar 17, 2020
H6102
237 
•HR 6102 IH
Congress by the Secretary pursu-
1
ant to subsection (b)(1)(E). 
2
(bb) The number and titles 
3
of public meetings held on topics 
4
related to the process for the re-
5
view of in vitro clinical tests, and 
6
if such meetings were required by 
7
statute or pursuant to the rec-
8
ommendations 
transmitted 
to 
9
Congress by the Secretary pursu-
10
ant to subsection (b)(1)(E). 
11
(iv) RATIONALE FOR IVCT USER FEE 
12
PROGRAM CHANGES.—Beginning with fis-
13
cal year 2022, the Secretary shall include 
14
in the annual performance report under 
15
paragraph (1)— 
16
(I) data, analysis, and discussion 
17
of the changes in the number of full- 
18
time equivalents hired as agreed upon 
19
in the recommendations transmitted 
20
to Congress by the Secretary pursuant 
21
to subsection (b)(1)(E) and the num-
22
ber of full-time equivalents funded by 
23
budget authority at the Food and 
24
Drug Administration by each division 
25
01:17 Mar 17, 2020
H6102
238 
•HR 6102 IH
within the Center for Devices and Ra-
1
diological Health, the Center for Bio-
2
logics Evaluation and Research, the 
3
Office of Regulatory Affairs, and the 
4
Office of the Commissioner; 
5
(II) data, analysis, and discus-
6
sion of the changes in the fee revenue 
7
amounts and costs for the process for 
8
the review of in vitro clinical tests, in-
9
cluding identifying drivers of such 
10
changes; and 
11
(III) for each of the Center for 
12
Devices and Radiological Health, the 
13
Center for Biologics Evaluation and 
14
Research, the Office of Regulatory Af-
15
fairs, and the Office of the Commis-
16
sioner, the number of employees for 
17
whom time reporting is required and 
18
the number of employees for whom 
19
time reporting is not required. 
20
(v) ANALYSIS.—For each fiscal year, 
21
the Secretary shall include in the report 
22
under clause (i) an analysis of the fol-
23
lowing: 
24
01:17 Mar 17, 2020
H6102
239 
•HR 6102 IH
(I) The difference between the 
1
aggregate number of premarket appli-
2
cations filed under section 587B or 
3
section 587D of the Federal Food, 
4
Drug, and Cosmetic Act and the ag-
5
gregate number of major deficiency 
6
letters, not approvable letters, and de-
7
nials for such applications issued by 
8
the agency, accounting for— 
9
(aa) the number of applica-
10
tions filed under each of sections 
11
587B and 587D of the Federal 
12
Food, Drug, and Cosmetic Act 
13
during one fiscal year for which a 
14
decision is not scheduled to be 
15
made until the following fiscal 
16
year; and 
17
(bb) the aggregate number 
18
of applications under each of sec-
19
tions 587B and 587D of the 
20
Federal Food, Drug, and Cos-
21
metic Act for each fiscal year 
22
that did not meet the goals as 
23
identified by the recommenda-
24
tions transmitted to Congress by 
25
01:17 Mar 17, 2020
H6102
240 
•HR 6102 IH
the Secretary pursuant to sub-
1
section (b)(1)(E). 
2
(II) Relevant data to determine 
3
whether the Center for Devices and 
4
Radiological Health has met perform-
5
ance enhancement goals identified by 
6
the recommendations transmitted to 
7
Congress by the Secretary pursuant to 
8
subsection (b)(1)(E). 
9
(III) The most common causes 
10
and trends for external or other cir-
11
cumstances affecting the ability of the 
12
Food and Drug Administration to 
13
meet review time and performance en-
14
hancement goals identified by the rec-
15
ommendations transmitted to Con-
16
gress by the Secretary pursuant to 
17
subsection (b)(1)(E). 
18
(B) PUBLICATION.—With regard to infor-
19
mation to be reported by the Food and Drug 
20
Administration to industry on a quarterly and 
21
annual basis pursuant to recommendations 
22
transmitted to Congress by the Secretary pur-
23
suant to subsection (b)(1)(E), the Secretary 
24
shall make such information publicly available 
25
01:17 Mar 17, 2020
H6102
241 
•HR 6102 IH
on the internet website of the Food and Drug 
1
Administration not later than 60 days after the 
2
end of each quarter or 120 days after the end 
3
of each fiscal year, respectively, to which such 
4
information applies. 
5
(C) UPDATES.—The Secretary shall in-
6
clude in each report under subparagraph (A) 
7
information on all previous cohorts for which 
8
the Secretary has not given a complete response 
9
on all in vitro clinical test premarket applica-
10
tions and technology certification orders and 
11
supplements, premarket, and technology certifi-
12
cation notifications in the cohort. 
13
(2) CORRECTIVE ACTION REPORT.—Beginning 
14
with fiscal year 2022, for each fiscal year for which 
15
fees are collected under this section, the Secretary 
16
shall prepare and submit a corrective action report 
17
to the Committee on Health, Education, Labor, and 
18
Pensions and the Committee on Appropriations of 
19
the Senate and the Committee on Energy and Com-
20
merce and the Committee on Appropriations of the 
21
House of Representatives. The report shall include 
22
the following information, as applicable: 
23
(A) GOALS MET.—For each fiscal year, if 
24
the Secretary determines, based on the analysis 
25
01:17 Mar 17, 2020
H6102
242 
•HR 6102 IH
under paragraph (1)(A)(v), that each of the 
1
goals identified by the recommendations trans-
2
mitted to Congress by the Secretary pursuant 
3
to subsection (b)(1)(E) for the applicable fiscal 
4
year have been met, the corrective action report 
5
shall include recommendations on ways in which 
6
the Secretary can improve and streamline the in 
7
vitro clinical test premarket application and 
8
technology certification review process. 
9
(B) GOALS MISSED.—For each of the goals 
10
identified by the letters described in rec-
11
ommendations transmitted to Congress by the 
12
Secretary pursuant to subsection (b)(1)(E) for 
13
the applicable fiscal year that the Secretary de-
14
termines to not have been met, the corrective 
15
action report shall include— 
16
(i) a justification for such determina-
17
tion; 
18
(ii) a description of the types of cir-
19
cumstances, in the aggregate, under which 
20
applications or reports submitted under 
21
sections 587B and 587D of the Federal 
22
Food, Drug, and Cosmetic Act missed the 
23
review goal times but were approved dur-
24
ing the first cycle review, as applicable; 
25
01:17 Mar 17, 2020
H6102
243 
•HR 6102 IH
(iii) a summary and any trends with 
1
regard to the circumstances for which a re-
2
view goal was missed; and 
3
(iv) the performance enhancement 
4
goals that were not achieved during the 
5
previous fiscal year and a description of ef-
6
forts the Food and Drug Administration 
7
has put in place for the fiscal year in 
8
which the report is submitted to improve 
9
the ability of such agency to meet each 
10
such goal for the such fiscal year. 
11
(3) FISCAL
REPORT.—For fiscal years 2021 
12
and annually thereafter, not later than 120 days 
13
after the end of each fiscal year during which fees 
14
are collected under this subpart, the Secretary shall 
15
prepare and submit to the Committee on Health, 
16
Education, Labor, and Pensions of the Senate and 
17
the Committee on Energy and Commerce of the 
18
House of Representatives, a report on the implemen-
19
tation of the authority for such fees during such fis-
20
cal year and the use, by the Food and Drug Admin-
21
istration, of the fees collected during such fiscal year 
22
for which the report is made. 
23
(A) CONTENTS.—Such report shall include 
24
expenditures delineated by budget authority and 
25
01:17 Mar 17, 2020
H6102
244 
•HR 6102 IH
user fee dollars related to administrative ex-
1
penses and information technology infrastruc-
2
ture contracts and expenditures. 
3
(B) OPERATING
RESERVE.—Such report 
4
shall provide the amount of operating reserve 
5
balance available each year, and any planned al-
6
locations or obligations of such balance that is 
7
above 10 weeks of operating reserve for the pro-
8
gram. 
9
(4) 
PUBLIC
AVAILABILITY.—The 
Secretary 
10
shall make the reports required under paragraphs 
11
(1) through (3) available to the public on the inter-
12
net website of the Food and Drug Administration. 
13
(5) ENHANCED COMMUNICATION.— 
14
(A) COMMUNICATIONS WITH CONGRESS.— 
15
Each fiscal year, as applicable and requested, 
16
representatives from the Centers with expertise 
17
in the review of in vitro clinical tests shall meet 
18
with representatives from the Committee on 
19
Health, Education, Labor, and Pensions of the 
20
Senate and the Committee on Energy and Com-
21
merce of the House of Representatives to report 
22
on the contents described in the reports under 
23
this section. 
24
01:17 Mar 17, 2020
H6102
245 
•HR 6102 IH
(B) PARTICIPATION
IN
CONGRESSIONAL 
1
HEARING.—Each fiscal year, as applicable and 
2
requested, representatives from the Food and 
3
Drug Administration shall participate in a pub-
4
lic hearing before the Committee on Health, 
5
Education, Labor, and Pensions of the Senate 
6
and the Committee on Energy and Commerce 
7
of the House of Representatives, to report on 
8
the contents described in the reports under this 
9
section. Such hearing shall occur not later than 
10
120 days after the end of each fiscal year for 
11
which fees are collected under this section. 
12
Æ 
01:17 Mar 17, 2020
H6102
